

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
**WO 2004/027088 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**,  
C12N 9/10

(21) International Application Number:  
PCT/CA2003/001269

(22) International Filing Date: 20 August 2003 (20.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/412,002 20 September 2002 (20.09.2002) US

(71) Applicant (for all designated States except US): UNI-  
VERSITÉ LAVAL [CA/CA]; Cité universitaire, Québec,  
Québec G1K 7P4 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): GUILLEMETTE,  
Chantal [CA/CA]; 7605 La Fraîcheur, Québec, Québec  
G2K 2C7 (CA).

(74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill  
College Avenue, Montréal, Québec H3A 2Y3 (CA).


(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



**WO 2004/027088 A2**

(54) Title: METHOD FOR DETERMINING PREDISPOSITION TO A PHYSIOLOGICAL REACTION IN A PATIENT.

(57) Abstract: The present invention relates to a method for determining predisposition to a physiological reaction in a patient. Particularly, the present invention relates to a method for determining a predisposition to toxicity induced by a camptothecin analog or to an immunosuppressive mycophenolic acid-based therapy. This method comprises the characterization of nucleic acid sequences from the patient. The nucleic acid sequence encodes for an amino acid sequence or regulates the expression of UGT1A1, UGT1A7, UGT1A9 or their polymorphic variants. The method also comprises the analysis of haplotypic variation within these genes.

**BEST AVAILABLE COPY**

- 1 -

**METHOD FOR DETERMINING PREDISPOSITION TO A  
PHYSIOLOGICAL REACTION IN A PATIENT**

**TECHNICAL FIELD**

The present invention relates to a method for determining predisposition to a physiological reaction to a xenobiotic, a drug or an endogenously secreted compound, in a patient. Particularly, the present invention consists in a method comprising the characterization of a nucleic acid sequence from a patient. These nucleic acid sequences encode for amino acid sequences or regulate the expression of genes.

**BACKGROUND ART**

Recent evidences support the concept that polymorphic variation in genes encoding metabolism enzymes (MEs) are likely to play an important role in clinical response to therapeutic drugs and in exogenous or endogenous compound elimination.

Interindividual variations in response to a drug or to exogenous or endogenous compounds can be classified in three groups. The first segment of the population is known as poor metabolizers (PMs). These individuals often show accumulation of drugs or metabolites caused by a genetic defect in metabolizing enzymes and increased predisposition to adverse drug reactions is an important consequence of PM genotypes. In opposite, ultrarapid metabolizers (UMs) eliminate drugs excessively rapidly from the body. These patients, for example, do not develop sufficient high plasma levels of drugs and therefore do not respond to treatments, also giving rise to both clinical and economical complications. The remaining proportion of the population categorized as "normal" patients are named extensive metabolizers (EMs).

Some researchers have studied pharmacogenetics of human drug-metabolizing enzymes (DME), more specifically enzymes of the glucuronidation pathway and have demonstrated that glucuronidation, like other DME pathways, is also subject to interindividual variations. The glucuronidation reaction is catalyzed by UDP-glucuronosyltransferase enzymes (UGTs), a set of enzymes that

- 2 -

increase the polarity of xenobiotics, drugs and endogenous compounds to facilitate their excretion from the body. Glucuronidation reaction occurs on different functional groups that include hydroxyl, carboxyl, amino and sulfur. UGTs have the most important effect in both detoxification and promotion of excretion, via both urine and bile. Apart from being a major biochemical pathway well known for its role in drug metabolism, the glucuronidation system is also clearly involved in the homeostasis of numerous endogenous molecules, including steroids, thyroid hormones and bile acids.

Any perturbation in the glucuronidation pathway has the potential to modify the elimination, the detoxification or the pharmacokinetic parameters of a given drug, and consequently drug clearance. As a result, in situations where the activity of the glucuronidation pathway is reduced, it is to be expected that changes in the biological activity, sometimes toxicity, of the compounds will ensue. Therefore, the human genetic variations leading to differences in the glucuronidation rates could influence the activity of drugs and other chemicals, which undergo this conjugation.

As example, SN-38 or 7-ethyl-10-hydroxycamptothecin, which is the pharmacologically active metabolite of the anticancer drug irinotecan, undergoes extensive glucuronidation in human to form SN-38-G (10-O-glucuronyl-SN-38) and goes through significant biliary excretion and enterohepatic circulation. This drug is used globally in the first line treatment of advanced metastatic colorectal cancer (CRC). A major drawback of irinotecan-based chemotherapy is the high incidence of severe hematological and gastrointestinal toxicities, such as diarrhea. Diarrhea is believed to be secondary to the biliary excretion of SN-38, the extent of which is determined by SN-38 glucuronidation. Incidences of irinotecan-induced diarrhea can be serious and do not respond adequately to conventional antidiarrheal agents. It is believed that SN-38-G can be deconjugated to form SN-38 by intestinal glucuronidase enzyme, and further causes diarrhea by direct enteric injury. An inverse relationship between SN-38 glucuronidation rates and severity of diarrhea incidences in patients treated with irinotecan has been shown. These findings indicated that glucuronidation of SN-38 protects against irinotecan-

- 3 -

induced gastrointestinal toxicities. Therefore, the conversion of SN-38 to SN-38-G by both hepatic and intestinal UGTs is a critical step in the sequential metabolic pathway of irinotecan, and consequently in drug response and toxicity. Over the existing human UGTs, UGT1A1, UGT1A7 and UGT1A9 are  
5 known in the art to be SN-38 conjugators. On the other hand, UGT1A1 and UGT1A9 are highly expressed in the liver, the primary organ involved in the detoxification of irinotecan, and also in the gastrointestinal tract (GI) where toxicity takes place.

Mycophenolic acid (MPA) is also an extensively glucuronidated drug for which  
10 an interindividual variation of glucuronidation rates is observed. MPA is a metabolite of mycophenolate mofetil (MMF), and is commonly used as immunosuppressive agent. As MPA is known to be conjugated exclusively by the liver UGT1A9, interindividual variation observed with this substrate is therefore attributable only to the UGT1A9 isoform. The study of UGT1A9  
15 polymorphic variations thus plays a critical role in the control of immunosuppressive therapies and management of graft rejection.

Genetic variations among UGT isoforms have been demonstrated to be also implicated in the interindividual physiological response to drug administration. Therefore, glucuronidation pathway represented a target for many groups as a  
20 way to control irinotecan-associated side effects.

As example, international patent publication number WO 96/01127 describes a method and pharmaceutical compositions to reduce side effects of camptothecin analogs such as irinotecan, therefore reducing associated side effects. This reduction of toxicity would occur by reducing biliary transport or  
25 increasing UGT activity, by administering concomitantly a transport inhibitor or an UGT inducer.

US Patent no. 6,395,481 reports a method for detecting TA repeats polymorphic variations within the promoter region of the *UGT1A1* gene to evaluate predispositions to drug sensitivity associated with low levels of UGT enzymes  
30 expression.

- 4 -

International patent publication number WO 02/48400 reports a method for estimating the susceptibility in an individual to adverse side effects caused by the administration of irinotecan. This method is also based on the evaluation of the TA repeats within the promoter region of *UGT1A1*, but also includes the analysis of single nucleotide polymorphisms at two other positions within the exon 1.

International patent publication number WO 03/013536 reports a method for selecting a suitable irinotecan therapy for a cancer patient that comprises determining whether the patient has one or multiple variant alleles of the *UGT1A1* gene and adjusting irinotecan dosage and/or *UGT1A1*-modulating drugs consequently.

Considering overlapping substrate specificities of UGT enzymes, it is noteworthy that a higher expression of *UGT1A1* protein resulting from an increased gene expression could complement a deficient glucuronidation activity of an altered *UGT1A9* protein, or the contrary. An individual harboring two mutated genotypes would therefore have a normal phenotype and is less susceptible to develop a toxicity to a drug than a patient having the low metabolizer phenotype. Therefore, the genotyping studies that consider only one gene encoding a xenobiotic conjugating enzyme are less likely to be accurate than a global analysis of the whole set of genes.

Based on the state of the prior art described hereinabove, it would be highly desirable to be provided with a new diagnostic tool to determine accurately a predisposition to physiological adverse response following drug administration in standard conditions. This would allow to provide physicians with guiding means in determining drugs to be used in a specific treatment.

#### **DISCLOSURE OF INVENTION**

One aim of the present invention is to provide a method for determining a predisposition to a physiological reaction of an individual to a biologically active compound. This method comprises characterizing nucleotide sequence of the individual for at least one of the *UGT1A1*, *UGT1A7* or *UGT1A9* gene, or a part

- 5 -

thereof. The presence of at least one polymorphic or haplotypic variation in this nucleotide sequence is indicative of the predisposition to the physiological reaction.

5 In accordance with the method described herein, the predisposition may be a hereditary predisposition and the physiological reaction in the patient may be a beneficial reaction, an adverse reaction or a side effect to a compound.

Another aim of the present invention is to provide a method wherein determining the genetic sequence comprises determining the presence of at least one polymorphic or haplotypic variation in *UGT1A1*, *UGT1A7* or *UGT1A9* gene. These variations may include variations of the number of TA repeats in a  
10 TATA box of the *UGT1A1* gene, C<sup>-2208</sup>T substitution, C<sup>-2152</sup>T substitution, C<sup>-2141</sup>T substitution, T<sup>1887</sup>G substitution, T<sup>1818</sup>C substitution, C<sup>-665</sup>T substitution, T<sup>440</sup>C substitution, C<sup>-331</sup>T substitution, T<sup>275</sup>A substitution, G<sup>-87</sup>A substitution, G<sup>8</sup>A missence mutation, a T<sup>98</sup>C missence mutation, or a combination of these variations in the *UGT1A9* gene. Alternatively and/or additionally, G<sup>353</sup>T, T<sup>397</sup>G, C<sup>401</sup>A, G<sup>402</sup>A, G<sup>427</sup>C or T<sup>632</sup>C missence mutations can be determined in the *UGT1A7* gene.  
15

Another aim of the present invention is to provide a nucleotide sequence for determining a predisposition to a physiological reaction comprising at least one  
20 nucleotide sequence selected from the group consisting of SEQ ID NO: 36 to SEQ ID NO: 68, or the complementary sequences thereof.

For the purpose of the present invention the following terms are defined below.

The expression "adverse physiological reaction" is intended to mean any physiological reaction that provides a negative physiological effect to an  
25 individual.

The term "ASO" is intended to mean Allele Specific Oligonucleotide analysis.

The term "ASP" is intended to mean Allele Specific PCR analysis.

- 6 -

The expressions "beneficial physiological reaction" or "beneficial reaction" are intended to mean any physiological reaction that provides a positive physiological effect to an individual.

The term "BPD" is intended to mean benzo(a)pyrene-trans-7,8-dihydrodiol.

- 5 The term "CPT-11" is intended to mean 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin.

The term "DHPLC" is intended to mean denaturing high-performance liquid chromatography.

- 10 The term "gene" is intended to mean a segment of nucleic acid involved in producing a polypeptide chain; it includes regions preceding the coding region (promoter, leader sequence), regions following coding region (trailer) and intervening sequences (introns) between individual coding segments (exons).

The term "GI" is intended to mean gastrointestinal tract.

The term "MPA" is intended to mean mycophenolic acid.

- 15 The term "PhIP" is intended to mean 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

The term "RFLP" is intended to mean Restriction Fragment Length Polymorphism analysis.

The term "SN-38" is intended to mean 7-ethyl-10-hydroxycamptothecin.

- 20 The term "SSCP" is intended to mean Single Strand Conformation Polymorphism analysis.

The term "UGT" is intended to mean uridine diphosphoglucuronosyltransferase.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

- 25 Fig. 1 illustrates the metabolic pathway of irinotecan hydrochloride (CPT-11);

- 7 -

Fig. 2 illustrates the entero-hepatic cycle of irinotecan biotransformation;

Fig. 3 illustrates the major role of UGT1A9 in SN-38 glucuronidation;

Fig. 4 illustrates the distribution of SN-38-G formation by human liver samples.

Figs. 5a to 5f illustrate methods for detecting SNPs;

5 Figs. 6a to 6d illustrate the missence mutations in the human first exons of *UGT1A7* and *UGT1A9* genes;

Fig. 7 illustrates the expression of the UGT1A9 and UGT1A9 proteins in human liver microsomes;

10 Figs. 8a to 8e illustrate the effect of UGT1A9 promoter polymorphisms on protein expression;

Figs. 9 illustrates the effect of the UGT1A9 (-2152) polymorphic variation on MPA glucuronidation activity;

Fig. 10 illustrates the effect of the UGT1A9 (-1818) polymorphic variation on SN-38 glucuronidation activity;

15 Figs. 11a to 11d illustrate the effect of the UGT1A9 (-665) polymorphic variation on glucuronidation activity;

Figs 12 illustrates the effect of UGT1A9 (-275) polymorphic variation on MPA glucuronidation activity;

20 Figs. 13a and 13b illustrate the correlation between the UGT1A9 protein expression and glucuronidation activity;

Figs. 14a to 14d illustrate the relative expression of UGT1A7 and UGT1A9 protein and their relative activities on SN-38;

Figs. 15a to 15c illustrate the glucuronidation rates of the variant UGT1A9 allozymes;



- 8 -

Figs. 16a to 16f illustrate the immunofluorescence localization of UGT1A9\*1, UGT1A9\*2 and UGT1A9\*3;

Figs. 17a to 17c illustrate the relationship between UGT1A1 TATA box polymorphic variations and protein expression or glucuronidation activity;

- 5 Figs. 18a and 18b illustrate the correlative association between UGT1A1 protein expression and glucuronidation activity; and

Fig. 19 illustrates the predictive value of the haplotype determination of UGT1A9 and UGT1A1; and

- 10 Figs. 20a and 20b illustrate a sequence alignment of UGT1A proteins at selected positions.

#### **MODES OF CARRYING OUT THE INVENTION**

- In accordance with the present invention, there is provided a method for determining a predisposition to a physiological reaction in an individual comprising characterizing nucleotide sequence of at least one of the *UGT1A1*,  
15 *UGT1A7* or *UGT1A9* gene or a part thereof of the individual, where the nucleotide sequence is indicative of the predisposition to a physiological reaction. The individual of the present invention is a human or an animal, but is preferably a patient having a colorectal cancer or a solid tumor. The predisposition determined with the present method is any higher or lower  
20 susceptibility, sensibility, diathesis, proneness, proclivity, tendency, sensitivity, responsiveness, resistance or constitutional sickness to the physiological reaction. This predisposition may be a hereditary predisposition, a non-hereditary congenital predisposition or an acquired predisposition.

- The physiological reaction of the present invention comprises a beneficial  
25 reaction to a compound, an adverse reaction to a compound or a side effect. Among predisposition to an adverse physiological reaction to a compound, toxicity induced by an anti-cancer drug or a decreased responsiveness to an immunosuppressive agent are preferred. Toxicity to drug may be caused by an increased concentration of the drug in plasma, this increased concentration

- 9 -

being attributable to a lower glucuronidation metabolism of this compound or a decreased responsiveness to a drug, the latter being induced by an excessive glucuronidation-mediated elimination form of this compound from the organism. An anti-cancer agent that can be targeted through carrying out the present invention can be a camptothecin analog, such as 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin (Irinotecan, CPT-11) or 7-ethyl-10-hydroxycamptothecin (SN-38).

As CPT-11 or its active metabolite SN-38 are topoisomerase inhibitors, cells showing higher levels of these enzymes are likely more sensitive to topoisomerase inhibition. Resistance to the drug occurs generally in cells that have low levels of topoisomerase. Resistance to Irinotecan may also result from reduced conversion of the inactive prodrug CPT-11 to SN-38, attributable to reduced enzyme levels or, possibly, enzyme mutations. Additionally, an increased catabolic processing of the inhibitors contributes to reduce their availability within the cell, lowers inhibitor activity and favors drug resistance. It has also been reported that human colon tumors express high levels of the multiple-drug-resistance (MDR1) proteins. This class of enzyme may limit access of certain drugs to cells. *In vitro* data have demonstrated that camptothecin and its noncharged derivatives such as irinotecan overcome MDR1-mediated resistance. MDR1-mediated resistance to irinotecan may result from its rapid passive diffusion, its absence of interaction with MDR1, or a combination of both characteristics.

Alternatively, the sensitivity to drugs, as for example anticancer drugs, can be observed in cell lines deficient in DNA repair mechanisms. Indeed, DNA repair mechanisms can reverse drug-induced damage caused to the DNA. Therefore, DNA damage that goes unrepaired may result in significant genetic alterations or apoptosis.

The adverse physiological reaction as intended herein does not include the side effects observed with the majority of the population treated with the drug, but comprises physiological reactions that cause more serious threats in particular patients than what is generally expected with that drug in a majority of patients.

- 10 -

In fact, the susceptibility, sensitivity, responsiveness or resistance is higher or lower to what is observed in a patient having an anticipated physiological reaction to the same drug. These adverse physiological reactions are generally traduced by gastrointestinal, hematologic, hepatic, dermatologic, respiratory and neurologic disorders. Although gastrointestinal adverse reactions include nausea and vomiting, the most preoccupying and severe side effect observed is diarrhea. It has been observed that this particular toxicity is attributable to an accumulation of unconjugated SN-38 in the intestine. As SN-38 metabolism rates inversely correlate with the intensity of diarrhea in patients treated with increasing doses of CPT-11, the interindividual differences in pharmacokinetics of SN-38 are suggested to be responsible for the variation in drug side effects. Glucuronidation, which participates in the catabolic process of SN-38 is thus proposed to participate to this interindividual variation and the UGT1A9 enzyme would be responsible, at least in part, for these glucuronidation variations. As example, the UGT1A9(C<sup>3</sup>Y) and UGT1A9(M<sup>33</sup>T) isoforms, trivially named UGT1A9\*2 and UGT1A9\*3, respectively, were shown to have a significantly reduced glucuronidation efficiency toward SN-38 (see Table 1). Therefore, individuals that hold one of these polymorphic variations would be more susceptible to present such adverse physiological reactions.

A person skilled in the art will understand that the invention is not limited to adverse physiological reactions to camptothecin analogs but rather finds uses in the determination of predisposition to physiological reactions to any other glucuronidated compound. Clinically and toxicologically important compounds include mycophenolic acid (MPA), flavopiridol, an anticancer agent under development and a number of xenobiotics, particularly a variety of pre-carcinogens such as the benzo(a)pyrene-trans-7,8-dihydrodiol (BPD), precursor to the potent mutagen benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide. Glucuronidation is an effective transforming pathway of pyrene to the 1-pyrenylglucuronide, a well-known urinary biomarker for the assessment of human exposure to polycyclic aromatic hydrocarbons. In addition, some UGT isoforms, such as UGT1A9, play a critical role in the detoxification of food-borne carcinogenic heterocyclic amines. Among those, 2-amino-1-methyl-6-

- 11 -

phenylimidazo[4,5-b]pyridine (PhIP), the most abundant carcinogenic heterocyclic amine found in well-cooked meats, has been shown to be extensively glucuronidated by UGT1A9 in humans. Genetic polymorphisms is a possible determinant factor of detoxifying UGT1A9 activity and the large  
5 interindividual variability in the metabolism of these carcinogens and therapeutics drugs. Finally, a skilled artisan will understand that the present invention also concerns endogenously produced compounds that include, but are not limited to steroids, hormones, fatty acids or bilirubin.

The method of the present invention may further comprise a step of obtaining a  
10 nucleic acid sample from the individual and/or extracting nucleic acid material from the biological sample. In such cases, the nature of the biological sample may be adapted for the purpose of the determination and may include saliva, semen, blood, hairs or any specimen comprising at least one cell from a human origin. This specimen can be collected directly on a human body or,  
15 alternatively, on any object on which nucleic acid molecules from a human origin could be found. The latter option is of particular interest in cases where inter-generation transmission of a gene (pedigree) is investigated, some members of the cohorts having disappeared. Nucleic acid extraction may include a further step of amplification to ensure an appropriate availability of  
20 material, wherein said amplification is preferably performed by polymerase chain reaction (PCR) amplification, wherein PCR amplification is performed using primers that specifically hybridize to a UGT1A9-encoding nucleic acid sequence. Nucleic acid molecules can be either single strand (ss) or double strand (ds) RNA or DNA, as well as DNA/RNA hybrid molecules. In the  
25 presence of ssRNA, a step of reverse transcription of the RNA molecule can be performed prior to PCR amplification.

One embodiment of the present invention is to determine the genetic profile of an individual or a patient comprising determining the presence of at least one polymorphic or haplotypic variation in UGT genes. The *UGT1A1*, *UGT1A7* and  
30 *UGT1A9* genes are the preferred candidate genes according to the present invention, where haplotypic variations can be found in a specific gene or considered simultaneously on multiple genes.

- 12 -

The putative UGT1A9 variations which can be investigated to determine a predisposition to a physiological reaction are C<sup>-2208</sup>T substitution, C<sup>-2152</sup>T substitution, C<sup>-2141</sup>T substitution, T<sup>-1887</sup>G substitution, T<sup>-1818</sup>C substitution, C<sup>-665</sup>T substitution, T<sup>-440</sup>C substitution, C<sup>-331</sup>T substitution, T<sup>-275</sup>A substitution, G<sup>-87</sup>A substitution, G<sup>8</sup>A missense mutation (C<sup>3</sup>Y), a T<sup>98</sup>C missense mutation (M<sup>33</sup>T), or a combination of these variations. The G<sup>8</sup>A missense mutation is generally associated with a decreased predisposition or susceptibility to an anti-cancer agent whereas the T<sup>98</sup>C missense mutation is associated with an increased predisposition or susceptibility to the same anti-cancer agent. Mutations that can be determined in the *UGT1A7* gene are G<sup>353</sup>T missense mutation (G<sup>115</sup>S), T<sup>397</sup>G missense mutation (N<sup>129</sup>K), C<sup>401</sup>A and G<sup>402</sup>A missense mutations (R<sup>131</sup>K), G<sup>427</sup>C missense mutation (E<sup>139</sup>D) or T<sup>632</sup>C missense mutation (W<sup>208</sup>R), while the UGT1A1 variation is a TA<sub>7</sub> mutation in the TATA box. A person skilled in the art will recognize that any polymorphic or haplotypic variation found in a UGT gene that modify the expression of the UGT protein, its stability, its substrate specificity, its glucuronidation kinetic parameters or its primary, secondary, tertiary or quaternary structures also represents an aspect of the present invention.

The analysis of a nucleic acid molecule to identify a polymorphic or haplotypic variation can be performed by Restriction Fragment Length Polymorphism (RFLP) analysis, Allele Specific Oligonucleotide (ASO) analysis, Allele Specific PCR (ASP) analysis, Single Strand Conformation Polymorphism (SSCP) analysis, electronic microchip assay, denaturing high-performance liquid chromatography (DHPLC), allelic discrimination assays (Taqman), sequencing or using a DNA chip-based genotyping method, among others.

In one embodiment of the present invention, the analysis for determining a predisposition or a susceptibility to a drug, as for example but not limited to, an anti-cancer agent in a patient may be restrained to the analysis of UGT1A9 polymorphisms or combined with the analysis of other genes susceptible to lead to a predisposition or susceptibility to the anti-cancer agent (haplotype analysis). The latter genes may encode other drug-conjugating enzymes, such as UGT enzymes as described hereinabove, enzymes that mediate the

- 13 -

bioconversion of the CPT-11 molecule into SN-38 (carboxyesterase) or transport enzyme.

Since UGT1A1, UGT1A6, UGT1A7, UGT1A8 and UGT1A10 are the other UGT enzymes that conjugate CPT-11 and SN-38 molecules, the genes that encode these enzymes are targets used to investigate the glucuronidation haplotype of an individual, where at least one of these genes is analyzed concomitantly to UGT1A9. Polymorphic variations in other conjugating enzymes, belonging to the class of carboxyltransferases, sulfotransferases, glutathione S-transferase, methyltransferases or arylamine N-acetyltransferases,  $\beta$ -glucuronidases could also be investigated in concomitance to the UGT1A9 gene.

The transport enzymes described herein include, but are not limited to, ATP-binding cassette (ABC) proteins ABCA1, ABCA2, ABCA3, ABCA4, ABCA5, ABCA6, ABCA7, ABCA8, ABCA9, ABCA10, ABCA11, ABCA12, ABCA13, ABCA14, ABCB1, ABCB2, ABCB3, ABCB4, ABCB5, ABCB6, ABCB7, ABCB8, ABCB9, ABCB10, ABCB11, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC6, ABCC7, ABCC8, ABCC9, ABCC10, ABCC11, ABCC12, ABCC13, ABCD1, ABCD2, ABCD3, ABCD4, ABCE1, ABCF1, ABCF2, ABCF3, ABCG1, ABCG2, ABCG4, ABCG5, ABCG8, Breast cancer resistance protein (BCRP), multi-drug resistance protein (MRP) and P-glycoproteins.

As DNA repair mechanisms could be implicated in the hypersensitivity to camptothecin analogs, haplotype analysis that investigate these mechanism concomitantly to UGT haplotyping analysis is also one embodiment of the present invention. Genes that encode for DNA mismatch repair (MMR), homologous recombination (HR), non-homologous end joining (NHEJ) and single-strand annealing (SSA) systems, as well as Rad and ATPase proteins could therefore be analyzed by a skilled artisan simultaneously to UGT sequences.

In a further embodiment of the present invention, there is provided an isolated nucleotide molecule comprising an allelic variant of a polymorphic region of a

- 14 -

UGT1A1 gene, wherein the allelic variant comprises at least one TATA box polymorphic variation within the UGT1A1 promoter region.

According to another embodiment of the present invention, there is provided an isolated nucleotide molecule comprising an allelic variant of a polymorphic region of a UGT1A7 gene, wherein the allelic variant comprises at least one  
5 nucleotide sequence selected from the group consisting of those set forth in SEQ ID No: 60 to SEQ ID NO: 68, or the complement thereof.

Also, there is provided an isolated nucleotide molecule comprising an allelic variant of a polymorphic region of a UGT1A9 gene, wherein the allelic variant  
10 comprises at least one nucleotide sequence selected from the group consisting of those set forth in SEQ ID NO: 36 to SEQ ID NO: 59, or the complement thereof.

In a further embodiment, there is provided an isolated amino acid sequence comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71 or a fragment thereof. These amino acid sequences may be encoded by a nucleotide  
15 sequence comprising at least one sequence selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, a fragment or the complementary sequences thereof. Alternatively, the expression of the amino acid sequence may be regulated by a nucleotide sequence comprising at least  
20 one sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO:  
25 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, a fragment or the complementary sequences thereof.

- 15 -

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

### **EXAMPLE I**

#### **Distribution of SN-38-Glucuronide Formation In Human Liver Microsome Samples**

To obtain statistical data on interindividual variation of SN-38 glucuronidation, we measured the SN-38-G formation, as currently known in the background art, with microsomes preparations from each patient liver sample. The glucuronide formation rates were regrouped into ranges and every sample was categorized within these ranges.

The following results show a mean for glucuronidation rate of 0.61 pmol/mg of protein/minute (Table 1). Data also indicate a substantive distribution of the glucuronidation rates. Fig. 4 illustrates the distribution of the glucuronidation rates obtained with liver samples.

**TABLE 1**  
**Statistical data of SN-38 glucuronide formation by human liver samples**

Quantiles			Moments	
100.0%	maximum	1.9735	Mean	0.6117859
99.5%		1.9735	Std Dev	0.5014612
97.5%		1.9309	Std Err Mean	0.0723797
90.0%		1.5699	upper 95% Mean	0.7573947
75.0%	quartile	0.9279	lower 95% Mean	0.4661772
50.0%	median	0.4204	N	48
25.0%	quartile	0.2763	Sum Wgts	48
10.0%		0.1641	Sum	29.365725
2.5%		0.1113	Variance	0.2514633
0.5%		0.1063	Skewness	1.3394982
0.0%	minimum	0.1063	Kurtosis	0.6950696
			CV	81.966773

25

### **EXAMPLE II**



- 16 -

**Identification of UGT1A9 Variants****MATERIAL AND METHODS****DNA samples**

- 5 DNA samples of 201 Caucasian subjects were obtained from the Quebec Family Study (QFS) (Simonen *et al.*, 2002, *Med. Sci. Sports Exerc.* 34: 1137-1142). Unrelated Caucasian subjects were recruited at the Massachusetts General Hospital (n=100) and genomic DNA from African-American subjects were kindly provided by Robert Millikan (Lineberger Comprehensive Cancer
- 10 Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7435, USA) (n=20). These samples had been anonymized prior to their reception in our laboratory. All subjects have provided written consent for the use of their DNA for experimental purposes, and the present study was reviewed and approved by Institutional Review Boards (CHUL Research Center
- 15 and Laval University).

- 17 -

**Resequencing of the *UGT1A9* gene and genotyping**

Polymerase chain reaction (PCR) was used to amplify the first exon of the *UGT1A9* gene. Three pairs of primers were designed to amplify overlapping fragments covering the first exons, a small portion of the 5'-flanking region and the intron-exon boundary (listed in Table 1). PCR amplification and DNA sequencing were performed according to protocols of Faucher *et al* (Faucher *et al.*, 2002, *Hum. Mol. Genet.* 11: 2077-2090). Amplicons were sequenced with an ABI 3700<sup>TM</sup> automated sequencer using Big Dye<sup>TM</sup> (Perkin Elmer<sup>TM</sup>) dye primer chemistry. Samples were sequenced on both strands with nested primers listed in Table 2. Samples with ambiguous sequencing chromatograms and samples with single nucleotide polymorphisms (SNPs) were subjected to a second, independent amplification, followed by DNA sequencing. Sequences were analyzed with Staden preGap4 and Gap4 programs. These programs align sequence chromatograms and identify areas in which polymorphisms might be present. Each chromatogram was then evaluated individually to confirm variation in the sequences.

To determine the prevalence of *UGT1A9* alleles in the population, a portion of the first exon, which includes the newly discovered polymorphisms, was amplified by PCR using specific oligonucleotides #37 and #38 (SEQ ID NO: 1 and 2). PCR amplifications were performed in a final reaction volume of 50 µL containing 25 ng of genomic DNA, 20 pmol of each primer, 1X reaction buffer, 100 µM dNTPs, 4 % DMSO and 2 U of the *Taq* DNA polymerase. The amplification conditions were: denaturation at 96°C for 5 min, 35 cycles of 30 sec at 94°C, 40 sec at 58°C and 1 min at 72°C, with a final extension step of 7 min at 72°C. Reactions were performed in a Perkin Elmer<sup>TM</sup> model 9700 thermal cycle. ASOs were designed to detect by hybridization the missense mutations in the *UGT1A9* amplification products. Four ASOs were designed to specifically hybridize to the sequence corresponding to a G or an A at codon 3 (Fig. 5e) and a T or a C at codon 33 (Fig. 5f) and hybridization performed as previously described (Guillemette *et al.*, 2000, *Pharmacogenetics* 10: 629-644).

- 18 -

**TABLE 2**  
**Primer sequences for UGT1A9**

<b>Primers</b>	<b>Sequences</b>	<b>SEQ ID NO:</b>
<b>PCR amplification UGT1A9</b>		
#37	5' - gtgctggtatttctccc	1
#38	5' - gtcaaaaatgtcattgtatgaacc	2
#39	5' - gatctggaccgggagttcaa	3
#40	5' - gtgtggctgtagagatcatact	4
#41	5' - catgcactggaggaacattatta	5
#42	5' - ggtacacgcattggcac	6
<b>Direct sequencing UGT1A9</b>		
#7	5' - ctcccacctactgtatc	11
#8	5' - gttcaaggcttttgccc	12
#9	5' - catttattatgccaccg	13
<b>Allelic specific oligos UGT1A9</b>		
C <sup>3</sup>	5' - atggcttgacagggt	14
Y <sup>3</sup>	5' - atggcttacacagggt	15
M <sup>33</sup>	5' - agtgcccatggatggga	16
T <sup>33</sup>	5' - agtgcccacggatggga	17
<b>Site-directed mutagenesis UGT1A9</b>		
C <sup>3</sup> to Y <sup>3</sup> (Forward)	5' - gttctctgatggcttacacagggtggaccag	28
C <sup>3</sup> to Y <sup>3</sup> (Reverse)	5' - ctggccaccctgtgtaagccatcagagaaac	29
M <sup>33</sup> to T <sup>33</sup> (Forward)	5' - gctactggtagtgcccacggatgggagccactgg	30
M <sup>33</sup> to T <sup>33</sup> (Reverse)	5' - ccagtggctcccatccgtgggcactaccagtagc	31

*Bold : nucleic acid polymorphism*

#### 5 Methods for UGT1A9 SNPs detection

UGT1A9 first exon was amplified in unrelated subjects. Allelic discrimination PCR was used to genotype UGT1A9 codons 3 and 33. The probe marked with FAM fluorochrome was designed to detect the *wild type* allele. The other probe used to detect the polymorphic alleles were marked with TET fluorochrome.

- 10 Duplicate filters were hybridized separately with the corresponding  $\gamma$ -<sup>32</sup>P labeled oligonucleotides. The positive signals detected with both ASOs indicated heterozygous individuals for the polymorphism in contrast with a positive signal with one probe only, which indicated that the subject was homozygous.
- 15 Identification of missense mutations in the human UGT1A9 first exon by direct sequencing of PCR products.

- 19 -

Specific primers were used to amplify the exon 1 *UGT1A9* (SEQ ID NO: 1 to SEQ ID NO: 6). The nonsynonymous polymorphisms in the third codon (C<sup>3</sup>Y) (a) and in codon 33 (M<sup>33</sup>T) of *UGT1A9* (b) are illustrated in Fig. 6.

#### 5 Functional analysis of the conjugating activity of *UGT1A9* variants

Microsomal fractions from HEK-293 cells stably expressing human *UGT1A9*\*1, *UGT1A9*\*2 and *UGT1A9*\*3 were used in enzymatic assays. Reactions (100 µl volume) contained 50 mM Tris-HCl, pH 7.3, 10 mM MgCl<sub>2</sub>, 100µg/mL phosphatidylcholine, 1 mM UDP-glucuronic acid, 40 to 60 µg of membrane protein. SN-38, MPA or other substrates were added in concentrations ranging from 1 to 200 µM and the reaction was incubated 30 min. at 37 °C with agitation. Human liver microsome were incubated in the same condition for control. Reaction was stopped by the addition of 200 µL MeOH + 1 % HCl 2N, followed by centrifugation at 14 000 rpm for 10 minutes. Supernatant was filtered through a 0.22 µm filter and 100 µL of water was added. For SN-38 and SN-38-glucuronide detection, 10 µL samples were injected on a liquid chromatographic system coupled to a fluorescence detector. Time-course experiments were realized to determine the linearity of the glucuronidation reaction. For determination of V<sub>max</sub> and K<sub>m</sub>, HEK-293 cells stably expressing *UGT* enzymes were incubated in the presence of varying SN-38 concentrations from 1 to 200 µM for the corresponding period of 30 min. All reactions rates were shown to be linear for these times.

A liquid chromatographic method was developed to quantify SN-38 glucuronidation of *UGT* cell line-derived microsomes and human liver microsomes. Samples were analyzed using high performance liquid chromatography (Alliance 2695, Waters, Milford, MA). Chromatographic separation was achieved with a Colombus C18 column 5-µm packing material, 50 x 3.2 mm (Phenomenex, Torrance, CA) using a two-solvent gradient system : A (water + 1 mM ammonium formate); B (MeOH + 1 mM ammonium formate). At a constant flow rate (0.7 ml/min), a linear gradient from 20 to 65 % B was run over 3 min, held 0.8 min and a second gradient until 95 % of B was run over 2 min and then re-equilibrated to 20 % B over 2 min. The effluent from the HPLC

- 20 -

system (Alliance 2695) was connected directly to a fluorescence detector (Waters, Milford, MA) using an excitation wavelength of 460 nm and an emission of 460 nm. Retention time for SN-38 and SN-38-glucuronide were respectively 3.5 and 4.6 min. Determination of the glucuronidation rates  
5 obtained with other substrates was performed as currently known in the art.

## **RESULTS**

**Identification of two novel missense mutations in the human *UGT1A9* gene and their distribution in healthy individuals.**

10 The strategy used to identify polymorphisms in the *UGT1A9* gene was a PCR amplification of the exon 1, followed by direct DNA sequencing. Inclusion of a portion of the adjacent intron and 5'-flanking region in the PCR fragment was performed in order to assure the specific amplification of the *UGT1A9* gene. The *UGT1A9* was resequenced on both strands for 35 subjects. DNA samples from  
15 Caucasian-American subjects was shown to contain one SNP, whereas an additional SNP was observed in an African-American subject. No insertion-deletion events were observed within the area sequenced.

The nucleotide change producing the first cSNP (SNPs in the coding region) was a change of a G to an A at nucleotide 8. The polymorphic change results in  
20 the substitution of Cysteine by a Tyrosine (C<sup>3</sup>Y) in the signal peptide of the *UGT1A9* protein corresponding to the *UGT1A9*\*2 allele (SEQ ID NO: 37). The second nucleotide change, T<sup>98</sup>C, leads to a Methionine to a Threonine at codon 33 (M<sup>33</sup>T) corresponding to the *UGT1A9*\*3 allele (SEQ ID NO: 38). Figs. 6a and 6b illustrate the sequence analysis of three genotypes: homozygous *wild*  
25 *type* \*1/\*1 and heterozygous \*1/\*2 or \*1/\*3.

To determine the allelic frequency of *UGT1A9* allozymes in the population, we genotyped unrelated subjects including 301 Caucasians of whom 201 were French-Canadians, and 20 African-American subjects. Only one African-American individual had the C<sup>3</sup>Y mutation whereas 12 individuals, all Caucasian  
30 subjects, were shown to have the M<sup>33</sup>T mutation (illustrated in Fig. 5f). A total of 5 % of individuals were found heterozygous for the *UGT1A9*\*3 allele in the French-Canadian population and 3 % of the remaining Caucasian-American

- 21 -

subjects. None of the 20 African-American subjects were found to have the UGT1A9\*3 allele (Table 3).

**TABLE 3**  
**Allelic frequency and prevalence of UGT1A9 alleles**

	n	Allele frequency			Genotype frequency (%) <sup>a</sup>		
		*1	*2	*3	*1/*1	*1/*2	*1/*3
Amino acid change		Cys <sup>3</sup> Met <sup>33</sup>	Tyr <sup>3</sup> Met <sup>33</sup>	Cys <sup>3</sup> Thr <sup>33</sup>			
Functional change		"Wild type"	Similar activity	Decreased activity			
<b>Population characteristics</b>							
Caucasian (French Canadian)	201	0.978	0.000	0.022	95	0	4.4
Caucasian (American)	100	0.964	0.000	0.036	97	0	3
African (American)	20	0.975	0.025	0.000	95	5	0

- 5 <sup>a</sup> Subjects homozygous for variant UGT1A9 alleles were not observed in the population tested.

#### Functional analysis of the conjugating activity of UGT1A9 variants

- 10 Table 4 shows that the presence of a threonine at position 33 (UGT1A9\*3) is correlated to 96.3% decreased conjugation rate for SN-38 while the presence of a tyrosine at codon 3 is associated to a 16.7% increased activity. Moreover, modulation of the UGT1A9 glucuronidation activity is substrate specific since conjugation of eugenol, 2-hydroxyestradiol, 4-hydroxyestrone and 4 methylumbelliferone is increased or decreased in a proper way for each
- 15 substrate. The presence of a threonine at position 33 does not affect significantly the affinity of the protein for SN-38 but decreases by approximately 20-folds its glucuronidation rate (Table 5) while the affinity of UGT1A9 for MPA is dramatically reduced by the presence of codon 33 variation (Table 6).

20

**TABLE 4**  
**Substrate-dependent modulation of the UGT1A9 activity by codons 3 and 33.**

Substrates	% glucuronide formation relative to UGT1A9*1	
	UGT1A9*2	UGT1A9*3

- 22 -

Eugenol	↓ 28.4 %	↑ 716 %
2-OH-E2	↓ 26.6 %	↑ 1727 %
4-OH-E1	↓ 19.0 %	↓ 90.3 %
4-MU	↓ 19.2 %	↓ 66.2 %
SN-38	↑ 16.7 %	↓ 96.3 %
Flavopiridol	ns	ns

TABLE 5

Kinetic analysis of SN-38 glucuronidation by UGT1A9\*1, \*2 and \*3

	1A9*1	1A9*2	1A9*3
Km	3.03 ± 0.72	5.15 ± 1.81	3.21 ± 0.95
Vmax	316.34 ± 52.03	324.68 ± 95.09	15.50 ± 8.40 p < 0.001
Vmax / Km (Cl <sub>int</sub> )	104	63	5

TABLE 6

Kinetic analysis of MPA glucuronidation by UGT1A9\*1, \*2 and \*3

UGT1A9 alleles	Km μM	Vmax pmol/min/mg	Vmax/Km
1A9*1	495	9406	19
1A9*2	303	8401	28
1A9*3	3225	14074	4

**EXAMPLE III****Identification of novel UGT1A9 promoter variants**

The primary objective of this study was to examine the genomic sequences of the *UGT1A9* gene promoter sequence to identify novel expression

- 23 -

polymorphisms and to determine whether or not these polymorphic variations would affect the expression of the UGT1A9 protein. To determine the effect of the polymorphic variations on the UGT1A9 protein expression, semi-quantitative immunoblot analyses were performed on liver microsomes from patients and correlated with their genotypes. Identification of novel polymorphisms has been performed by direct sequencing of a pool of DNA samples from patients. Determination of genotypes of each patient monitored was also performed by direct sequencing.

Liver microsomes from patients were prepared by differential centrifugation. The crude cell extracts were centrifuged at 12 000 x g at 4°C for 22 min to remove nuclei and other cellular debris. Supernatants were centrifuged at 105 000 x g for 60 min at 4°C to obtain the membrane fraction, which was homogenized in the buffer described above. Protein concentrations were determined using the Bradford method according to the manufacturer's recommendations.

To determine the level of UGT1A9 proteins expressed in the microsomal fractions obtained from liver microsomes, Western blot analyses were conducted as follows: Microsomal proteins (10 µg) from liver microsomes were separated by 10 % SDS-polyacrylamide gel electrophoresis. The separated proteins were transferred onto nitrocellulose membranes and probed with the antihuman UGT1A antiserum (1:1000 dilution) specific for the amino-terminal region of the UGT1A7, UGT1A8, UGT1A9 and UGT1A10 proteins. Given that UGT1A7, UGT1A8 and UGT1A10 are not expressed in liver tissue, immunodetection with this antiserum in human liver microsomes is specific to UGT1A9. In order to normalize sample loading, blots were re-probed with anti-calnexin antibody (1:2000 dilution; StressGen Biotechnologies Corp., Victoria, Canada), to detect a second ER-resident protein. A donkey antirabbit IgG antibody conjugated with the horseradish peroxidase (Amersham Corp., Oakville, Canada) was used as the secondary antibody (1:10 000 dilution). The resulting immunocomplexes were visualized using an enhanced chemiluminescence kit (ECL) (Renaissance, Quebec, Canada) and exposed on Kodak XB-1 film. The lowest signal has been used as standard to determine



- 24 -

the relative expression of UGT1A9 in each sample and results were monitored by Oneway analyses.

## RESULTS

Ten novel polymorphic variations were identified within the *UGT1A9* promoter region, namely a C(-2208)T substitution, a C(-2152)T substitution, a C(-2141)T substitution, a T(-1887)G substitution, a T(-1818)C substitution, a C(-665)T substitution, a T(-440)C substitution, a C(-331)T substitution, a T(-275)A substitution and a, G(-87)A substitution.

UGT1A9 protein expression is highly variable among tested samples, as shown on Fig. 7. Figs. 8a to 8e demonstrate a positive correlations between the presence of mutated nucleic acids in positions -2152 (Fig. 8a), -665 (Fig. 8b), -440 (Fig. 8c), -331 (Fig. 8d) and -275 (Fig. 8e) in the promoter region of the *UGT1A9* gene and the expression of higher level of UGT1A9 proteins.

### EXAMPLE IV

#### Effect of *UGT1A9* polymorphic variations on liver microsomes glucuronidation

One it has been established that polymorphic variations in the promoter region of the *UGT1A9* gene can modulated the expression of the *UGT1A9*, it was interesting to study the impact of these mutation on global glucuronidation by human liver microsomes. Therefore, a correlation study was undergone to determine if correlations could exist between C(-2152)T, T(-1818)C, C(-665)T and T(-275)A variations and SN-38, mycophenolic acid and 4-hydroxyestrone glucuronide formation. Glucuronidation activity was determined for each liver sample in nmoles/mg of proteins/min and further regrouped respective to the genotype of the patient, namely patient carrying a mutation or non-carrying (wild type) patients.

## Results

- 25 -

One way analyses demonstrate a correlative association between the presence of a mutated nucleic acid at position -2152 and glucuronidation of MPA (Fig. 9). Fig. 10 also shows a positive correlation between the formation of SN-38-glucuronide and the presence of one or both mutated alleles at position -1818 in the UGT1A9 promoter region. Nucleic acid change at position -665 correlates with higher glucuronidation rates with SN-38, (Fig. 11a), 4-hydroxyestrone (Fig. 11b) and mycophenolic acid (Fig. 11c). Finally, Fig. 12 shows a positive correlation between the presence of the -275 mutated alleles and higher glucuronidation rate with SN-38.

10

#### **EXAMPLE V**

##### **Effect of the expression of UGT1A proteins on glucuronidation by liver microsomes**

15 As UGT1A9 is considered as a major SN-38 glucuronidation enzyme, we attempted to determine if an association between the expression of this proteins and glucuronide formation could exist. As shown in Fig. 13a, there is a positive correlation between glucuronidation of SN-38 and protein level of UGT1A9. To ascertain that the enhancement of glucuronidation observed with this substrate is not attributable to a residual activity of other UGT isoforms, these experiments were reconducted using a probe substrate for UGT1A9, namely mycophenolic acid. Fig. 13b illustrates the positive correlation between UGT1A9 protein expression level and MPA glucuronidation.

20

#### **EXAMPLE VI**

##### **Identification of novel UGT1A7 variants**

25

The primary objective of the study was to examine the genomic sequences of the *UGT1A7* gene, for which functional polymorphisms have been described yet to identify novel polymorphic variations. The aim was to look for missense polymorphisms in a Caucasian population, to develop methods for SNPs detection and to evaluate their functional properties after *In vitro* expression of

30

- 26 -

enzyme variants. In turn, *UGT1A7* is a polymorphic gene for which there are at present four known allelic variants (Guillemette *et al.*, 2000, *Pharmacogenetics*, 10: 629-640). Based on *in vitro* metabolic studies, the *UGT1A7*\*3 and \*4 variants may potentially lead to a poor SN-38 glucuronidator phenotype.

## 5 MATERIAL AND METHODS

### **UGT1A7 haplotype determination**

DNA samples were obtained according to Example 2. To discriminate the polymorphisms at codons 129/131 and 139, a PCR technique using the Taqman® technology was used (Applied Biosystems, Branchburg, NJ, USA).

- 10 To discriminate the two alleles at codons 129/131, the exon 1 containing the codon 129/131 was amplified using primers 387 and 388 (SEQ ID NO: 20 and 21, respectively) shown in Table 4. Two probes were designed to identify the two different alleles, probe for N<sup>129</sup>/R<sup>131</sup> allele was marked with FAM fluorochrome and probe for K<sup>129</sup>/K<sup>131</sup> allele was marked with TET fluorochrome.
- 15 Also, specific primers were designed to amplify the region of exon 1 containing codon 139. Specific 21-mer probes were designed to identify the two different alleles. One of the probes, E<sup>139</sup>-FAM, was homologous to the *wild type* allele. The other probe, D<sup>139</sup>-VIC, contained the polymorphic nucleotide at codon 139 in order to be homologous to the D<sup>139</sup> mutant allele. Each PCR reaction was
- 20 performed with 25 ng of genomic DNA in a volume of 10 µL and containing 5 pmole of each primer and probe and 1 x Taqman® universal PCR master mix. PCR conditions were 50°C for 2 minutes, 95°C for 10 minutes followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. The ABI prism 7000™ system detected the different genotypes (Figs. 5a; 5c).

- 25 The polymorphism at codon 208 of *UGT1A7* was genotyped by PCR-RFLP. The polymorphism at codon 208 creates a restriction site for *Rsa I* enzyme. Digestion was performed with 5 µL of PCR product, 10 U of *Rsa I* and 1 x reaction buffer L (10mM Tris-HCl, 10mM MgCl<sub>2</sub>, 1mM DTE, PH 7.5) in a total volume of 10 µL. Reactions were incubated for 2 hours at 37°C and separated
- 30 on a 2% agarose gel to observe the different migration patterns. Homozygous *wild type* genotype at codon 208 generates a single fragment migrating at 590 bp. The heterozygous genotype generates a fragment of 590 pb representing

- 27 -

the *wild type* allele and two bands of 236 and 264 bp representing the polymorphic allele cut by *Rsa* I. Homozygous mutants at position 208 have a pattern of migration showing only two bands of 236 and 264 bp (Fig. 5b).

Allelic specific oligonucleotides (ASOs) were designed to detect UGT1A7 polymorphism at codon 115. PCR amplification using primers 292 and 293 was used to generate the target fragment containing the polymorphic site. Each ASO is composed of a 17-mer centered over the polymorphic nucleotide of each variant. The denatured PCR products were spotted onto filters, each one being subsequently hybridized with a single ASO using a method that has been described previously (Guillemette *et al.*, 2000, *Pharmacogenetics*, 10: 629-640). Conditions for ASO hybridization analysis have been described above and a typical result is illustrated in Fig. 5d.

#### Methods for UGT1A7 SNPs detection.

UGT1A7 first exon was amplified in unrelated subjects. (a) Allelic discrimination PCR was used to genotype UGT1A7 codons 129/131. The probe marked with FAM fluorochrome was designed to detect the *wild type* N<sup>129</sup>/R<sup>131</sup> allele. The other probe used to detect the polymorphic allele K<sup>129</sup>/K<sup>131</sup> was marked with TET fluorochrome. (b) PCR products amplified with primers #17 (SEQ ID No: 8) and #18 (SEQ ID No: 7) were digested using *Rsa* I enzyme to determine whether the patients were homozygous *wild type* W<sup>208</sup>, heterozygous W<sup>208</sup>/R<sup>208</sup> or homozygous R<sup>208</sup>. The 590 bp fragment represents the undigested PCR product whereas the 336 and 264 bp fragments result from the digestion of the 590 bp amplicon. (c) Allelic discrimination PCR was used to genotype the novel polymorphism at codon 139 of the *UGT1A7* gene. The FAM fluorochrome was used to mark the *wild type* probe E<sup>139</sup> and the VIC fluorochrome was used for the polymorphic probe D<sup>139</sup>. (d) Allelic specific oligonucleotides (ASOs) were designed to genotype the novel polymorphic variation at codon 115 of *UGT1A7* gene. (e) (f) A similar strategy was further used to detect variants at codons 3 and 33 of the *UGT1A9* gene. Duplicate filters were hybridized separately with the corresponding  $\gamma$ -<sup>32</sup>P labeled oligonucleotides. The positive signals detected with both ASOs indicated heterozygous individuals for the polymorphism in

- 28 -

contrast with a positive signal with one probe only, which indicated that the subject was homozygous.

**Identification of missense mutations in the human *UGT1A7* first exon by direct sequencing of PCR products.**

Specific primers were used to amplify the exon 1 of *UGT1A7* (Table 7). The nonsynonymous polymorphisms illustrated, along with the codon 115 (G<sup>115</sup>S) (c) and codon 139 (E<sup>139</sup>D) (d) polymorphisms of *UGT1A7* (see Fig. 6). The sequence illustrated in (a) and (b) correspond to the "sense" strand whereas (c) and (d) correspond to the "anti-sense" strand.

**TABLE 7**  
**Primer sequences for *UGT1A7***

<u>Primers</u>	<u>Sequences</u>	<u>SEQ ID NO:</u>
<b>PCR amplification <i>UGT1A7</i></b>		
#18	5'- cgctggacggcaccattg	7
#17	5'- gctaaaggggagataactacc	8
#122	5'- gctggacggcaccattg	9
#123	5'- ccctaagagaagctcggg	10
<b>Allelic specific oligos <i>UGT1A7</i></b>		
G <sup>115</sup>	5'- catccaatggtatttt	18
S <sup>115</sup>	5'- catccaatagtatttt	19
<b>Taqman® analysis (Codon 129/131) <i>UGT1A7</i></b>		
#387	5'- gcaccattgcgaagtgc	20
#388	5'- ggatcgagaaacactgcatcaa	21
N129/R131-FAM	5'- ttaatgacgaaaatt	22
K129/K131-TET	5'- tttaaggacaaaaaatt	23
<b>Taqman® analysis (Codon 139) <i>UGT1A7</i></b>		
#546	5'- gcgaagtgcattttcttattaacaa	24
#544	5'- aagccacagcgatcaaaaagg	25
E139-Fam	5'- atactaaaggagagtgttt	26
D139-Vic	5'- atactaaaggacagtgttt	27
<b>Site-directed mutagenesis <i>UGT1A7</i></b>		
E <sup>139</sup> to D <sup>139</sup> (Forward)	5'- aattagtagaataactaaaggacagtgtttgatgcagtgttc	32
E <sup>139</sup> to D <sup>139</sup> (Reverse)	5'- gaaacactgcatcaaaacaactgtccttaagtatttactaatt	33
G <sup>115</sup> to S <sup>115</sup> (Forward)	5'- gttcatccaatagtattttgac	34
G <sup>115</sup> to S <sup>115</sup> (Reverse)	5'- gtcaaaaatactattggatgaac	35

*Bold : nucleic acid polymorphism*

**15 RESULTS**

- 29 -

**Identification of two novel polymorphisms in the coding region of the *UGT1A7* gene and haplotypic structure analysis of the *UGT1A7* gene.**

The exon 1 of *UGT1A7* was amplified by PCR in 117 subjects, 54 Caucasians and 63 African-Americans, and then sequenced. Two novel polymorphisms were found at codon 115 and 139 (Figs. 6c; 6d). At codon 115, a nucleotide change of a G to an A leads to an amino acid change from Glycine to Serine (G<sup>115</sup>S). A G to C mutation at codon 139 leads to an amino acid change from Glutamate to Aspartate (E<sup>139</sup>D).

When combined with the previously described variations at codon 129/131 and 208, nine haplotypes were found to exist (*UGT1A7* \*1 to \*9, Table 4). Four alleles were previously described, \*1 to \*4, and novel alleles correspond to *UGT1A7*\*5 S<sup>115</sup>N<sup>129</sup>R<sup>131</sup>E<sup>139</sup>W<sup>208</sup> (Genbank AF434903), *UGT1A7*\*6 G<sup>115</sup>N<sup>129</sup>R<sup>131</sup>D<sup>139</sup>W<sup>208</sup> (Genbank AF434904), *UGT1A7*\*7 G<sup>115</sup>K<sup>129</sup>K<sup>131</sup>D<sup>139</sup>W<sup>208</sup> (Genbank AF461758), *UGT1A7*\*8 G<sup>115</sup>K<sup>129</sup>K<sup>131</sup>D<sup>139</sup>R<sup>208</sup> (Genbank AF436810) and *UGT1A7*\*9 S<sup>115</sup>K<sup>129</sup>K<sup>131</sup>E<sup>139</sup>W<sup>208</sup> (Genbank AF463483).

According to their prevalence in the population tested, the nine variant alleles were separated in two categories: the common and the rare alleles. The common alleles \*1, \*2 and \*3, are present at a allelic frequency of 0.31 to 0.32. The rare alleles are *UGT1A7*\*4 to \*9, with frequencies between 0.002 to 0.025. The allelic frequencies for the polymorphisms at codon 115 and 139 were 0.04 and 0.06, respectively and found specifically in African-American individuals.

- 30 -

TABLE 8

## Allelic frequency and prevalence of UGT1A7 alleles

UGT1A7 alleles		Function <sup>b</sup>	Frequency <sup>c</sup>
UGT1A7*1 <sup>a</sup>		High	32.18
UGT1A7*2	K <sup>129</sup> /K <sup>131</sup>	High	30.60
UGT1A7*3	K <sup>129</sup> /K <sup>131</sup> /R <sup>208</sup>	Low	31.55
UGT1A7*4	R <sup>208</sup>	Low	2.52
UGT1A7*5	S <sup>115</sup>	Low	0.47
UGT1A7*6	D <sup>139</sup>	High	0.16
UGT1A7*7	K <sup>129</sup> /K <sup>131</sup> /D <sup>139</sup>	High	2.06
UGT1A7*8	K <sup>129</sup> /K <sup>131</sup> /D <sup>139</sup> /R <sup>208</sup>	Low	0.16
UGT1A7*9	S <sup>115</sup> /K <sup>129</sup> /K <sup>131</sup>	Low	0.32

<sup>a</sup> UGT1A7\*1: G<sup>115</sup>/N<sup>129</sup>/R<sup>131</sup>/E<sup>139</sup>/W<sup>208</sup>; only position differing from \*1 are indicated

5 <sup>b</sup> Based on in vitro experiments: Low : significantly lower SN-38G formation versus \*1 allele.

High : no significant difference in activity compared to \*1 allele.

<sup>c</sup> Population of 167 Caucasian and 150 African-American subjects.

- 31 -

**TABLE 9**  
**Frequency of the UGT1A7 alleles**

UGT1A7 genotypes <sup>a</sup>	Population (n=317) <sup>b</sup>	Frequency (%)
<b>*1/*1</b>	30	9.46
<b>/ *2</b>	57	17.98
<b>*1/*3 *2/*4</b>	72	22.71
<b>*1/*4</b>	6	1.89
<b>*1/*6</b>	1	0.32
<b>*1/*7 *2/*6</b>	7	2.21
<b>*1/*8 *3/*6 *4/*7</b>	1	0.32
<b>*2/*2</b>	39	12.30
<b>*2/*3</b>	55	17.35
<b>*2/*7</b>	3	0.95
<b>*2/*8 *3/*7</b>	1	0.32
<b>*2/*9</b>	1	0.32
<b>*3/*3</b>	35	11.04
<b>*3/*7</b>	2	0.63
<b>*4/*4</b>	5	1.58
<b>*5/*5</b>	1	0.32
<b>*5/*9</b>	1	0.32
Low activity genotypes <sup>c</sup>	42	13.26
Intermediate activity genotypes <sup>d</sup>	138	43.54

<sup>a</sup> In bold: Genotypes considered to evaluate allelic frequencies.

<sup>b</sup> 167/317 Caucasian ; 150/317 African-American subjects.

<sup>c</sup> With two low activity alleles.

<sup>d</sup> With one low activity allele.

#### EXAMPLE IV

Relative expression of the UGT1A7 and UGT1A9 variants and SN-38  
glucuronidation activities of UGT1A7 and UGT1A9 allozymes

#### **MATERIAL AND METHODS**

##### **UGT1A7 and UGT1A9 expression studies**

All five novel UGT1A7 variant alleles were generated by PCR site-directed mutagenesis using pcDNA3-vector containing either UGT1A7\*1, \*2, \*3 or \*4 variant alleles as the starting construction. Primers having SEQ ID NO: 32, 33, 34 and 35 (Table 7) were used for site-directed mutagenesis. The variant



- 32 -

alleles \*5 (SEQ ID NO: 50) and \*6 (SEQ ID NO: 51) were generated using \*1 (SEQ ID NO: 46) as the template, the \*7 (SEQ ID NO: 52) and \*9 (SEQ ID NO: 54) variants were obtained using the \*2 (SEQ ID NO: 47) allele as template and the \*8 (SEQ ID NO: 53) was created from \*3 (SEQ ID NO: 48) allele.

5 Expression constructs for the UGT1A9 cDNA sequence construct and constructs for the two nonsynonymous cSNPs were created using the same strategy. The expression plasmid pcDNA3-UGT1A9\*1 was obtained by subcloning the *Bam*HI-*Xho*I fragment of pBK-CMV / UGT1A9\*1 (kindly provided by Dr Alain Belanger from CHUL Research Center, Laval University,

10 Québec, Canada) into the *Bam*HI-*Xho*I site of pcDNA3 expression vector. Mutations were all verified by sequencing. Stable HEK293 cells were transfected with variant pcDNA3-UGT1A7 and pcDNA3-UGT1A9 expression plasmids using the following procedure that has been described previously (Guillemette *et al.*, 2000, *Pharmacogenetics*, 10: 629-640). HEK293 cells in the

15 exponential growth phase were seeded at a density of  $3.25 \times 10^6$  cells/culture dish. Briefly, cells were grown in Dulbecco's-modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS), 1 % Sodium Pyruvate (NaPy) and 0.1 mg/mL Amikacin in a humidified incubator at 37°C with an atmosphere of 5 % CO<sub>2</sub>. The next day, cells at 60 % of confluence were washed with DMEM

20 without FBS. Then, cells were incubated with 5 mL of the same medium containing 30 µL Exgen 500™ (MBI fermentas, Burlington, ON, Canada) and 15 µg of the appropriate pcDNA3-UGT expression plasmids. Transfections were stopped after 3 hours by the addition of fresh DMEM with 10 % FBS. After 48 hours, geneticin (1 mg/mL) (Invitrogen life technologies, Carlsbad, CA) was

25 added to begin the selection process. During the following 4 weeks, fresh medium with antibiotic was added every 2 days until colonies of resistant cells became visible and for amplification of geneticin-resistant cell populations.

Microsomes were prepared by differential centrifugation. The crude cell extracts were centrifuged at 12 000 x g at 4°C for 22 min to remove nuclei and other

30 cellular debris. Supernatants were centrifuged at 105 000 x g for 60 min at 4°C to obtain the membrane fraction, which was homogenized in the buffer

- 33 -

described above. Protein concentrations were determined using the Bradford method according to the manufacturer's recommendations.

To determine the level of UGT proteins expressed in the microsomal fractions obtained from the stably transfected cells, Western blot analyses were conducted as follows. Microsomal proteins (10 µg) from HEK293 cells stably expressing human UGT1A9 and UGT1A7 variants were separated by 10 % SDS-polyacrylamide gel electrophoresis. The separated proteins were transferred onto nitrocellulose membranes and probed with the antihuman UGT1A antiserum RC71 (1:1000 dilution) specific for the conserved C-terminal region of the protein. In order to normalize sample loading, blots were re-probed with anti-calnexin antibody (1:2000 dilution; StressGen Biotechnologies Corp., Victoria, Canada), to detect a second ER-resident protein. A donkey antirabbit IgG antibody conjugated with the horseradish peroxidase (Amersham Corp., Oakville, Canada) was used as the secondary antibody (1:10 000 dilution). The resulting immunocomplexes were visualized using an enhanced chemiluminescence kit (ECL) (Renaissance, Quebec, Canada) and exposed on Kodak™ XB-1 film. The relative levels of UGT1A allozymes and calnexin were determined by integrated optical density (IOD) using Bioimage programs visage 110S (Genomic solution inc., Ann Arbor, MI, USA) and compared to the \*1  
20 respective UGT1A9 (SEQ ID NO: 36) and UGT1A7 (SEQ ID NO: 60) alleles.

Western blot analyses of UGT1A7 and UGT1A9 variants expressed in HEK293 cells were performed on microsomal proteins (10 µg) separated on a 10 % SDS-polyacrylamide gel. After transferring the proteins, the membranes were probed with an anti-UGT1A RC-71 polyclonal antibody and with an anti-calnexin  
25 antibody. The relative levels of UGT1A9 (a) and UGT1A7 proteins (b) were determined by semi-quantitative densitometric analysis of the Enhanced chemiluminescence (ECL) image. The *in vitro* SN-38 activity was assessed using microsomal fractions prepared from HEK293 cells expressing the \*1 and variant UGT1A9 (c) and UGT1A7 (d) alleles and incubated with 5 µM of SN-38  
30 as described in Materials and Methods.

## RESULTS

- 34 -

**Recombinant allozyme Western blot analysis.**

Semi-quantitative Western blot analyses (Figs. 14a and 14b) showed high levels of immunoreactive UGT protein in all membrane fractions from HEK293 cell lines stably expressing UGTs. An anti-calnexin polyclonal antibody was also  
5 used in combination as an internal reference. Significant expression of all UGT1A7 and UGT1A9 alleles was found adequate allowing enzymatic assays to be performed.

**EXAMPLE IV****10      Loss of function variants of the UGT1A7 and UGT1A9 enzymes****MATERIAL AND METHODS****Enzyme assays**

Recombinant allozymes were assayed for UGT activity with the two anticancer  
15 agents, SN-38 and flavopiridol, as substrates. Microsomal fractions from HEK293 (40 to 60 µg) were added to a reaction mixture (100 µL) containing 50 mM Tris-HCl, pH 7.3, 10 mM MgCl<sub>2</sub>, 100 µg/mL phosphatidylcholine and 2 mM UDP-glucuronic acid. SN-38 was added in concentrations ranging from 0.1 to 200 µM whereas flavopiridol was used at two concentrations: 5 and 200 µM.  
20 Commercially available human liver microsomes (Human Cell Culture Center Inc., Laurel, MD) were incubated in the same conditions for all experiments. Time-course experiments were performed to determine the linearity of the glucuronidation reaction. For the determination of  $V_{max}$  and  $K_m$ , HEK293 cells stably expressing UGT1A9 enzymes were incubated in the presence of various  
25 concentrations of SN-38 ranging from 0.1 to 200 µM and incubated for 30 min as described above whereas UGT1A7 membranes preparations were incubated for 3 hours. All reaction rates were shown to be linear in these conditions. Reactions with SN-38 were stopped by the addition of 200 µL MeOH + 1 % HCl 2N, followed by centrifugation at 14 000 x g for 10 minutes. The supernatants  
30 were filtered through a 0.22 µm membrane and 100 µL of water was added to the filtrate. For the detection of SN-38 and its glucuronide (SN-38G), 10 µL

- 35 -

samples were injected in a liquid chromatographic system (HPLC) coupled to fluorescence detector as described below.

A HPLC method was developed to quantify the rates of SN-38 glucuronidation from the various microsomal fractions under study. The HPLC system used was an Alliance 2695 (Waters, Milford, MA) equipped with a 50 x 3.2 mm Columbus C18 column (Phenomenex, Torrance, CA). The chromatographic separation was achieved with a two-solvent gradient system: solvent A (water + 1 mM ammonium formate); solvent B (MeOH + 1 mM ammonium formate). A linear gradient starting at 20 % solvent B was generated over a 3 min period and at a constant flow rate (0.7 mL/min) until a plateau was reached at 65% solvent B and held for 0.8 min. Then a second gradient ranging from 65% to 95% solvent B was generated during the following 2 min. Finally, the column was re-equilibrated to 20 % solvent B for 2 min. The column was connected to a fluorescence detector model 474 (Waters, Milford, MA) and the molecules were excited at a wavelength of 370 nm and an emission of 425 nm. The retention times for SN-38 and SN-38G were 4.49 and 3.12 min, respectively. Because we could not perform kinetic analysis with the UGT1A9\*3 using the previously used electrospray ion-trap mass spectrometry method, the fluorescence detection was preferred since it was more sensitive in these conditions and allowed the detection of SN-38G formed by UGT1A9\*3 microsomes at low concentrations of SN-38.  $K_m$  calculated for the human liver microsomes using both analytical methods were shown to be similar ( $6.8 \pm 3.0 \mu\text{M}$  with the LCQ detector and  $4.8 \pm 0.8 \mu\text{M}$  with the fluorescent detection (data not shown)). Glucuronidation assay using flavopiridol as substrate were performed as previously described (Ramirez *et al.*, 2002, *Pharm. Res.* 19: 588-594). Relative glucuronidation activities for flavopiridol (5 and 7 glucuronides) were determined for one hour using 5 and 200  $\mu\text{M}$  of substrate and in the same experimental conditions as used for SN-38.

- 36 -

## RESULTS

### Recombinant UGT1A7 and UGT1A9 enzyme SN-38 kinetics.

The functional genomic studies were focused on two anticancer drugs, SN-38 and Flavopiridol. UGT1A7 was previously shown to have the highest intrinsic clearance with SN-38 as substrate along with UGT1A1 and UGT1A9 (Gagne *et al.*, 2002, *Mol. Pharmacol.* 62:608-617) whereas UGT1A9 is the main UGT involved in the metabolism of flavopiridol (Ramirez *et al.*, 2002, *Pharm. Res.* 19: 588-594).

The chromatograms obtained after separation of the reaction products following enzymatic assays with 5  $\mu$ M of SN-38 and the UGT1A9 variant allozyme preparations are depicted in Fig. 15 a), b) and c) \*3. The formation of SN-38G by the UGT1A9\*3 enzyme is markedly reduced, with only 3.8 % residual activity compared to the *wild type* enzyme (Fig. 15c). Our results thus demonstrate that the M<sup>33</sup>T polymorphism dramatically impairs the conjugation rate of SN-38 whereas no significant effect was observed with the UGT1A9\*2 allozyme. In contrast, the formation of flavopiridol-G was not statistically different for UGT1A9\*2 and UGT1A9\*3 compared to the UGT1A9\*1 allele at both low and high concentrations (5  $\mu$ M and 200  $\mu$ M of flavopiridol), suggesting a substrate specific impact of this amino acid variation in the UGT1A9 protein.

To determine if the amino acid change at codon 33 affects enzyme activity by an alteration of kinetic properties, glucuronidating activity of UGT1A9 allozymes was assessed using a wide range of SN-38 concentrations (0.1 to 200  $\mu$ M). A non significant higher apparent  $K_m$  value for the UGT1A9\*2 variants was observed as determined at least in three independent experiments. Both UGT1A9\*1 and UGT1A9\*3 alleles demonstrated a similar apparent  $K_m$  of  $3.03 \pm 0.51$  and  $3.21 \pm 0.95$ , respectively (Table 9). As a result, decreases in level of enzyme activity observed for the UGT1A9\*3 allele could not be attributed to the alterations of substrate affinity. However  $V_{max}$  values were about 26 times lower for UGT1A9\*3 compared with UGT1A9\*1 ( $11.89 \pm 2.61$  versus  $316.34 \pm 52.03$  pmol/min/mg of protein,  $p < 0.002$ ).

- 37 -

In the analysis of UGT1A7 allozymes, the highest SN-38 glucuronidating activity was observed for UGT1A7\*1, \*2, \*6 and \*9. Three novel low activity alleles were identified and the \*5, \*7 and \*8 alleles presented 38-76% lower rates of SN-38G formation compared to UGT1A7\*1, similar to the range of activity of the \*3 and \*4 alleles previously identified as low SN-38 glucuronidating activity alleles (Gagne *et al.*, 2002, *Mol. Pharmacol.* 62:608-617).

**TABLE 10**  
**Kinetic parameters for SN-38 glucuronidation by human UGT1A9**  
**allozymes**

UGT1A9 allozymes	Apparent $K_m$ ( $\mu$ M)	$V_{max}$ (pmol/min/mg protein)	Catalytic efficiencies $V_{max}/K_m$ ( $\mu$ L/h/mg)
UGT1A9*1	3.02 $\pm$ 0.51	316.34 $\pm$ 52.03	105
UGT1A9*2	5.15 $\pm$ 1.81	324.38 $\pm$ 95.09	63
UGT1A9*3	3.21 $\pm$ 0.95	11.89 $\pm$ 2.61 *	4

The values of apparent  $K_m$  and  $V_{max}$  for the formation of SN-38 glucuronide were determined using microsomal preparations from UGT1A9-HEK293 cells. Values were expressed as the mean  $\pm$  SD of at least three independent experiments performed in duplicate from Lineweaver-Burk plots. \*  $p < 0.002$  compared to UGT1A9\*1.

#### **EXAMPLE V**

**Immunofluorescence localization of UGT1A9\*1, UGT1A9\*2 and UGT1A9\*3 proteins.**

#### **MATERIAL AND METHODS**

##### **Immunofluorescence visualization**

One cSNP found in the UGT1A9 first exon was located in the signal peptide, thus immunofluorescence experiments were designed to localize the expressed protein within the cells. Stable HEK293 cells expressing human UGT1A9\*1, UGT1A9\*2 and UGT1A9\*3 and also with cells transfected with pcDNA3 vector

- 38 -

alone were seeded on culture slides (VWR Scientific, West Chester, PA) and allowed to grow for 18 h. Then, cells were washed three times with PBS and fixed for 20 min with paraformaldehyde 2 % (w/v, Sigma, St. Louis, MO) in PBS. The slides were washed three times with PBS before permeabilization of the membranes for 40 min in PBS containing Saponin 0.2 % (w/v, Sigma, St. Louis, MO). After three washes with PBS, the cells were incubated for 30 min with gelatin 0.2 % in PBS (w/v, Sigma, St. Louis, MO). The permeabilized cells were incubated with a rabbit anti-UGT1A primary antibody (RC-71) at a 1:1000 dilution (v/v) in PBS containing Saponin 0.1 % and bovine serum albumin 1.5 %.

Slides were incubated for 1 h and then washed three times with PBS. A goat anti-rabbit secondary antibody (Alexa Fluor 488, Molecular Probes Inc., Eugene, OR) was added at a 1:400 dilution in the same buffer as the primary antibody, and slides were incubated for 30 min at room temperature in the dark. Cells were then washed three times with PBS. Cell counterstaining was achieved by incubating the slides for 30 sec in the dark at room temperature with a 1:1000 (v/v) dilution of diamidino-2-phenylindole (DAPI, Molecular Probes Inc., Eugene, OR). Finally, cells were washed with PBS and mounted with a mounting medium (Sigma, St. Louis, MO). For visualization, a Fluoview confocal microscope (BX-61, Olympus, Melville, NY) with a 100 X oil objective was used.

On Fig. 16, HEK293 cells stably expressing pcDNA3 (a) or human UGT1A9 alleles (d), (g), (j) were fixed, permeabilized and then treated with a rabbit anti-UGT1A primary antibody (RC-71), followed by a goat anti-rabbit secondary antibody. Cell counterstaining of the nuclei was performed using DAPI (b), (e), (h), (k). To confirm the localization of the UGT proteins, a combination of the images obtained with the antibodies and the counterstain are shown in (c), (f), (i), (l).

## RESULTS

To determine if the subcellular localization of UGT1A9 was affected by the codon 3 mutational polymorphism in the signal peptide region, immunofluorescence experiments were carried out. Coloration with diamidino-2-phenylindole (DAPI) was restricted to the nucleus (Figs. 16e, h and k) whereas the low background observed in the pcDNA3 control vector is due to

- 39 -

autofluorescence (Figs. 16a, b and c). UGT1A9\*1, UGT1A9\*2 and UGT1A9\*3 proteins were localized in the cytoplasm and the perinuclear zone as well as in the endoplasmic reticulum (Figs. 16d, g and j).

5

**EXAMPLE VI****Effect of UGT1A1 TATA box variations on UGT1A1 protein expression and glucuronidation activity**

Although a correlative association between TATA box polymorphic variation is reported in prior art, the UGT1A7 and UGT1A9 interindividual variations of the present invention remained unknown at this time and their effect on SN-38 glucuronidation therefore remained unconsidered. In an attempt to decipher the particular function of every participating isoform in SN-38-G formation, we were interested to determine whether or not a correlative association could be made between the number of TA repeat in the TATA box of UGT1A1 promoter region and UGT1A1 protein expression even though novel polymorphic variations were taken into account. As shown in Fig. 17, the presence of TA<sub>6</sub> genotype on both alleles is associated with a higher protein expression while the presence of a TA<sub>7</sub> repeat on only one allele is sufficient to decrease UGT1A1 protein expression. The lowest protein expression level is observed with TA<sub>7</sub> homozygous patients. As shown in Figs. 17b and 17c, the correlative association is also observed between glucuronidation of the probe substrate estradiol and the number of TA repeats. A similar correlative association is found with SN-38.

As UGT1A1 is considered as a major SN-38 glucuronidation enzyme, we attempted to determine if an association between the expression of this protein and glucuronide formation could exist. As shown in Fig. 18a, there is a positive correlations between glucuronidation of SN-38 and protein level of UGT1A1. To ascertain that the enhancement of glucuronidation observed with this substrate is not attributable to a residual activity of other UGT isoforms, this experiment was reconducted using probe substrates for UGT1A1, namely estradiol,. As seen in fig. 18b a positive correlation exists between UGT1A1 protein level and estradiol-3-G formation. Since estradiol is an endogenously produced



- 40 -

compound and formation of estradiol-3-G is exclusively mediated by UGT1A1, these results demonstrate that a biochemical analysis of serum estradiol-3-G could be properly used to monitor a higher or lower UGT1A1 expression in a patient and therefore, be used as an indicator for determining a predisposition to a physiological reaction to a xenobiotic or an endogenous compound. Finally, Fig. 19 shows the predictive value of the haplotype determination of UGT1A9 and UGT1A1. This haplotype determination includes the genotyping of the *UGT1A9* promoter region and the determination of the number of TA repeats in the TATA box of the *UGT1A1* promoter, which is a more accurate indicator of SN-38 glucuronidation level than the determination of the TA repeats in the TATA box of the *UGT1A1* promoter alone.

#### **EXAMPLE VI**

##### **Haplotyping the UGT1A genes**

###### **Statistical analysis**

Results were expressed as mean  $\pm$  standard deviation (SD). Differences in kinetic parameters between *UGT* allelic variants were evaluated for statistical significance by paired Student's *t* test. All tests were two-sided. The haplotype frequencies will be estimated using the PHASE 1.0.1 software and Hardy-Weinberg equilibrium and linkage disequilibrium analyses will be performed using ARLEQUIN 2.0™ software.

###### **RESULTS**

**Analysis of the haplotypic structure of the *UGT1* gene in subjects with *UGT1A9\*1* or *UGT1A9\*3* alleles.**

Haplotypes of the *UGT1A* gene were analyzed in subjects with the *UGT1A9\*1/\*3* low SN-38 glucuronidation activity genotype.

- 41 -

TABLE 11

## UGT1A9 promoter haplotype analysis

Haplotype number	-2208	-2152	-2141	-1887	-1818	-843	-440	-331	-275	-27	UGT1A1 exon 1 codon 23	TATA box	UGT1A7 exon 208	Haplotype frequency	% of the population
1	G	C	G	T	T	G	T	C	T	G	T			179	31,34
2	G	G	G	T	T	G	T	G	T	A				3	0,53
3	G	G	G	T	T	G	T	G	T	G	T			126	22,79
4	G	C	G	T	T	G	T	C	T	G	T			18	2,87
5	C	G	C	T	T	G	T	C	T	G	T			81	10,85
6	C	G	C	G	T	C	T	C	T	G	T			83	14,77
7	C	G	C	G	T	G	T	C	T	G	T			3	0,53
8	C	G	C	T	T	G	T	C	T	G	T			68	11,74
9	T	C	G	T	T	G	T	C	T	G	T			1	0,16
10	C	G	T	T	T	G	T	C	T	G	T			1	0,16
11	C	T	C	T	T	G	T	C	T	G	T			6	0,89
12	G	C	T	G	T	C	T	C	T	G	T			7	1,25
13	C	C	G	G	T	C	T	C	T	G	T			1	0,16
14	C	C	C	T	G	C	T	C	T	G	T			1	0,16
15	C	C	T	G	T	G	T	C	T	G	T			1	0,16
16	C	C	T	G	T	T	C	T	G	T	G	T		1	0,16
17	C	C	C	T	T	G	T	C	T	G	T			1	0,16
18	C	T	C	T	T	C	T	C	T	G	T			6	1,07
19	C	C	C	T	T	C	T	C	T	G	T			1	0,16
20	G	C	C	T	G	C	T	C	T	G	T			1	0,16
21	C	C	C	T	G	T	C	T	G	T	G	T		1	0,16

5

TABLE 12

## UGT1A9 and UGT1A1 promoters haplotype analysis

Haplotype number	-2208	-2152	-2141	-1887	-1818	-843	-440	-331	-275	-27	UGT1A1 exon 1 codon 23	TATA box	UGT1A7 exon 208	Haplotype frequency	% of the population
22	G	C	G	T	T	G	T	C	T	G	T			13	12,04
23	G	G	G	T	T	G	T	G	T	G	T			1	0,93
24	C	G	G	T	T	G	T	G	T	G	T			23	21,20
25	C	C	C	T	T	G	T	C	T	G	T			13	12,04
26	C	G	C	G	T	C	T	C	T	G	T			10	9,20
27	C	G	C	T	T	C	T	C	T	G	T			3	2,78
28	C	C	C	G	T	T	C	T	G	T	G	T		1	0,93
29	C	C	C	T	T	C	T	C	T	G	T			2	1,85
30	C	C	C	T	G	C	T	C	T	G	T			13	12,04
31	T	C	C	T	T	G	T	C	T	G	T			1	0,93
32	G	C	T	T	T	G	T	C	T	G	T			1	0,93
33	G	C	T	T	T	G	T	C	T	G	T			1	0,93
34	G	T	C	T	T	T	C	T	G	T	G	T		1	0,93
35	C	T	C	T	T	T	C	T	G	T	G	T		4	3,70
36	C	C	C	T	T	C	T	C	T	G	T			2	1,85
37	C	C	C	T	T	C	T	C	T	A				3	2,78
38	G	C	C	G	T	T	C	T	G	T	G	T		1	0,93
39	C	G	G	T	T	G	T	C	T	G	T			1	0,93
40	C	C	C	G	T	T	C	T	G	T	G	T		1	0,93
41	C	C	C	T	G	C	T	C	T	G	T			3	2,78
42	C	C	C	T	T	C	T	C	T	G	T			1	0,93
43	C	C	C	T	T	C	T	C	T	G	T			1	0,93
44	C	T	C	T	T	C	T	C	T	G	T			6	5,58

10

- 42 -

TABLE 13

UGT1A9, UGT1A1 and UGT1A7 haplotype analysis.

Haplotype number	-2208	-2152	-2141	-1887	-665	-440	-331	-275	-57	1A9 exon 1 codon 83	UGT1A1 TATA box	UGT1A7 codon 208	Haplotype frequency	% of the population
45	T	T	C	T	C	T	C	T	T	T	T	C	138	30,63
46	T	T	C	C	T	T	C	T	T	T	T	T	63	20,58
47	G	T	C	C	T	T	C	T	T	T	T	T	72	16,93
48	T	C	C	C	T	T	C	T	T	T	T	T	61	14,28
49	T	C	T	G	T	T	C	T	T	T	T	T	45	9,88
50	T	T	C	C	T	T	C	T	T	T	T	T	21	4,85
61	T	C	C	C	T	T	C	T	T	T	T	T	7	1,68
52	T	T	C	T	C	T	C	T	T	T	T	T	8	1,33
53	T	T	C	C	T	T	C	T	T	T	T	T	6	1,33
54	T	T	C	C	T	T	C	T	T	T	T	T	3	0,68
55	T	T	C	T	C	T	C	T	T	T	T	T	2	0,44
56	T	C	C	C	T	T	C	T	T	T	T	T	1	0,22
57	G	T	C	T	T	T	C	T	T	T	T	T	1	0,22
58	T	C	T	C	T	T	C	T	T	T	T	T	1	0,22
59	G	T	C	C	T	T	C	T	T	T	T	T	1	0,22
60	T	C	C	T	C	T	C	T	T	T	T	T	3	0,68
61	T	C	C	C	T	T	C	T	T	T	T	T	1	0,22
62	T	C	C	C	T	T	C	T	T	T	T	T	1	0,22

5

TABLE 14

Allele Frequencies

	-2208		-2152		-2141		-1887	
	Allele or genotype	Frequency	Allele or genotype	Frequency	Allele or genotype	Frequency	Allele or genotype	Frequency
		Am		Am		Am		Am
Homo. WT	C	0,99	C	0,95	C	0,99	T	0,85
	T	0,01	T	0,05	T	0,01	G	0,15
	CC	0,98	CC	0,90	CC	0,98	TT	0,75
Heterozygous	CT	0,02	CT	0,10	CT	0,02	TG	0,21
Homo. var.	TT	0,00	TT	0,00	TT	0,00	GG	0,04
		N=48		N=48		N=48		N=48

	-1818		-665		-440		-331		-275	
	Allele or genotype	Frequency	Allele or genotype	Frequency	Allele or genotype	Frequency	Allele or genotype	Frequency	Allele or genotype	Frequency
		Am		Am		Am		Am		Am
	T	0,71	C	0,58	T	0,30	C	0,30	T	0,92
	C	0,29	T	0,42	C	0,70	T	0,70	A	0,08
	TT	0,50	CC	0,23	TT	0,15	CC	0,15	TT	0,85
	TC	0,42	CT	0,71	TC	0,31	CT	0,31	TA	0,15
	CC	0,08	TT	0,08	CC	0,54	TT	0,54	AA	0,00
		N=48		N=48		N=48		N=48		N=46

10

- 43 -

TABLE 15

Functional UGT1A1, UGT1A7 and UGT1A9 SNPs frequency in the French-Canadian population.

	UGT1A9 Codon 33		UGT1A7 Codon 208		UGT1A1 TATA box	
Wild-type allele	T	0,98	T	0,62	6	0,67
Mutant allele	C	0,02	C	0,38	7	0,33

5

**EXAMPLE VII**

Multiple protein sequence alignment of UGT1A proteins at selected positions

10

UGT1A7\*1, UGT1A9\*1 and their genetic variant proteins UGT1A7 (a) and UGT1A9 (b) are aligned with close members of the UGT1A subfamily and the rat UGT1A7 Isoenzyme. The varying amino acid positions are indicated with bold characters.

15

**DISCUSSION**

After resequencing the first exons of *UGT1A7* and *UGT1A9* genes, 4 polymorphic sites in the targeted regions were identified. Two polymorphic UGT1A9 variants were discovered, UGT1A9\*2 C<sup>3</sup>Y and UGT1A9\*3 M<sup>33</sup>T. In addition, the presence of two novel nonsynonymous UGT1A7 SNPs, G<sup>115</sup>S and E<sup>139</sup>D, combined with previously described missense polymorphisms at codons 129/131 and 208, generated five additional UGT1A7 alleles (\*5 through \*9). Based on the *in vitro* functional genomic assays, the UGT1A7\*3, \*4, \*5, \*8 and \*9 alleles and the UGT1A9\*3 allele were all identified as low SN-38 glucuronidating alleles. Results demonstrate that the coinheritance of UGT1A1, UGT1A7 variants and especially the loss of function UGT1A9 polymorphism determine individual's susceptibility to irinotecan-induced toxicity. Thus, findings lay emphasis on the necessity to analyze combination of UGT1A1, UGT1A7 and UGT1A9 polymorphisms (haplotypes) rather than looking for a single

30

- 44 -

polymorphism present in the *UGT1A1* gene to predict patients at higher risk of developing irinotecan-induced toxicity in a clinical setting.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further  
5 modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as  
10 follows in the scope of the appended claims.

**CLAIMS:**

1. A method for determining predisposition to a physiological reaction of an individual to a biologically active compound comprising characterizing nucleotide sequence of at least one of the *UGT1A1*, *UGT1A7* or *UGT1A9* gene or a part thereof of said individual, wherein the presence of at least one polymorphic or haplotypic variation in said nucleotide sequence is indicative of said predisposition to a physiological reaction.
2. The method of claim 1, wherein said predisposition is a hereditary predisposition.
3. The method of claim 1, wherein said predisposition is a higher or lower susceptibility, sensibility, diathesis, proneness, proclivity, tendency, sensitivity, responsiveness, resistance or constitutional sickness to said physiological reaction.
4. The method of claim 1, wherein said physiological reaction is a beneficial reaction.
5. The method of claim 1, wherein said physiological reaction is an adverse reaction or a side effect.
6. The method of claim 1, wherein said biologically active compound is a xenobiotic.
7. The method of claim 6, wherein said xenobiotic is a drug, a carcinogen or a pre-carcinogen.
8. The method of claim 7, wherein said drug is an anti-cancer agent or an immunosuppressive agent.
9. The method of claim 8, wherein said anti-cancer agent is a camptothecin or an analog thereof.

- 46 -

10. The method of claim 9, wherein said camptothecin analog is 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin (irinotecan, CPT-11), 7-ethyl-10-hydroxycamptothecin (SN-38).
11. The method of claim 8, wherein said immunosuppressive agent is mycophenolic acid (MPA).
12. The method of claim 1, wherein said individual is a human or an animal.
13. The method of claim 1, wherein said individual is a patient with cancer.
14. The method of claim 13, wherein said patient has a colorectal cancer or a solid tumor.
15. The method of claim 1, wherein determining genetic sequence is performed on a DNA or a RNA sample.
16. The method of claim 1, wherein said polymorphic or haplotypic variation is a UGT1A9 variation.
17. The method of claim 16, wherein said UGT1A9 variation is at least one of a C<sup>-2208</sup>T substitution, a C<sup>-2152</sup>T substitution, a C<sup>-2141</sup>T substitution, a T<sup>1887</sup>G substitution, a T<sup>-1818</sup>C substitution, a C<sup>-665</sup>T substitution, a T<sup>-440</sup>C substitution, a C<sup>-331</sup>T substitution, a T<sup>-276</sup>A substitution, a G<sup>-87</sup>A substitution, a G<sup>8</sup>A missence mutation (C<sup>3</sup>Y), a T<sup>98</sup>C missence mutation (M<sup>33</sup>T) or combination thereof.
18. The method of claim 17; wherein said G<sup>8</sup>A missence mutation is associated with a decreased predisposition or susceptibility to an anti-cancer agent.
19. The method of claim 17, wherein said G<sup>8</sup>A missence mutation is associated with a decreased responsiveness to an immunosuppressive agent.

- 47 -

20. The method of claim 17, wherein said T<sup>98</sup>C missense mutation is associated with an increased adverse reaction to an anti-cancer agent.

21. The method of claim 1, wherein said polymorphic or haplotypic variation is a UGT1A7 variation.

22. The method of claim 21, wherein said UGT1A7 variation is a G<sup>353</sup>T missense mutation, a T<sup>397</sup>G missense mutation, a C<sup>401</sup>A missense mutation, a G<sup>402</sup>A missense mutations, a G<sup>427</sup>C missense mutation, a T<sup>632</sup>C missense mutation or combination thereof.

23. The method of claim 1, wherein said polymorphic or haplotypic variation is a UGT1A1 variation.

24. The method of claim 23, wherein said UGT1A1 variation is a TA<sub>7</sub> mutation in the TATA box.

25. An isolated nucleotide sequence comprising at least one nucleotide sequence selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, a fragment or the complementary sequences thereof, for determining predisposition to a physiological reaction.

26. The nucleotide sequence of claim 25, wherein said sequence is an allelic variant of UGT1A1, UGT1A7 or UGT1A9.



- 48 -

27. An isolated amino acid sequence comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71 or a fragment thereof.
28. The amino acid sequence of claim 27, wherein said sequence is encoded by a nucleotide sequence comprising at least one sequence selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, a fragment or the complementary sequences thereof.
29. The amino acid sequence of claim 27, wherein the expression of said sequence is regulated by a nucleotide sequence comprising at least one sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, a fragment or the complementary sequences thereof.




Fig. 1




Fig. 2




Fig. 3

4/28




Fig. 4

5/28




Fig. 5

6/28




Fig. 6

7/28





Fig. 7



8/28

**Oneway Analysis of UGT1A9 protein expression By promoter variant****-2152 non-carrier: (0)****-2152 carrier: (1)**

t-Test

Estimate  
Analysis of Variance  
Source  
-2152

Difference  
-3511.44

DF  
1

Sum of Squares  
55229128

t-Test  
-3.805

DF  
46

Mean Square  
55229128

Prob > |t|  
0.0004

F Ratio  
14.4795


Prob > F  
0.0004

Fig. 8a

9/28

**Oneway Analysis of UGT1A9 protein expression By -665 promoter variant**

-665 non carrier: (0)  
-665 heterozygous: (1)  
-665 homozygous: (2)



Analysis of Variance  
Source  
-665

DF  
2

Sum of Squares  
0.2354303

Mean Square  
0.117715

F Ratio  
3.6937


Prob > F  
0.0331

Fig. 8b

10/28

Oneway Analysis of UGT1A9 protein expression By -440 promoter variant

-440 non carrier: (0)  
-440 heterozygous: (1)  
-440 homozygous: (2)



Analysts of Variance	DF	Sum of Squares	Mean Square	F Ratio	Prob > F
Source					
-440	2	1.0529458	0.526473	5.8967	0.0053

Fig. 8c

11/28

-2152 carriers: (1)  
-2152 non carriers: (O)




Fig. 9

12/28

- 1818 non carriers: (0)
- 1818 heterozygous: (1)
- 1818 homozygous: (2)




Fig. 10

13/28



**SN-38-Glucuronide formation****-665 carriers: (1)****-665 non carriers: (0)**

Fig. 11a

14/28

**4OHEstrone-Glucuronide formation****-665 carriers: (1)****-665 non carriers: (0)****Analysis of Variance**

Source  
Porteur vs non porteur de mut -665  
Error  
C. Total

DF  
1  
46  
47

Sum of Squares  
822,270  
10888,756  
11711,026

Mean Square  
822,270  
236,712

F Ratio  
3,4737

Prob > F  
0,0687


**Fig. 11b**

15/28

## MPA-glucuronide formation

-665 carriers: (1)

-665 non carriers: (0)



Analysis of Variance  
Source  
Porteur vs non porteur de mut -665  
Error  
C. Total

DF	Sum of Squares	Mean Square
1	0,0800407	0,080041
46	1,2828249	0,027890
47	1,3628656	


F Ratio	Prob > F
2,8689	0,0870

Fig. 11c



16/28

-275 carriers: (1)  
-275 non carriers: (0)




Analysis of Variance					
Source	DF	Sum of Squares	Mean Square	F Ratio	Prob > F
-275	1	0,1011341	0,101134	3,6868	0,0611
Error	46	1,2818314	0,027431		
C. Total	47	1,3829656			

Fig. 12

17/28

SN-38 G formation (nmoles/mg/min) By UGT1A1 protein level


**Parameter Estimates**

Term	Estimate	Std Error	t Ratio	Prob> t
Intercept	-1,153565	0,071888	-16,05	<.0001
Racine raw data Ac518 relative to lowes	0,2128557	0,017751	11,99	<.0001

Fig. 13a

18/28

SN-38 G formation (nmoles/mg/min) By UGT1A9 protein level (relative to the lowest)

**Parameter Estimates**

Term	Estimate	Std Error	t Ratio	Prob> t
Intercept	-0,853447	0,117342	-7,27	<.0001
AC#520 Raw data relative to lowest	0,0614746	0,013224	4,65	<.0001

Fig. 13b

19/28




Fig. 14

20/28




Fig. 15

21/28




Fig. 16

22/28




Fig. 17a

23/28




Fig. 17b



24/28




Fig. 17c

25/28




Fig. 18a

26/28




Fig. 18b

27/28




Fig. 19

28/28

a)		115	129 131	139	208
	UGT1A7	LLTSSSN	GIFDLFFSNCRSLFND	RKLVEYLKESCFDAVF	MTFKERVVNHIMHLE
	UGT1A7V	LLTSSSN	SIIDLFFSNCRSLFKDKKLVEYLKDSCFDAVF	MTFKERVVNHIMHLE	
	UGT1A8	LFLSSSN	GFFNLFFSHCRSLFND	RKLVEYLKESCFDAVF	MTFKERVVNHIMHLE
	UGT1A9	LLMGSYND	IFDLFFSNCRSLFKDKKLVEYLKESCFDAVF	MTFKERVVNHIMHLE	
	UGT1A10	LLMSSSS	SGFLDLFFSHCRSLFND	RKLVEYLKESCFDAVF	MTFKERVVNHIVHLE
	UGT1A7Rat	LLTSPAQ	GFFELLFSHCRSLFKDKKLVEYLKQSSCFDAVF	MTFKERVVNLISYMG	
b)		3	33		
	UGT1A9	MACTGW	VVPMDGS		
	UGT1A9V	MAYTGW	VVPTDGS		
	UGT1A1	MAVESQ	LIPVDGS		
	UGT1A3	MATGLQ	LVPIDGS		
	UGT1A4	MARGLQ	LVPTDGS		
	UGT1A5	MATGLQ	LVPTDGS		
	UGT1A6	MACLLR	LVPQDGS		
	UGT1A7	MARAGW	LVPMDGS		
	UGT1A8	MARTGW	LVPMDGS		
	UGT1A10	MARAGW	LVPMDGS		

Fig. 20

## SEQUENCE LISTING

<110> UNIVERSITE LAVAL  
Guillemette, Chantal

<120> Method for determining predisposition to  
a physiological reaction in a patient

<130> 6013-118PCT

<150> 60/412,002

<151> 2002-09-20

<160> 71

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 17

<212> DNA

<213> Homo sapiens

<220>

<221> primer\_bind

<222> (1)...(17)

<223> UGT1A9 #37 (Forward)

<400> 1

gtgctggtat ttctccc

17

<210> 2

<211> 24

<212> DNA

<213> Homo sapiens

<220>

<221> primer\_bind

<222> (1)...(24)

<223> UGT1A9 #38 (Reverse)

<400> 2

gtcaaaaatg tcattgtatg aacc

24

<210> 3

<211> 20

<212> DNA

<213> Homo sapiens

<220>

<221> primer\_bind

<222> (1)...(20)

<223> UGT1A9 #39 (Forward)

<400> 3

gatctggacc gggagttcaa

20

2/40

<210> 4  
<211> 22  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(22)  
<223> UGT1A9 #40 (Reverse)

<400> 4  
gtgtggctgt agagatcata ct

22

<210> 5  
<211> 25  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(25)  
<223> UGT1A9 #41 (Forward)

<400> 5  
catgcacttg gaggaacatt tatta

25

<210> 6  
<211> 18  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(18)  
<223> UGT1A9 #42 (Reverse)

<400> 6  
gagtacacgc attggcac

18

<210> 7  
<211> 18  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(18)  
<223> UGT1A7 #18 (Forward)

<400> 7  
cgctggacgg caccattg

18

<210> 8  
<211> 22  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(22)  
<223> UGT1A7 #17 (Reverse)

<400> 8  
gctaaagggg agataactta cc

22

<210> 9  
<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(17)  
<223> UGT1A7 #122 (Forward)

<400> 9  
gctggacggc accattg

17

<210> 10  
<211> 19  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(19)  
<223> UGT1A7 #123 (Reverse)

<400> 10  
ccctaagaga agtctgggg

19

<210> 11  
<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(17)  
<223> UGT1A9 #7 (Forward)

<400> 11  
ctccaccta ctgtatc

17

<210> 12  
<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(17)  
<223> UGT1A9 #8 (Forward)



4/40

<400> 12  
gttcaaggct tttgcc  
17

<210> 13  
<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(17)  
<223> UGT1A9 #9 (Forward)

<400> 13  
catattattat gccaccg  
17

<210> 14  
<211> 16  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(16)  
<223> ASO UGT1A9 C3 (Forward)

<400> 14  
atggcttgca cagggt  
16

<210> 15  
<211> 16  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(16)  
<223> ASO UGT1A9 Y3 (Forward)

<400> 15  
atggcttaca cagggt  
16

<210> 16  
<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(17)  
<223> ASO UGT1A9 M33 (Forward)

<400> 16  
agtgcccatg gatggga  
17

<210> 17

5/40

<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(19)  
<223> ASO UGT1A9 T33 (Forward)

<400> 17  
agtgccacg gatggga

17

<210> 18  
<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(17)  
<223> ASO UGT1A7 G115 (Forward)

<400> 18  
catccaatgg tatTTTT

17

<210> 19  
<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(17)  
<223> ASO UGT1A7 S115 (Forward)

<400> 19  
catccaatag tatTTTT

17

<210> 20  
<211> 19  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(19)  
<223> Tagman UGT1A7 codon 139/131 #387 (Forward)

<400> 20  
gcaccattgc gaagtgc

19

<210> 21  
<211> 22  
<212> DNA  
<213> Homo sapiens

<220>

6/40

<221> primer\_bind  
<222> (1)...(22)  
<223> Taqman UGT1A7 codon 139/131 #388 (Reverse)

<400> 21  
ggatcgagaa acactgcatc aa 22

<210> 22  
<211> 16  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(16)  
<223> Taqman UGT1A7 codon 139/131 K129/K131-FAM  
(Forward)

<400> 22  
ttaatgaccg aaaatt 16

<210> 23  
<211> 17  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(17)  
<223> Taqman UGT1A7 codon 139/131 K129/K131-TET  
(Forward)

<400> 23  
tttaaggaca aaaaatt 17

<210> 24  
<211> 26  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(26)  
<223> Taqman UGT1A7 codon 139 #546 (Forward)

<400> 24  
gcgaagtgc ttttctctat taacaa 26

<210> 25  
<211> 20  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(20)  
<223> Taqman UGT1A7 codon 139 #544 (Reverse)

7/40

<400> 25  
aagccacagc gatcaaaagg 20

<210> 26  
<211> 21  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(21)  
<223> Taqman UGT1A7 codon 139 E139-Fam (Forward)

<400> 26  
atacttaaag gagagttggt t 21

<210> 27  
<211> 21  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(21)  
<223> Taqman UGT1A7 codon 139 D139-Vic (Forward)

<400> 27  
atacttaaag gacagttggt t 21

<210> 28  
<211> 31  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(31)  
<223> Forward C3Y UGT1A9

<400> 28  
gttctctgat ggcttacaca gggtaggacca g 31

<210> 29  
<211> 31  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(31)  
<223> Reverse C3Y UGT1A9

<400> 29  
ctgggtccacc ctgtgtaagc catcagagaa c 31

<210> 30

8/40

<211> 34  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(34)  
<223> Forward M33T UGT1A9

<400> 30  
gctactggta gtgcccacgg atgggagcca ctgg

34

<210> 31  
<211> 34  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(34)  
<223> Reverse M33T UGT1A9

<400> 31  
ccagtggctc ccatccgtgg gcactaccag tagc

34

<210> 32  
<211> 45  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(45)  
<223> Forward E139D UGT1A7

<400> 32  
aattagtaga atacttaaag gacagttggt ttgatgcagt gtttc

45

<210> 33  
<211> 45  
<212> DNA  
<213> Homo sapiens

<220>  
<221> primer\_bind  
<222> (1)...(45)  
<223> Reverse E139D UGT1A7

<400> 33  
gaaacactgc atcaaaacaa ctgtccttta agtattctac taatt

45

<210> 34  
<211> 23  
<212> DNA  
<213> Homo sapiens

<220>

9/40

<221> primer\_bind  
 <222> (1)...(23)  
 <223> Forward G115S UGT1A7

<400> 34  
 gttcatccaa tagtattttt gac

23

<210> 35  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> primer\_bind  
 <222> (1)...(23)  
 <223> Reverse G115S UGT1A7

<400> 35  
 gtcaaaaata ctattggatg aac

23

<210> 36  
 <211> 2585  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> (1)...(2585)  
 <223> UGT1A9\*1

<400> 36  
 atggccttgca cagggtggac cagccccctt cctctatgtg tgtgtctgct gctgacctgt 60  
 ggctttgccc aggcagggaa gctactggta gtgcccattg atgggagcca ctgggtcacc 120  
 atgaggtcgg tgggtggagaa actcattctc agggggcatg aggtggttgt agtcatgcca 180  
 gaggtgagtt ggcaactggg aagatcactg aattgcacag tgaagactta ttcaacttca 240  
 tataccctgg aggatctgga ccgggagttc aaggcttttg cccatgctca atggaaagca 300  
 caagtacgaa gtatatatto tctattaatg ggttcataca atgacatttt tgacttattt 360  
 ttttcaaatt gcaggagttt gtttaaagac aaaaaattag tagaatactt aaaggagagt 420  
 tcttttgatg cagtgtttct cgatcctttt gataactgtg gcttaattgt tgccaaatat 480  
 ttctccctcc cctccgtggt cttcgccagg ggaatacttt gccactatct tgaagaaggt 540  
 gcacagtgcc ctgctcctct ttctatgtc cccagaatto tcttagggtt ctccagatgcc 600  
 atgactttca aggagagagt acggaaccac atcatgcaat tggaggaaca tttattatgc 660  
 caccgttttt tcaaaaatgc cctagaaata gcctctgaaa ttctccaaac acctgttacg 720  
 gagtatgato tctacagcca cacatcaatt tgggtgttgc gaacggactt tgttttggac 780  
 tatcccaaac ccgtgatgcc caacatgatc ttcatgtgtg gtatcaactg ccatcagggg 840  
 aagccgttgc ctatggaatt tgaagcctac attaatgott ctggagaaca tggaattgtg 900  
 gttttctctt tgggatcaat ggtctcagaa attccagaga agaaagctat ggcaattgct 960  
 gatgcttttg gcaaaatccc tcagacagtc ctgtggcggt acactggaac ccgaccatcg 1020  
 aatcttgoga acaacacgat acttggttaag tggctacccc aaaacgatct gcttggtcac 1080  
 ccgatgaccc gtgcctttat caccatgctt ggttcccatg gtgtttatga aagcatatgc 1140  
 aatggcgctt ccattggtgat gatgcccttg tttggtgatc agatggacaa tgcaaagcgc 1200  
 atggagacta agggagctgg agtgaccctg aatgttctgg aaatgacttc tgaagattta 1260  
 gaaaatgctc taaaagcagt catcaatgac aaaagtatac aggagaacat catgcgcctc 1320  
 tccagccttc acaaggaccg ccgggtggag ccgctggacc tggcctgtgt ctgggtggag 1380  
 tttgtgatga ggcacaaggg cgcgcacac ctgcgcctcg cagccacga cctcacctgg 1440  
 taccagtacc attccttggc cgtgattggt ttccctcttg ccgtcgtgct gacagtggcc 1500  
 ttcatcacct ttaaatgttg tgcttatggc taccggaaat gcttggggaa aaaagggcga 1560

10/40

```

gttaagaaag cccacaaatc caagacccat tgagaagtgg gtgggaaata aggtaaaatt 1620
ttgaaccatt ccctagtcac ttccaaactt gaaaacagaa tcagtgttaa attcatttta 1680
ttcttattaa ggaaatactt tgcataaatt aatcagcccc agagtgtctt aaaaaattct 1740
cttaataaaa aataatagac tcgctagtca gtaaagatat ttgaatatgt atcgtgcccc 1800
ctctgggtgc tttgatcagg atgacatgtg ccatttttca gaggacgtgc agacaggctg 1860
gcattctaga ttacttttct tactctgaaa catggcctgt ttgggagtgc gggattcaaa 1920
gggtgtccca cggctgcccc tactgcaaat ggcagtttta atcttatctt ttggcttctg 1980
cagatgggtg caattgatcc ttaaccaata atggtcagtc ctcactctcg tegtgttca 2040
taggtgccac cttgtgtgtt taaagaaggg aagctttgta ccttttagagt gtagggtgaa 2100
tgaatgaatg gcttggagtg cactgagaac agcatatgat ttcttgcttt ggggaaaaag 2160
aatgatgcta tgaaattggt ggggtggtgta tttgagaaga taatcattgc ttatgtcaaa 2220
tggagctgaa tttgataaaa acccaaaata cagctatgaa gtgctgggca agtttacttt 2280
ttttctgatg tttctacaa ctaaaaataa attaataaat ttatataaat tctatttaag 2340
tgttttctac ggtgtcgcac ttatttcttg ttaagtgtca ttttctaatt acaaaagtaa 2400
tgcattgatta tgacagaaag tttggaaaat atagaggttc acacacacac gccttcattg 2460
cgtgtgcacg cataaatgca tgagaaaaga aaaataacca gtaatcacat cggccagaaa 2520
taacccagct tacaattgtg gcaaatcac atacttataa atattgcaga tatattaagt 2580
atacc 2585

```

<210> 37  
 <211> 2585  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> (1)...(2585)  
 <223> UGT1A9\*2

```

<400> 37
atggcttaaca cagggtggac cagccccctt cctctatgtg tgtgtctgct gctgacctgt 60
ggctttgccg aggcagggaa gctactggta gtgccatgg atgggagcca ctggttcacc 120
atgaggtcgg tggtggagaa actcattctc agggggcatg aggtggttgt agtcatgcca 180
gaggtgagtt ggcaactggg aagatcactg aattgcacag tgaagaotta ttcaacttca 240
tataccctgg aggatctgga cggggagtgc aaggettttg cccatgctca atggaaagca 300
caagtacgaa gtatatattc tctattaatg ggttccatca atgacatttt tgacttattt 360
ttttcaaatt gcaggagtgt gtttaagac aaaaaattag tagaatactt aaaggagagt 420
tcttttgatg cagtgtttct cgatcctttt gataactgtg gcttaattgt tgccaaatat 480
ttctccctcc cctccgtggt cttcgccagg ggaatacttt gccactatct tgaagaaggt 540
gcacagtgcc ctgctcctct ttctatgtc ccagaatto tcttaggggt ctcagatgcc 600
atgactttca aggagagagt acggaaccac atcatgcaat tggaggaaca tttattatgc 660
cacggttttt tcaaaaatgc cctagaaaata gctctgaaa ttctccaaac acctgttacg 720
gagtatgac tctacagcca cacatcaatt tggttgttgc gaacggactt tgttttggac 780
tatcccaaac ccgtgatgcc caacatgac ttcatgtgtg gtatcaactg ccatcaggga 840
aagccgttgc ctatggaatt tgaagcctac attaatgctt ctggagaaca tgggaattgtg 900
gttttctctt tgggatcaat ggtctcagaa attccagaga agaaagctat ggcaattgct 960
gatgcttttg gcaaaatccc tcagacagtc ctgtggcggg acaactggaac ccgaccatcg 1020
aatcttgcga acaacacgat acttggttaag tggctacccc aaaacgatct gcttggtcac 1080
ccgatgaccc gtgcctttat caccatgctt gggtcccatg gtgtttatga aagcatatgc 1140
aatggcgttc ccatggtgat gatgcccttg tttggtgatc agatggacaa tgcaaagcgc 1200
atggagacta agggagctgg agtgaccctg aatgttctgg aatgacttc tgaagattta 1260
gaaaatgtct taaaagcagt catcaatgac aaaagttaca aggagaacat catgcccctc 1320
tcagcccttc acaaggaccg ccgggtggag ccgtggacc tggccgtgtt ctgggtggag 1380
tttgtgatga ggcacaaggg cgcgccacac ctgcgcccg cagccacga cctcacctgg 1440
taccagtacc attccttggg cgtgatttgt ttctcttgg ccgtcgtgct gacagtggcc 1500
ttcatcacct ttaaatgttg tgcttatggc taccggaaat gcttggggaa aaaaggcgga 1560
gttaagaaag cccacaaatc caagacccat tgagaagtgg gtgggaaata aggtaaaatt 1620

```

ttgaaccatt	ccctagtcac	ttccaaactt	gaaaacagaa	tcagtggttaa	attcattttta	1680
ttcttattaa	ggaaataactt	tgcataaatt	aatcagcccc	agagtgcttt	aaaaaattot	1740
cttaaatata	aataatagac	tcgctagtc	gtaaaagatat	ttgaatatgt	atcgtgcccc	1800
ctctggtgto	tttgcacagg	atgacatgtg	ccattttttca	gaggacgtgc	agacaggctg	1860
gcattctaga	ttactttttct	tactotgaaa	catggcctgt	ttgggagtg	gggattcaaa	1920
gggtggtccca	cggctgcccc	tactgcaaat	ggcagtttta	atcttatctt	ttggcttctg	1980
cagatgggtg	caattgatcc	taaaccaata	atggtcagtc	ctcatctctg	togtgcttca	2040
taggtgccc	cttgtgtgtt	taaagaagg	aagctttgt	ccttttagagt	gtaggtgaaa	2100
tgaatgaatg	gcttggagtg	cactgagaac	agcatatgat	ttcttgcttt	ggggaaaaag	2160
aatgatgcta	tgaattggt	gggtggtgta	tttgagaaga	taatcattgc	ttatgtcaaa	2220
tggagctgaa	tttgataaaa	acccaaaata	cagctatgaa	gtgctgggca	agtttacttt	2280
ttttctgatg	tttctacaa	ctaaaaata	attataaat	ttatataaat	tctatttaag	2340
tgttttctact	gggtgcgcac	ttattttctg	ttaagttgca	ttttctaat	acaaaagtaa	2400
tgcattgatta	tgacagaaag	tttggaaaat	atagagggtc	acacacacac	gccttcattg	2460
cgtgtgcacg	cataaatgca	tgagaaaaga	aaaataacca	gtaatcacat	cggccagaaa	2520
taacccacgt	tacaattgtg	gcaaatacac	atacttataa	atattgcaga	tatattaagt	2580
atacc						2585

&lt;210&gt; 38

&lt;211&gt; 2585

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1) ... (2585)

&lt;223&gt; UGT1A9\*3

&lt;400&gt; 38

atggcttgca	caggggtggac	cagccccctt	cctctatgtg	tgtgtctgct	gctgacctgt	60
ggcttttgcg	aggcaggga	gctactggta	gtgcccacgg	atgggagcca	ctgggttcacc	120
atgaggtcgg	tggtggagaa	actcattctc	agggggcatg	aggtgggtgt	agtcattgcca	180
gaggtgagtt	ggcaactggg	aagatcactg	aattgcacag	tgaagactta	ttcaacttca	240
tataccctgg	aggatctgga	ccgggagttc	aaggcctttg	cccattgctc	atggaaagca	300
caagtagcaa	gtatatatct	tctattaatg	gggttcataca	atgacatttt	tgacttattt	360
ttttcaaat	gcaggagttt	gtttaaagac	aaaaaattag	tagaataactt	aaaggagagt	420
tcttttgatg	cagtgtttct	cgatcctttt	gataactgtg	gcttaattgt	tgccaaatat	480
ttctccctcc	cctccgtggt	cttcgccagg	ggaatacttt	gccactatct	tgaagaagg	540
gcacagtgcc	ctgctcctct	ttcctatgtc	cccagaatcc	tcttaggggt	ctcagatgcc	600
atgactttca	aggagagagt	acggaaccac	atcatgcact	tggaggaaca	tttattatgc	660
caccgttttt	tcaaaaatgc	cctagaaata	gcctctgaaa	ttctccaaac	acctgttacg	720
gagtatgac	tctacagcca	cacatcaatt	tggttggtgc	gaacggactt	tgttttggac	780
tatcccaaac	cgtgatgcc	caacatgac	ttcattgggtg	gtatcaactg	ccatcagggg	840
aagccgttgc	ctatggaatt	tgaagcctac	attaatgott	ctggagaaca	tgggaattgtg	900
gtttttctct	tggtatcaat	ggtctcagaa	attccagaga	agaaagctat	ggcaattgct	960
gatgctttgg	gcaaaatccc	tcagacagtc	ctgtggcggt	acactggaac	ccgaccatcg	1020
aatcttgcca	acaacacgat	acttgtttaag	tggctacccc	aaaacgatct	gcttggtcac	1080
ccgatgacct	gtgcctttat	cacctatgct	ggttcccatg	gtgtttatga	aagcatatgc	1140
aatggcggtc	ccatgggtgat	gatgcccttg	tttgggtgac	agatggacaa	tgcaaaagcg	1200
atggagacta	aggagctgg	agtgacctg	aatgttctgg	aatgacttc	tgaagattta	1260
gaaaatgctc	taaaagcagt	catcaatgac	aaaagttaca	aggagaacat	catgcgcctc	1320
tccagccttc	acaaggaccg	cccggtggag	ccgctggacc	tggcctgtgt	ctgggtggag	1380
tttgtgatga	ggcacaagg	cgcgccacac	ctgcgccccg	cagcccacga	cctcacctgg	1440
taccagtacc	attccttgga	cgtgattggt	ttctctctgg	cgtcgtgtgt	gacagtggcc	1500
ttcatcacct	ttaaattgtt	tgcttatggc	taccggaaaat	gcttggggaa	aaaaggggcg	1560
gttaagaaag	cccacaaatc	caagacccat	tgagaagtgg	gtgggaaata	aggtaaaatt	1620
ttgaaccatt	ccctagtcac	ttccaaactt	gaaaacagaa	tcagtggttaa	attcattttta	1680



12/40

ttcttatttaa	ggaaataactt	tgcataaatt	aatcagcccc	agagtgcctt	aaaaaattct	1740
cttaaataaaa	aataatagac	tcgctagtc	gtaaagatat	ttgaatatgt	atcgtgcccc	1800
ctctgggtgc	tttgcacagg	atgacatgtg	ccatttttca	gaggacgtgc	agacaggctg	1860
gcattctaga	ttacttttct	tactctgaaa	catggcctgt	ttgggagtg	gggattcaaa	1920
gggtgggtcca	cggctgcccc	tactgcaaat	ggcagtttta	atcttatctt	ttggcttctg	1980
cagatgggtg	caattgatcc	ttaaccaata	atggtcagtc	ctcatctctg	tcgtgcttca	2040
taggtgccac	cttctgtggt	taaagaagg	aagctttgta	ccttttagagt	gtaggtgaaa	2100
tgaatgaatg	gcttggagtg	cactgagaac	agcatatgat	ttcttgcttt	ggggaaaaag	2160
aatgatgcta	tgaaattggg	gggtgggtga	tttgagaaga	taatcattgc	ttatgtcaaa	2220
tggagctgaa	tttgataaaa	acccaaaata	cagctatgaa	gtgctgggca	agtttacttt	2280
ttttctgatg	tttctacaaa	ctaaaaataa	attaataaat	ttatataaat	tctatttaag	2340
tgttttcaat	gggtgcgc	ttatttcttg	tttaagttgca	ttttctaatt	acaaaagtaa	2400
tgcattgatta	tgacagaaag	tttggaaaat	atagagggtc	acacacacac	gccttcattg	2460
ogtgtgcatg	cataaatgca	tgagaaaaga	aaaataacca	gtaatcacat	cgcccagaaa	2520
taacccacgt	tacaattgtg	gcaaatcac	atacttataa	atattgcaga	tatattaagt	2580
atacc						2585

&lt;210&gt; 39

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)... (2372)

&lt;223&gt; UGT1A9 Haplotype 1

&lt;400&gt; 39

ctgttttgcc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctgggtctc	aactcctggc	ctcccgatg	acgcccacct	tgacctcca	aagtgtctgg	240
actacaggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccataa	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tgttatatac	tgattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggag	480
tggatcatga	taaaggctct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agagggtggg	tggttttggc	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtacactt	ggtgtaaott	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtctc	tcttccccat	720
ttgctttagt	ttcagtgccc	attcatggaa	gggtttgtgt	tgtaaaaaa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaact	gtttaatagg	aatttgtttt	ctggcatggc	840
ttcttctatg	tcttctttag	tatctgggtac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtgggtgc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgcagg	1020
caagtagacc	actttgacac	cttcagtggt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaaaga	ctttgaaaaga	cgtctcttta	ctggcaagat	attacctgac	1140
ttcaggggca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atggggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgtctag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcggtgt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttcccact	cgtgctgatg	tatcttagga	1560
aagccattta	aaataggaga	cgttactttt	ccatcaagtc	cctggtatgg	tccatggaag	1620
cagggttgct	agttctcatt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaat	aggagggttag	1740

13/40

gaggtcagtg	ctaagggcct	tgttttcttt	gcttagagta	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaattt	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactctt	actttatctt	tctgaacctt	caaggtccaa	1920
aagcattggt	taataattct	gcttctaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atataattct	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcagggt	ttgtgctggt	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctoagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcaggggaagc	tactggtagt	gcccattgat	gggagccact	ggttcacccat	2340
gaggtcgggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 40

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1) ... (2372)

&lt;223&gt; UGT1A9 Haplotype 2

&lt;400&gt; 40

ctgttttgcc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggttcaag	tgattctect	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tgttggccag	180
gctgggtotcc	aactcctggc	ctcccgtgat	acgcccacct	tgacctccca	aagtgtctggg	240
actacaggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tggtatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaaat	aagtattcat	taagtgggaag	480
tggatcatga	taaaggctct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggttttgct	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtacactt	gggtgaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtccct	tcttccccat	720
ttgctttagt	ttcagtgcct	attcatggaa	gggttttgtg	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgcccnaact	gtttaatagg	aatttgtttt	ctggcatggc	840
ttcttctatg	tcttctttat	tatctgggtac	tgattcnaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtggtgtc	tattcattct	tgaattttctc	acagattcat	960
atcttgaaag	accatattccc	ccaccttttg	ttgtgtgaatt	agagatattg	ggtttgcagg	1020
caagtagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaaagaa	ctttgaaaga	cgtctcttta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agcatgggtg	ctgtgaaagg	aggggtgaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgctcag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcgatg	tatcttagga	1560
aagccattta	aaataggaga	cggttacttt	ccatcaagtc	cctgggtatg	tccatggaaag	1620
cagggtttgtc	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaat	aggaggttag	1740
gaggtcagtg	ctaagggcct	tgttttcttt	gcttagagta	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaattt	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactctt	actttatctt	tctgaacctt	caaggtccaa	1920
aagcattggt	taataattct	gcttctaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tatctcagca	2040

14/40

aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gagtcagggt	ttgtgctggt	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcaggggaagc	tactggtagt	gccccatggat	gggagccact	ggttcaccat	2340
gaggtcgggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 41

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1) ... (2372)

&lt;223&gt; UGT1A9 Haplotype 3

&lt;400&gt; 41

ctgttttggc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctggctctcc	aactcctggc	ctcccgatg	acgcccacct	tgacctccca	aagtgtctgg	240
actacagggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccataa	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tggtatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggaag	480
tggtatcatga	taaaggtcct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggttttggc	gtttcagggg	tgccagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtagacatt	ggtgtaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgctt	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcct	tcttcccat	720
ttgctttagt	ttcagtgccc	attcatggaa	gggtttgtgt	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaaact	gtttaatagg	aatttgtttt	ctggcatggc	840
ttcttctatg	tcttcttttag	tatctgggtac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtggtgtc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgcagg	1020
caagttagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaagggtt	ggaggctagc	1260
aggcttatgg	atggggggcag	tcctattttg	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaagcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgctcag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tgcgaaggat	tgggcgggca	acttcccact	gcgtgcgatg	tatcttagga	1560
aagccattta	aaataggaga	cggttacttt	ccatcaagtc	cctggtagtg	tccatggaag	1620
cagggttgct	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccattt	aggagggttag	1740
gaggtcagtg	ctaaggccct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaattt	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttaatttt	actttatctt	tctgaacctt	caagggtccaa	1920
aagcattgggt	taataattct	gcttctaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	cctctatttg	gggtcagggt	ttgtgctggt	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggottgcaca	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcaggggaagc	tactggtagt	gccccatggat	gggagccact	ggttcaccat	2340

15/40

gaggtcggtg gtggagaaac tcattctcag gg

2372

&lt;210&gt; 42

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 4

&lt;400&gt; 42

ctgttttggc	cggtcggtg	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cggtttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctgggtctcc	aactcctggc	ctcccgatg	acgcccacot	tgacctccca	aagtgctggg	240
actacagggtg	tgagccacca	cgccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tggttatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggag	480
tggtatcatga	taaaggctct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agagggtggg	tggttttgct	gtttcagggtg	gggcagagggtg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtacactt	ggtgtaactt	tacagaattt	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcct	tcttcccat	720
ttgctttagt	ttcagtggcc	atctatggaa	gggttttgtg	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgocaaact	gtttaatagg	aatttggttt	ctggcatggc	840
ttctttctatg	tcttcttttag	tatctggtac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atctttctgtt	gattcctctg	gtgtgggtgc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgagg	1020
caagtagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcaggggaca	aagtaaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgctcag	cagactgaga	gagacaagta	catattttcc	tgaaggagg	1440
cactggagtg	atggcgtggt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtctc	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcgatg	tatttttagga	1560
aagccattta	aaataggaga	cggttacttt	ccatcaagtc	cctgggtatg	tccatggaag	1620
cagggttgctc	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaat	aggagggttag	1740
gaggtcagtg	ctaagggcct	tggtttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaaggtaa	atctaaaattt	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactttt	actttatctt	tctgaacctt	caagggtccaa	1920
aagcattggt	taataattct	gcttctaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaaacatt	gtcagtgact	gatttttttt	2100
tatgaagga	taaaaacacg	ccctctattg	gggtcagggt	ttgtgctggt	atttctccca	2160
cctaactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacaca	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgcccag	gcagggaagc	tactggtagt	gccccaggat	gggagccact	ggttcaccat	2340
gaggtcggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 43

&lt;211&gt; 2372

&lt;212&gt; DNA

16/40

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)... (2372)

&lt;223&gt; UHT1A9 Haplotype 5

&lt;400&gt; 43

ctgttttggc	cggtgtggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cggtttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctggctctc	aactcctggc	ctcccgtgat	acgccacact	tgacctccca	aagtgcctggg	240
actacaggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tggttatatac	tgtattatca	caatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggag	480
tggatcatga	taaaggctct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agagggtggg	tggttttgc	gtttcagggg	tgccagaggg	ggaagaagt	gagggaaga	600
gaggagagac	aggtagactt	gggtgaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcct	tcttccccat	720
ttgctttagt	ttcagtgcct	attcatggaa	gggtttgtgt	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaaact	gtttaatagg	aattttgttt	ctggcatggc	840
ttcttctatg	tcttctttag	tatctgttac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtgtgtgc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgccag	1020
caagtagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atggggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaaggcat	agcatgggta	ctgtgaaagg	aggggtgaaa	cacaaagtgt	acatcacctc	1380
tgacctcaag	gagtgtctag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcgatg	tatttttagga	1560
aagccattta	aaataggaga	cggttacttt	coatcaagtc	cctgggtatg	tccatggaag	1620
cagggtgtgc	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaat	aggagggttag	1740
gaggtcagtg	ctaagggcct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaattt	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactttt	actttatctt	tctgaacctt	caagggtccaa	1920
aagcattggg	taataattct	gcttctaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctgggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcagggt	ttgtgctggg	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcagggaagc	tactggtagt	gcccattggat	gggagccact	ggttcaccat	2340
gaggtcgggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 44

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)... (2372)

17/40

&lt;223&gt; UGT1A9 Haplotype 6

&lt;400&gt; 44

ctgttttgcc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctggtctcc	aactcctggc	ctcccgtgat	acgcccacct	tgacctcca	aagtgtggg	240
actacagggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cgtaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tgttatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggaag	480
tggatcatga	taaaggtcct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggttttgct	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtacactt	gggtgaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcc	tcttccccat	720
ttgtcttagt	ttcagtgccc	attcatggaa	gggtttgtgt	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaaact	gtttaatagg	aatttgtttt	ctggcatggc	840
ttcttctatg	tottcttttag	tatctggtac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtggtgtc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgagg	1020
caagtagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agoatgggta	ctgtgaaagg	aggggtgaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgtctcag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcgatg	tatcttagga	1560
aagccattta	aaataggaga	cggttacttt	ccatcaagtc	cctggtatgg	tccatggaag	1620
cagggttgct	agtctcatth	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaatth	aggagggttag	1740
gaggtcagtg	ctaagggcct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaattt	tgctctggga	caaattccaa	1860
aaaaaatttag	ctttaatcaa	atttactttt	actttatctt	tctgaacctt	caagggtccaa	1920
aagcattgggt	taataattct	gcttctaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcagggt	ttgtgctggg	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcagggaagc	tactggtagt	gcccattggat	gggagccact	ggttcaccat	2340
gaggctcgggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 45

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 7

&lt;400&gt; 45

ctgttttgcc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120

18/40

```

accacctgca gctaattttt tgcattttta gtagagatag ggtttcacca tgttggccag 180
gctggtctcc aactcctggc ctcccgtgat acgcccacct tgacctccca aagtgtctgg 240
actacagggtg tgagccacca cgcccaggca cacatagaat ttttgactcc ctaaaaattt 300
actattaata gcctactgtg cactagaagc cgtaccaata acagaaacag ttgcttaaca 360
catatttggc atgttatatg tgttatatac tgtattatca taatgaagtc agctagagaa 420
aagaaaatgt tattaagaaa atcttaagga agagaaaatt aagtattcat taagtgaag 480
tggatcatga taaaggtctt cctcttgatt gtccctccatt gagtaggctg agaaggagga 540
agagggtgggt tggttttgct gtttcagggg tggcagaggg ggaagaagtg gaggaagaag 600
gaggagagac aggtacactt ggtgtaactt tacagaatta catcataatt attatttgac 660
ttttttgect ttgcaattct ttgaaaatgc ttttttacag tactagtcct tcttcccat 720
ttgctttagt ttcatggccc attcatggaa gggtttgtgt tgtaaaataa gtcaaaagta 780
gtcttaataa ttggaagcct ttgccaaaact gtttaatagg aatttgtttt ctggcatggc 840
ttcttctatg tcttctttag tatctggtag tgattcaaaa gcactcatct ccatcaagtc 900
atcttctgtt gattcctctg gtgtgggtgc tattcattct tgaatttctc acagattcat 960
atcttgaaag accatatccc ccaccttttg ttgctgaatt agagatattg ggtttgcagg 1020
caagtagacc actttgacac cttcagtggt gaactcatgg gttctgggtg gctaggggca 1080
ttgtccaaaa atcaaaagaa ctttgaaaga ccgtctctta ctggcaagat attacctgac 1140
ttcagggaaca aagttaatgat agaaccaatc cagaaaaagt gttcttgccg aggccttctt 1200
gtacaacaaa aaaactggca gtgggtattg atcttttccc tttagggtt ggaggctagc 1260
aggcttatgg atgggggcag tcttatttgt aaacccaaac atacaaacat acaaactatg 1320
tcaaaggcat agcatgggta ctgtgaaagg aggggtgaaaa cacaaagtgt acatcacctc 1380
tgacctcaag gactgctcag cagactgaga gagacaagta catattttcc tgaaggaggg 1440
cactggagtg atggcgtgtt tagaatgtgc aagttgagcg gtcactgaga ggcagctcag 1500
cagagtgtctc tcgcaaggat tgggcgggca acttcccact gcgtgcatg tatttttagga 1560
aagccattta aaataggaga cggttacttt ccatcaagtc cctgggtatg tccatggaag 1620
cagggttgtc agtctcattt cagcatttta gaggtctctc agggtttgga aatggaagaa 1680
gagaagcagc aatatgtatg cattgcagag acacaggcga gcccgaattt aggagggttag 1740
gaggtcagtg ctaagggcct tgttttcttt gcttagagca tgagttgcca tcttctctgg 1800
acagagagta tttggttgcc taaaggtaaa atctaaattt tgctctggga caaattccaa 1860
aaaaaattag cttaaatcaa atttactttt actttatctt tctgaacctt caagggtccaa 1920
aagcattggg taataattct gcttctaacc ttaacattgc agcacagggc atgttctgcc 1980
cccaaggcaa agaccataag ctactgttgt ctggaaaaca tacaatataga tatctcagca 2040
aaagctactc atatatctt gttcttttgg gtaaatcatt gtcagtgaat gatttttttt 2100
tatgaaagga taaaacacg ccctctattg gggtcagggt ttgtgctggg atttctccca 2160
cctactgtat cataggagct tagattccca gctgcttgct ctgagctgca gttctctgat 2220
ggcttgca ca ggggtggacca gccccttcc tctatgtgtg tgtctgtgct tgacctgtgg 2280
ctttgccgag gcagggaagc tactggtagt gccatggat gggagccact ggttcacat 2340
gaggtcgggt gtggagaaac tcattctcag gg 2372

```

&lt;210&gt; 46

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 8

&lt;400&gt; 46

```

ctgttttgcc cgggctggag tataatggcg tgatctcagc tcaatgcaac ctccgcttcc 60
cgggttcaag tgattctcct gctcagcct ccagagtagc tgggattaca ggcatgcaac 120
accacctgca gctaattttt tgcattttta gtagagatag ggtttcacca tgttggccag 180
gctggtctcc aactcctggc ctcccgtgat acgcccacct tgacctccca aagtgtctgg 240
actacagggtg tgagccacca cgcccaggca cacatagaat ttttgactcc ctaaaaattt 300
actattaata gcctactgtg cactagaagc cttaccaata acagaaacag ttgcttaaca 360
catatttggc atgttatatg tgttatatac tgtattatca caatgaagtc agctagagaa 420

```

19/40

aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggaag	480
tggatcatga	taaaggtcct	cctcttgatt	gtcctocatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggtttttgc	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	agggtacactt	gggtgaactt	tacagaatta	catcataatt	attattttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcct	tcttccccat	720
ttgcttttagt	ttcagtgccc	attcatggaa	gggtttgtgt	tgtaaaaata	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaaaot	gtttaatagg	aattttgttt	ctggcatggc	840
ttctttctatg	tcttcttttag	tatctgggtac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtgggtgc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaaag	accatatccc	ccaccttttg	ttgtctgaatt	agagatatgt	ggtttgacagg	1020
caagtagacc	actttgacac	cttcagtggt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcaggggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atggggggcag	tcctattttgt	aaaccccaac	atacaaacat	acaaactatg	1320
tcaaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgctcag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttccact	gcgtgcgatg	tatcttagga	1560
aagcoatttta	aaataggaga	cggttacttt	ccatcaagtc	cctgggtatg	tccatggaag	1620
cagggtttgtc	agtctcattt	cagcattttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gcccccaatt	aggagggttag	1740
gaggtcagtg	ctaagggcct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaaggtaaa	atctaaattt	tgctctggga	caaattccaa	1860
aaaaaatttag	ctttaatcaa	atttactttt	actttatctt	tctgaacott	caagggtccaa	1920
aagcatttgg	taataattct	gcttctaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaa	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcaggtt	ttgtgctggg	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgccaca	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgcccgag	gcagggaagc	tactggtagt	gcccattggat	gggagccact	ggttccaccat	2340
gaggtcgggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 47

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 9

&lt;400&gt; 47

ctgtttttgcc	tgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tgttggcoag	180
gctgggtctcc	aactcctggc	ctcccgtgat	acgcccacct	tgacctccca	aagtgtctggg	240
actacagggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaaccaata	acagaaacag	ttgcttaaca	360
catattttggc	atgttatatg	tgttatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggaag	480
tggatcatga	taaaggtcct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggtttttgc	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	agggtacactt	gggtgaactt	tacagaatta	catcataatt	attattttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcct	tcttccccat	720



20/40

```

ttgcttttagt ttcagtgcgc attcatggaa ggggtttgtgt tgtaaaataa gtcaaaagta 780
gtcttaataa ttggaagcct ttgccaaaact gtttaaatagg aatttggttt ctggcatggc 840
ttcttctatg tcttcttttag tatctggtac tgattcaaaa gcactcatct ccatcaagtc 900
atcttctgtt gattcctctg gtgtggtgtc tattcattct tgaatttctc acagattcat 960
atcttgaaag accatatccc ccaccttttg ttgctgaatt agagatattg ggtttgcagg 1020
caagtagacc actttgacac cttcagtgtt gaactcatgg gttctgggtg gctaggggca 1080
ttgtccaaaa atcaaaagaa ctttgaaaaga cegtctctta ctggcaagat attacctgac 1140
ttcagggaca aagtaattgat agaaccaatc cagaaaaagt gttcttgccg aggccttctt 1200
gtacaacaaa aaaactggca gtgggtattg atcttttccc ttttaaggctt ggaggctagc 1260
aggcttatgg atgggggagc tcctatttgt aaacccaaac atacaaacat acaaactatg 1320
tcaaaggoat agcatgggta ctgtgaaagg aggggtgaaaa cacaaggtg acatcacctc 1380
tgacctcaag gagtgtctag cagactgaga gagacaagta catattttcc tgaaggagg 1440
cactggagtg atggcgtgtt tagaatgtgc aagttagcgc gtcactgaga ggcagctcag 1500
cagagtgtct tcgcaaggat tgggcgggca acttcccact gcgtgcgatg tatttttaga 1560
aagccattta aaataggaga cggttacttt ccatcaagtc cctggtatgg tccatggaag 1620
caggggtgtc agtctcattt cagcatttta gaggtctctc aggggttggg aatggaagaa 1680
gagaagcagc aatatgtatg cattgcagag acacaggcga gccccaattt aggagggttag 1740
gaggtcagtg ctaagggcct tgttttcttt gcttagagca tgagttgcca tcttctctgg 1800
acagagagta tttggttgcc taaaggtaaa atctaaattt tgctctggga caaattccaa 1860
aaaaaattag ctttaataca atttactttt actttatctt tctgaacctt caagggtcaa 1920
aagcattggt taataattct gctactaaac ttaacattgc agcacagggc atgttctgoc 1980
cccaaggcaa agaccataag ctactgttgt ctggaaaaaaca tacaatatga tatctcagca 2040
aaagctactc atatatcttt gttcttttgg gtaaatcatt gtcagtgaat gatttttttt 2100
tatgaaagga taaaaacacg ccctctattg gggtcagggt ttgtgtctgg atttctccca 2160
cctactgtat cataggagct tagattccca gctgcttgc ctcagctgca gttctctgat 2220
ggcttgacac ggggtggacca gcccccttcc tctatgtgtg tgtctgctgc tgacctgtg 2280
ctttgcccag gcagggaagc tactggtagt gcccatggat gggagccact ggttcaccat 2340
gaggtcggtg gtggagaaac tcattctcag gg 2372

```

&lt;210&gt; 48

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 10

&lt;400&gt; 48

```

ctgttttgcc cgggctggag tataatggcg tgatctcagc tcaatgcaac ctccgcttcc 60
cgggttcaag tgattcttct gcctcagcct ccagagtagc tgggattaca ggcattgcac 120
accacctgca gctaattttt tgcattttta gtagagatag ggtttcacca tgttggccag 180
gtgtgtctcc aactcctggc ctcccgtgat acgcccacct tgacctccca aagtgtctgg 240
actacagggtg tgagccacca cggccaggca cacatagaat ttttgactcc ctaaaaattt 300
actattaata gcctactgtg cactagaagc ottaccaata acagaaacag ttgcttaaca 360
catatttggc atgttatatg tgttatatac tgtattatca taatgaagtc agctagagaa 420
aagaaaatgt tattaagaaa atcttaagga agagaaaatt aagtattcat taagtggaag 480
tggatcatga taagggtott cctottgatt gtccctccatt gtagtaggctg agaaggagga 540
agagggtgggt tggttttgct gtttcagggtg tggcagagggt ggaagaagtg gaggaagaag 600
gaggagagac aggtacactt ggtgtaactt tacagaatta catcataatt attatttgac 660
ttttttgccc ttgcaattct ttgaaaatgc ttttttacag tactagtctt tcttccccat 720
ttgcttttagt ttcagtgcgc attcatggaa ggggttgtgt tgtaaaataa gtcaaaagta 780
gtcttaataa ttggaagcct ttgccaaaact gtttaaatagg aatttggttt ctggcatggc 840
ttcttctatg tcttcttttag tatctggtac tgattcaaaa gcactcatct ccatcaagtc 900
atcttctgtt gattcctctg gtgtggtgtc tattcattct tgaatttctc acagattcat 960
atcttgaaag accatatccc ccaccttttg ttgctgaatt agagatattg ggtttgcagg 1020

```

21/40

caagtagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgtctag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgttc	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcgatg	tatttttagga	1560
aagccattta	aaataggaga	cggttacttt	ccatcaagtc	cctgggtatg	tccatggaag	1620
caggtttgtc	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaatth	aggaggttag	1740
gaggtcagtg	ctaagggcct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaaggtaa	atctaaatth	tgtcttgggg	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactttt	actttatctt	tctgaacott	caaggtccaa	1920
aagcattggg	taataattct	gctactaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
ccaaggcaca	agaccataag	ctactgttgt	ctggaaaaac	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcaggtt	ttgtgctggg	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcagggaagc	tactggtagt	gcccattgat	gggagccact	ggttcaccat	2340
gaggtcgggt	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 49

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 11

&lt;400&gt; 49

ctgttttggc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggtttaag	tgattctoct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accactgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tgttgccag	180
gctggctctc	aactcctggc	ctcccgtagt	acgccacctt	tgacctccca	aagtgtggg	240
actacagggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaatth	300
actattaata	gcctactgtg	cactagaagc	cttaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tgttatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggag	480
tggatcatga	taaaggtcct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggttttgct	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtacactt	ggtgtaactt	tacagaatta	catcataath	attatttgac	660
ttttttgctt	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcct	tcttcccat	720
ttgctttagt	ttcagtgcct	attcatggaa	gggttttgtt	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaaact	gtttaatagg	aatttggttt	ctggcatggc	840
ttcttctatg	tcttcttttag	tatctgttac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtggtgtc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatatgt	ggtttgacag	1020
caagtagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320

tcaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgtcag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtc	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcatg	tatttttagga	1560
aagccattta	aaataggaga	cggttacttt	ccatcaagtc	cctggtatgg	tccatggaag	1620
caggggtgtc	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccatttt	aggaggttag	1740
gaggtcagtg	ctaaggccct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaattt	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactttt	actttatctt	tctgaacctt	caaggtccaa	1920
aagcattggt	taataattct	gtactaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	cctctatttg	gggtcaggtt	ctgtgctggt	atttctccca	2160
cctactgtat	ctaggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcagggaagc	tactggtagt	gcccattgat	gggagccact	ggttcaccat	2340
gaggtcggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 50

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 12

&lt;400&gt; 50

ctgttttgcc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctgggtctcc	aaactcctggc	ctcccgtgat	acgcccacct	tgacctccca	aagtgtctggg	240
actacagggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccata	acagaacacg	ttgcttaaca	360
catatttggc	atgttatatg	tggtatatac	tgtattatca	caatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtgggaag	480
tggatcatga	taaaggctct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agagggtgggt	tggttttgct	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	agggtacact	ggtgtaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcct	tcttcccat	720
ttgctttagt	ttcagtgcct	attcatggaa	gggtttgtgt	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaaact	gtttaatagg	aatttgtttt	ctggcatggc	840
ttcttctatg	tcttctttag	tatctggtag	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtggtgtc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgcagg	1020
caagtagacc	actttgacac	cttcagtggt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgtcag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtc	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcatg	tatcttagga	1560
aagccattta	aaataggaga	cggttacttt	ccatcaagtc	cctggtatgg	tccatggaag	1620

23/40

cagggttgtc	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaat	aggaggttag	1740
gaggtcagt	ctaagggcct	tgttttcttt	gcttagagca	tgagttgoca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaat	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactttt	actttatctt	tctgaacctt	caaggtccaa	1920
aagcattggt	taataattct	gctttotaaac	ttaacattgc	agcacagggc	atgtttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgaot	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcagggt	ttgtgctggg	atttctccca	2160
cctactgtat	cataggagct	tagattccca	ggtgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcagggaagc	tactggtagt	gcccacggat	gggagccact	ggttcaccat	2340
gaggtcggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 51

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 13

&lt;400&gt; 51

ctgttttgcc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctcogcttcc	60
cgggttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctgtctctc	aactcctggc	ctcccgtgat	acgccacact	tgacctccca	aagtgtctggg	240
actacagggt	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaat	300
actattaata	gcctactgtg	cactagaagc	cgtaccaata	acagaaacag	ttgcttaaca	360
catatttgcc	atggttatatg	tggttatatac	tgattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggaag	480
tggatcatga	taaaggctct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agagggtggg	tggttttctg	gtttcagggg	tggcagaggg	ggaagaagt	gaggaagaag	600
gaggagagac	aggtacactt	gggtgaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtccct	tcttccccat	720
ttgctttagt	ttcagtgccc	attcatggaa	gggtttgtgt	tgtaaaaata	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgcaaaact	gtttaatagg	aatttgtttt	ctggcatggc	840
ttcttctatg	tcttctttag	tatctgggtac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtgggtgc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgagg	1020
caagtagacc	actttgacac	cttcagtggt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaaaga	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggagggttagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaaagtg	acatcacctc	1380
tgacctcaag	gagtgctcag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcgatg	tatcttagga	1560
aagccattta	aaataggaga	cggttacttt	ccatcaagtc	cctgggtatg	tccatggaag	1620
cagggttgtc	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaat	aggaggttag	1740
gaggtcagt	ctaagggcct	tgttttcttt	gcttagagta	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaat	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactttt	actttatctt	tctgaacctt	caaggtccaa	1920

24/40

```

aagcattgggt taataattct gcttctaacc ttaacattgc agcacagggc atgtttotgcc 1980
cccaaggcaa agaccataag ctactgttgt ctggaaaaca tacaaataga tatctcagca 2040
aaagctactc atatattctt gttcttttgg gtaaatcatt gtcagtgcact gatttttttt 2100
tatgaaagga taaaaacacg ccctctattg gggtcagggt ttgtgctggg atttctccca 2160
cctactgtat cataggagct tagattccca gctgcttgct ctcagctgca gttctctgat 2220
ggcttgacaca ggggtggacca gccccttcc tctatgtgtg tgtctgctgc tgacctgtgg 2280
ctttgcgag gcagggaagc tactggtagt gcccatggat gggagccact ggttcaccat 2340
gaggtcgggtg gtggagaaac tcattctcag gg 2372

```

&lt;210&gt; 52

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2)

&lt;223&gt; UGT1A9 Haplotype 14

&lt;400&gt; 52

```

ctgttttgcc cgggctggag tataatggcg tgatctcagc tcaatgcaac ctcogettcc 60
cgggttcaag tgattctcct gcctcagcct ccagagtagc tgggattaca ggcattgcacc 120
accacctgca gtaatttttt tgcattttta gtagagatag ggtttcacca tgttgccag 180
gctggctctc aactcctggc ctcccgtagt acgcccacct tgacctccca aagtgcctggg 240
actacagggtg tgagccacca cgcacaggca cactagaat ttttgactcc ctaaaaattt 300
actattaata gcctactgtg cactagaagc cttaccaata acagaaacag ttgcttaaca 360
catatttggc atgttatatg tggtatatac tgtattatca caatgaagtc agctagagaa 420
aagaaaatgt tattaagaaa atcttaagga agagaaaatt aagtattcat taagtggag 480
tggatcatga taaaggtctt cctcttgatt gtccctcatt gagtaggctg agaaggagga 540
agaggtgggt tggttttgct gtttcagggtg tggcagaggg ggaagaagtg gaggaagaag 600
gaggagagac aggtacactt ggtgtaactt tacagaatta catcataatt attatttgac 660
ttttttgcct ttgcaattct ttgaaaatgc ttttttacag tactagtcct tcttcccat 720
ttgcttttagt ttcagtgccc attctaggaa gggtttgtgt tgtaaaataa gtcaaaagta 780
gtcttaataa ttggaagcct ttgccaaact gttaaatagg aatttgtttt ctggcatggc 840
ttcttctatg tcttctttag tatctggtac tgattcaaaa gcactcatct ccatcaagtc 900
atcttctgtt gattctctct gtgtggtgtc tattcattct tgaatttctc acagattcat 960
atcttgaaag accatatccc ccaccttttg ttgctgaatt agagatattg ggtttgacag 1020
caagtagacc actttgacac cttcagtggt gaactcatgg gttctgggtg gctaggggca 1080
ttgtccaaaa atcaaaagaa ctttgaaaga ccgtctctta ctggcaagat attacctgac 1140
ttcagggaca aagtaatgat agaaccaatc cagaaaaagt gttcttgccg aggccctctt 1200
gtacaacaaa aaaactggca gtgggtattg atcttttccc ttaaggctt ggaggctagc 1260
aggcttatgg atgggggcag tctatttgt aaacccaaac atacaaacat acaaactatg 1320
tcaaaggcat agcatgggtg ctgtgaaagg aggggtgaaa cacaagttg acatcacctc 1380
tgacctcaag gactgctcag cagactgaga gagacaagta catattttcc tgaaggagg 1440
cactggagtg atggcgtgtt tagaatgtgc aagttagcgc gctactgaga ggcagctcag 1500
cagagtgtct tcgcaaggat tgggctggga acttccact gogtgcgatg tatcttagga 1560
aagccattta aaataggaga cggttacttt ccattcaagtc cctgggtatgg tccatggaag 1620
cagggttgct agtctcattt cagcatttta gaggtctctc aggggttgga aatggaagaa 1680
gagaagcagc aatatgtatg cattgcagag acacaggcga gccccattt aggaggttag 1740
gaggtcagtg ctaagggcct tgttttcttt gcttagagta tgagttgcca tcttctctgg 1800
acagagagta tttggttgcc taaaggtaaa atctaaattt tgcctctggga caaattccaa 1860
aaaaaattag ctttaatcaa atttactctt actttatctt tctgaacctt caaggtccaa 1920
aagcattgggt taataattct gcttctaacc ttaacattgc agcacagggc atgttctgcc 1980
cccaaggcaa agaccataag ctactgttgt ctggaaaaca tacaaataga tatctcagca 2040
aaagctactc atatattctt gttcttttgg gtaaatcatt gtcagtgcact gatttttttt 2100
tatgaaagga taaaaacacg ccctctattg gggtcagggt ttgtgctggg atttctccca 2160
cctactgtat cataggagct tagattccca gctgcttgct ctcagctgca gttctctgat 2220

```

25/40

```

ggcttgacaca ggggtggacca gcccccttcc totatgtgtg tgtctgctgc tgacctgtgg 2280
ctttgccgag gcagggaagc tactggtagt gcccatggat gggagccact gggttcacat 2340
gaggtcgggtg gtggagaaac tcattctcag gg 2372

```

<210> 53  
 <211> 2372  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> (1)...(2372)  
 <223> UGT1A9 Haplotype 15

```

<400> 53
ctgttttgcc cgggctggag tataatggcg tgatctcagc tcaatgcaac ctccgcttcc 60
cgggttcaag tgattcttct gcctcagcct ccagagtagc tgggattaca ggcattgcacc 120
accacotgca gctaattttt tgcattttta gtagagatag ggtttcacca tgttggccag 180
gctggtctcc aactcctggc ctcccgatgat acgcccacct tgacctcca aagtgtggg 240
actacagggtg tgagccacca cggccaggca cacatagaat ttttgactcc ctaaaaattt 300
actattaata gcctactgtg cactagaagc cgtaccaata acagaaacag ttgcttaaca 360
catatttggc atgttatatg tgttatatac tgtattatca taatgaagtc agctagagaa 420
aagaaaatgt tattaagaaa atcttaagga agagaaaatt aagtattcat taagtgaag 480
tggatcatga taaaggtctt cctcttgatt gtctccatt gagtaggctg agaaggagga 540
agagggtggg tggttttgct gtttcagggg tggcagaggg ggaagaagtg gaggaagaag 600
gaggagagac aggtacactt ggtgtaactt tacagaatta catcataatt attatttgac 660
ttttttgctt ttgcaattct ttgaaaatgc ttttttacag tactagtctt tcttcccat 720
ttgctttagt ttcagtgcct attcatggaa gggtttgtgt tgtaaaataa gtcaaaagta 780
gtcttaataa ttggaagcct ttgccaact gttaataagg aatttgtttt ctggcatggc 840
ttctctctatg tcttctttag tatctggtac tgattcaaaa goactcatct ccatcaagtc 900
atcttctgtt gattctcttg gtgtggtgtc tattcattct tgaatttctc acagattcat 960
atcttgaaag accatatccc ccaccttttg ttgctgaatt agagatatgg ggtttgcagg 1020
caagtagacc actttgacac cttcagtgtt gaactcatgg gttctgggtg gctaggggca 1080
ttgtccaaaa atcaaaagaa ctttgaaaga ccgtctctta ctggcaagat attacctgac 1140
ttcagggaca aagtaatgat agaaccaatc cagaaaaagt gttcttgccg aggccttctt 1200
gtacaacaaa aaaactggca gtgggtattg atcttttccc ttttaaggctt ggaggctagc 1260
aggcttatgg atgggggcag tctattttgt aaacccaaac atacaaacat acaaactatg 1320
tcaaaggcat agcatgggta ctgtgaaagg aggggtgaaa cacaagttg acatcacctc 1380
tgacctcaag gagtgtcag cagactgaga gagacaagta catattttcc tgaaggaggg 1440
cactggagtg atggcgtgtt tagaatgtgc aagttgagcg gtcactgaga ggcagctcag 1500
cagagtgtct tcgcaaggat tgggcgggca acttcccact gogtgcgatg tatttttagga 1560
aagccattta aaataggaga cgtttacttt ccatcaagtc cctggtaggg tccatggaag 1620
cagggttgct agtctcattt cagcatttta gaggttctc agggtttggg aatggaagaa 1680
gagaagcagc aatatgtatg cattgcagag acacaggcga gcccgaattt aggaggttag 1740
gaggtcagtg ctaaggcctt tgttttcttt gcttagagca tgagttgcca tcttctctgg 1800
acagagagta tttggttgcc taaaggtaaa atctaaattt tgccttgagg caaattccaa 1860
aaaaaattag ctttaataca atttactttt actttatctt tctgaacctt caaggtccaa 1920
aagcatgggt taataattct gctactaaac ttaacattgc agcacagggc atgttctgcc 1980
cccaaggcaa agaccataag ctactgttgt ctggaaaaca tacaaataga tatctcagca 2040
aaagctactc atatatctt gtctttttgg gtaaatcatt gtcagtgaact gatttttttt 2100
tatgaaagga taaaaacacg cctctattg gggtcagggt ttgtgtgtgt atttctccca 2160
cctactgtat cataggagct tagattccca gctgcttgct ctgagctgca gttctctgat 2220
ggottgcaca ggggtggacca gcccccttcc totatgtgtg tgtctgctgc tgacctgtgg 2280
ctttgccgag gcagggaagc tactggtagt gcccatggat gggagccact gggttcacat 2340
gaggtcgggtg gtggagaaac tcattctcag gg 2372

```

<210> 54

26/40

<211> 2372  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>  
 <221> allele  
 <222> (1)...(2372)  
 <223> UGT1A9 Haplotype 16

<400> 54  
 ctgttttgcc cgggctggag tataatggcg tgatctcagc tcaatgcaac ctccgcttcc 60  
 cgggttcaag tgattcttct gcctcagcct ccagagtagc tgggattaca ggcattgcacc 120  
 accacctgca gctaattttt tgcattttta gtagagatag gggttcacca tgttgccag 180  
 gctgggtctcc aactcctggc ctcccgatgat acgcccacct tgacctocca aagtgcctggg 240  
 actacagggtg tgagccacca cggccaggca cacatagaat ttttgactcc ctaaaaattt 300  
 actattaata gctactgtg cactagaagc cgtaccaata acagaaacag ttgottaaca 360  
 catatttggc atgttatatg tgttatatac tgtattatca taatgaagtc agctagagaa 420  
 aagaaaatgt tattaagaaa atcttaagga agagaaaatt aagtattcat taagtggag 480  
 tggatcatga taaaggtctt cctcttgatt gtctccatt gagtaggctg agaaggagga 540  
 agaggtgggt tggttttgct gtttcagggg tggcagaggg ggaagaagtg gaggaagaag 600  
 gaggagagac aggtacaatt ggtgtaactt tacagaatta catcataatt attatttgac 660  
 ttttttgctt ttgcaattct ttgaaaatgc ttttttacag tactagtctt tcttccccat 720  
 ttgcttttagt ttcagtgcctt attcatggaa ggggtttgtg tgtaaaataa gtcaaaagta 780  
 gtcttaataa ttggaagcct ttgcaaaact gtttaatatg aatttgtttt ctggcatggc 840  
 ttcttctatg tcttcttttag tatctggtac tgattcaaaa gcactcatct ccatcaagtc 900  
 atcttctgtt gattcctctg gtgtggtgtc tattcattct tgaatttctc acagattcat 960  
 atcttgaaag accatatccc ccaccttttg ttgctgaatt agagatattg ggtttgcagg 1020  
 caagtagacc actttgacac cttcagtggt gaactcatgg gttctgggtg gctaggggca 1080  
 ttgtccaaaa atcaaaagaa ctttgaaaga ccgtctctta ctggcaagat attacctgac 1140  
 ttcagggaca aagtaatgat agaaccaatc cagaaaaagt gttcttgccg aggccttctt 1200  
 gtacaacaaa aaaactggca gtgggtattg atcctttccc ttaagggtt ggaggctagc 1260  
 aggccttatg atgggggcag tcttatttgt aaacccaaac atacaaacat acaaaactatg 1320  
 tcaaaaggcat agcatgggta ctgtgaaagg agggtgaaaa caciaaagt acatcacctc 1380  
 tgacctcaag gagtgctcag cagactgaga gagacaagta catattttcc tgaaggaggg 1440  
 cactggagtg atggcgtgtt tagaatgtgc aagttgagcg gtcactgaga ggcagctcag 1500  
 cagagtgtct tcgcaaggat tgggcgggca acttcccact gogtgcgatg tattttagga 1560  
 aagccattta aaataggaga cgggtacttt ccatcaagtc cctgggtatg tccatggaag 1620  
 cagggtgtgc agtctcattt cagcatttta gaggtctctc aggggttgga aatggaagaa 1680  
 gagaagcagc aatattgtat cattgcagag acacaggcga gcccattt aggagggttag 1740  
 gaggtcagtg ctaagggcct tgttttcttt gcttagagca tgagttgcca tcttctctgg 1800  
 acagagagta tttggttgcc taaaggtaaa atctaaattt tgccttgga caaattccaa 1860  
 aaaaaattag ctttaattcaa atttactttt actttatctt tctgaacctt caagggtccaa 1920  
 aagcattggt taataattct gcttctaacc ttaacattgc agcacagggc atgttctgcc 1980  
 cccaaggcaa agaccataag ctactgttgt ctggaaaaca tacaataga tatctcagca 2040  
 aaagctactc atatattctt gttcttttgg gtaaatcatt gtcagtgact gatttttttt 2100  
 tatgaaagga taaaaacacg ccctctattg gggtcagggt ttgtgctggt atttctccca 2160  
 cctactgtat cataggagct tagattccca gctgcttgct ctgagctgca gttctctgat 2220  
 ggcttgacaa ggggtggacca gcccccttcc tctatgtgtg tgtctgtgtg tgacctgtgg 2280  
 ctttgccgag gcagggaagc tactggtagt gcccatggat gggagccact ggttcaccat 2340  
 gaggtcgggt gtggagaaac tcattctcag gg 2372

<210> 55  
 <211> 2372  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>

27/40

&lt;221&gt; allele

&lt;222&gt; (1)... (2372)

&lt;223&gt; UGT1A9 Haplotype 17

&lt;400&gt; 55

ctgttttggc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctgggtctcc	aactcctggc	ctcccgtgat	acgcccacct	tgacctccca	aagtgcctggg	240
actacagggtg	tgagccacca	cggccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tgttatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggag	480
tgatcatga	taaaggtctt	cctottgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agagggtgggt	tggttttgc	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtacactt	ggtgtaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgáaaatgc	ttttttacag	tactagtcct	tcttcccat	720
ttgcttttagt	ttcagtgccc	attcatggaa	gggtttgtgt	tgtaaaaata	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgocaaact	gtttaatagg	aatttgtttt	ctggcatggc	840
ttcttctatg	tcttcttttag	tatctggtac	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctotg	gtgtgggtgc	tattcattct	tgaatttctc	acagattcat	960
atottgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgcagg	1020
caagtagacc	actttgacac	cttcagtggt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggecttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgcctcag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtggt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttccact	gcgtgcgatg	tatttttagga	1560
aagccattta	aaataggaga	cgggtacttt	ccatcaagtc	cctgggtatg	tccatggaag	1620
cagggttgct	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaat	aggaggttag	1740
gaggctcagt	ctaagggcct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaattt	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactttt	actttatctt	tctgaacctt	caaggctcaa	1920
aagcattggt	taataattct	gctactaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcagggt	ttgtgctggt	atttctocca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgctgc	tgacctgtgg	2280
ctttgccgag	gcagggaagc	tactggtagt	gcccattggat	gggagccact	ggttcaccat	2340
gaggtcgggt	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 56

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)... (2372)

&lt;223&gt; UGT1A9 Haplotype 18

&lt;400&gt; 56



28/40

ctgttttggc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggtttaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcatTTTTA	gtagagatag	ggtttccacca	tggtggccag	180
getgggtctcc	aactcctggc	ctcccgatgat	acgcccacct	tgacctccca	aagtgtctggg	240
actacaggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tggtatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggag	480
tgatcatga	taaagggtctt	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggttttgc	gtttcagggg	tgccagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtacactt	gggtgaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaatgc	ttttttacag	tactagtcct	tcttcccat	720
ttgctttagt	ttcagtgc	atccatggaa	gggtttgtgt	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaaact	gtttaatagg	aatttggttt	ctggcatggc	840
ttcttctatg	tcttctttag	tatctggtag	tgattcaaaa	gcactcatct	ccatcaagtc	900
atcttctgtt	gattcctctg	gtgtgggtgc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgagg	1020
caagtagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gctaggggca	1080
ttgtccaaaa	atcaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagttg	acatcacctc	1380
tgacctcaag	gagtgtctag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttcccact	gcgtgcatg	tatcttagga	1560
aagocattta	aaataggaga	cggttacttt	ccatcaagtc	cctgggtatg	tccatggaag	1620
cagggttgct	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gcccccaattt	aggaggttag	1740
gaggtcagtg	ctaagggcct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttggttgcc	taaaggtaaa	atctaaaattt	tgctctggga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactttt	actttatctt	tctgaacctt	caagggtocaa	1920
aagcattgg	taataattct	gtactaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctaactgtgt	ctggaaaaca	tacaaataga	tatctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgact	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcagggt	ttgtgctggt	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgacac	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgtctg	tgacctgtgg	2280
ctttgccgag	gcagggaagc	tactggtagt	gcccattggat	gggagccact	ggttcaccat	2340
gaggtcggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 57

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1) ... (2372)

&lt;223&gt; UGT1A9 Haplotpe 19

&lt;400&gt; 57

ctgttttggc	cgggctggag	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cgggtttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcatTTTTA	gtagagatag	ggtttccacca	tggtggccag	180
getgggtctcc	aactcctggc	ctcccgatgat	acgcccacct	tgacctccca	aagtgtctggg	240
actacaggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300

29/40

actattaata	gcctactgtg	cactagaagc	cttaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tgttatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggag	480
tggatcatga	taaaggctct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggttttgct	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600
gaggagagac	aggtacactt	ggtgtaactt	tacagaatta	catcataatt	attatttgac	660
ttttttgcct	ttgcaattct	ttgaaaaatgc	ttttttacag	tactagtcct	tcttccccat	720
ttgcttttagt	ttcagtgccc	attcatggaa	gggtttgtgt	tgtaaaataa	gtcaaaagta	780
gtcttaataa	ttggaagcct	ttgccaaact	gtttaatagg	aatttgTTTT	ctggcatggc	840
ttcttctatg	totttcttag	tatctggtag	tgattcaaaa	gcactcatct	ccatcaagtc	900
atottctgtt	gattcctctg	gtgtggtgtc	tattcattct	tgaatttctc	acagattcat	960
atcttgaaag	accatatccc	ccaccttttg	ttgctgaatt	agagatattg	ggtttgcagg	1020
caagtagacc	actttgacac	cttcagtgtt	gaactcatgg	gttctgggtg	gotaggggca	1080
ttgtccaaaa	atcaaaaagaa	ctttgaaaga	ccgtctctta	ctggcaagat	attacctgac	1140
ttcagggaca	aagtaatgat	agaaccaatc	cagaaaaagt	gttcttgccg	aggccttctt	1200
gtacaacaaa	aaaactggca	gtgggtattg	atcttttccc	tttaaggctt	ggaggctagc	1260
aggcttatgg	atgggggcag	tcctatttgt	aaacccaaac	atacaaacat	acaaactatg	1320
tcaaaggcat	agcatgggta	ctgtgaaagg	agggtgaaaa	cacaaagtgt	acatcacctc	1380
tgacctcaag	gagtgtctag	cagactgaga	gagacaagta	catattttcc	tgaaggaggg	1440
cactggagtg	atggcgtgtt	tagaatgtgc	aagttgagcg	gtcactgaga	ggcagctcag	1500
cagagtgtct	tcgcaaggat	tgggcgggca	acttccact	gcgtgcatg	tattcttaga	1560
aagccattta	aaataggaga	cgtttacttt	ccatcaagtc	cctggtagtg	tccatggaag	1620
cagggttgtc	agtctcattt	cagcatttta	gaggcttctc	agggtttgga	aatggaagaa	1680
gagaagcagc	aatatgtatg	cattgcagag	acacaggcga	gccccaat	aggaggttag	1740
gaggtcagtg	ctaagggcct	tgttttcttt	gcttagagca	tgagttgcca	tcttctctgg	1800
acagagagta	tttgggtgcc	taaaggtaaa	atctaaattt	tgtcttgga	caaattccaa	1860
aaaaaattag	ctttaatcaa	atttactctt	actttatctt	tctgaacctt	caagggtccaa	1920
aagcattggt	taataattct	gcttctaaac	ttaacattgc	agcacagggc	atgttctgcc	1980
cccaaggcaa	agaccataag	ctactgttgt	ctggaaaaca	tacaaataga	tattctcagca	2040
aaagctactc	atatattctt	gttcttttgg	gtaaatcatt	gtcagtgaat	gatttttttt	2100
tatgaaagga	taaaaacacg	ccctctattg	gggtcagggt	ttgtgtggtg	atttctccca	2160
cctactgtat	cataggagct	tagattccca	gctgcttgct	ctcagctgca	gttctctgat	2220
ggcttgccaca	gggtggacca	gcccccttcc	tctatgtgtg	tgtctgtctg	tgacctgtgg	2280
ctttgcgcag	gcaggggaagc	tactggtagt	gcccattggat	gggagccact	ggttcacat	2340
gaggtcgggtg	gtggagaaac	tcattctcag	gg			2372

&lt;210&gt; 58

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 20

&lt;400&gt; 58

ctgttttggc	cggttgagg	tataatggcg	tgatctcagc	tcaatgcaac	ctccgcttcc	60
cggtttcaag	tgattctcct	gcctcagcct	ccagagtagc	tgggattaca	ggcatgcacc	120
accacctgca	gctaattttt	tgcattttta	gtagagatag	ggtttcacca	tggtggccag	180
gctgggtctc	aactcctggc	ctcccgtgat	acgcccacct	tgacctccca	aagtgtctggg	240
actacaggtg	tgagccacca	cgcccaggca	cacatagaat	ttttgactcc	ctaaaaattt	300
actattaata	gcctactgtg	cactagaagc	cttaccaata	acagaaacag	ttgcttaaca	360
catatttggc	atgttatatg	tgttatatac	tgtattatca	taatgaagtc	agctagagaa	420
aagaaaatgt	tattaagaaa	atcttaagga	agagaaaatt	aagtattcat	taagtggag	480
tggatcatga	taaaggctct	cctcttgatt	gtcctccatt	gagtaggctg	agaaggagga	540
agaggtgggt	tggttttgct	gtttcagggg	tggcagaggg	ggaagaagtg	gaggaagaag	600

30/40

```

gaggagagac aggtacactt ggtgtaactt tacagaatta catcataatt attatttgac 660
ttttttgcct ttgcaattct ttgaaaatgc ttttttacag tactagtctt tcttccccat 720
ttgcttttagt ttcagtgcc attcatggaa ggggtttgtg tgtaaaataa gtcaaaagta 780
gtcttaataa ttggaagcct ttgccaaact gtttaatagg aatttgtttt ctggcatggc 840
ttcttctatg tcttcttttag tatctggtac tgattcaaaa gcactcatct ccatcaagtc 900
atcttctgtt gattcctotg gtgtggtgtc tattcattct tgaatttctc acagattcat 960
atcttgaaag accatatccc ccaccttttg ttgctgaatt agagatattg ggtttgagg 1020
caagtagacc actttgacac cttcagtgtt gaactcatgg gttctgggtg gctaggggca 1080
ttgtccaaaa atcaaaagaa ctttgaaaga ccgtctctta ctggcaagat attadctgac 1140
ttcagggaca aagtaatgat agaaccaatc cagaaaaagt gttcttgccg aggccttctt 1200
gtacaacaaa aaaactggca gtgggtattg atcttttccc ttaaggctt ggaggctagc 1260
aggtttatgg atggggggcag tcctatttgt aaacccaaac atacaaacat acaaactatg 1320
tcaaaggcat agcatgggta ctgtgaaagg aggggtgaaa cacaaagttg acatcacctc 1380
tgacctcaag gagtgtctcag cagactgaga gagacaagta catattttcc tgaaggaggg 1440
cactggagtg atggcgtgtt tagaatgtgc aagttgagcg gtcactgaga ggcagctcag 1500
cagagtgtct tgcgaaggat tgggggggca acttcccact gcgtgcatg tatcttagga 1560
aagccattta aataggaga cgtttacttt ccatcaagtc cctgggtatg tccatggaag 1620
cagggttgtc agtctcattt cagcatttta gaggtctctc aggggtttgga aatggaagaa 1680
gagaagcagc aatatgtatg cattgcagag acacaggcga gcccgaattt aggaggttag 1740
gaggtcagtg ctaagggcct tgttttcttt gcttagagca tgagttgcca tcttctctgg 1800
acagagagta tttggttgcc taaaggtaaa atctaaattt tgctctggga caaattccaa 1860
aaaaaattag cttaaatcaa atttactctt actttatott tctgaacctt caaggtccaa 1920
aagcattggt taataattct gcttctaaac ttaacattgc agcacagggc atgttctgcc 1980
cccaaggcaa agaccataag ctactgttgt ctggaaaaca tacaataaga tatctcagca 2040
aaagctactc atatatctt gtcttttgg gtaaatcatt gtcagtgaat gatttttttt 2100
tatgaaagga taaaaacacg cctctatttg gggtcagggt ttgtgctggt atttctccca 2160
cctactgtat cataggagct tagattccca gctgcttgct ctcagctgca gttctctgat 2220
ggcttgacaa gggtggaaca gccctcttcc tctatgtgtg tgtctgctgc tgacctgtg 2280
ctttgcgag gcagggaagc tactggtagt gcccatggat gggagccact ggttcacat 2340
gaggtcgggt gtggagaaac tcattctcag gg 2372

```

&lt;210&gt; 59

&lt;211&gt; 2372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(2372)

&lt;223&gt; UGT1A9 Haplotype 21

&lt;400&gt; 59

```

ctgttttgcc cgggctggag tataatggcg tgatctcagc tcaatgcaac ctccgcttcc 60
cgggttcaag tgattctcct gcctcagcct ccagagtagc tgggattaca ggcattgcacc 120
accacctgca gctaattttt tgcattttta gtagagatag ggtttcacca tgttggccag 180
gctggtctcc aactcctggc ctcccgtgat acgcccacot tgacctccca aagtgtctggg 240
actacagggt tgagccacca cgcocaggca cacatagaat ttttgactcc ctaaaaattt 300
actattaata gcctactgtg cactagaagc ottaccaata acagaaacag ttgcttaaca 360
catatttggc atgttatatg tgttatatac tgtattatca caatgaagtc agctagagaa 420
aagaaaatgt tattaagaaa atcttaagga agagaaaatt aagtattcat taagtggag 480
tggatcatga taaaggctct cctcttgatt gtcctccatt gtagaggctg agaaggagga 540
agagggtggg ttggttttgc gtttcagggg tggcagaggg ggaagaagtg gaggaagaag 600
gaggagagac aggtacactt ggtgtaactt tacagaatta catcataatt attatttgac 660
ttttttgcct ttgcaattct ttgaaaatgc ttttttacag tactagtctt tcttccccat 720
ttgcttttagt ttcagtcccc attcatggaa ggggtttgtg tgtaaaataa gtcaaaagta 780
gtcttaataa ttggaagcct ttgccaaact gtttaatagg aatttgtttt ctggcatggc 840
ttcttctatg tcttcttttag tatctggtac tgattcaaaa gcactcatct ccatcaagtc 900

```

31/40

```

atcttctgtt gattcctctg gtgtggtgtc tattcattct tgaattttct acagattcat 960
atcttgaaag accatatccc ccaccttttg ttgctgaatt agagatattg ggtttgagg 1020
caagtagacc aqtttgacac cttcagtggt gaactcatgg gttctgggtg gctaggggca 1080
ttgtccaaaa atcaaaaaga ctttgaaaga ccgtctctta ctggcaagat attacctgac 1140
ttcagggaca aagtaatgat agaaccaatc cagaaaaagt gttcttgccg aggccttctt 1200
gtacaacaaa aaaaotggca gtgggtattg atcttttccc ttttaaggctt ggaggctagc 1260
aggcttatgg atggggggcag tcctatttgt aaaccccaac atacaaacat acaaaactatg 1320
tcaaaggcat agcatgggta ctgtgaaagg aggggtgaaa cacaagttg acatcacctc 1380
tgacctcaag gagtgtcag cagactgaga gagacaagta catattttcc tgaaggaggg 1440
cactggagtg atggcgtgtt tagaatgtgc aagttgagcg gtcactgaga ggcagctcag 1500
cagagtgtct tcgcaaggat tggggcgggca acttcccact gcgtgogatg ttttttagga 1560
aagccattta aaataggaga cggttacttt ccatcaagtc cctggtatgg tccatggaag 1620
cagggttgtc agtctcattt cagcatttta gaggcttctc aggggtttgga aatggaagaa 1680
gagaagcagc aatatgtatg cattgcagag acacaggcga gcccgaattt aggaggttag 1740
gaggtcagtg ctaagggcct tgttttcttt gcttagagca tgagttgcca tcttctctgg 1800
acagagagta tttggttgcc taaaggtaaa atctaaattt tgctctggga caaattccaa 1860
aaaaaattag ctttaataca atttactttt actttatctt tctgaacctt caaggtccaa 1920
aagcattggt taataattct gcttctaaac ttaacattgc agcacagggc atgttctgcc 1980
cccaaggcaa agaccataag ctactgttgt ctggaaaaca tacaataga tatctcagca 2040
aaagctactc atatatcttt gttcttttgg gtaaatcatt gtcagtgaat gatttttttt 2100
tatgaaagga taaaaacacg ccctctattg gggtcagggt ttgtgctggt atttctccca 2160
cctactgtat cataggagct tagattccca gctgcttgc ctcagctgca gttctctgat 2220
ggcttgacac ggttgaggca gccccttcc tctatgtgtg tgtctgctgc tgacctgtgg 2280
ctttgccgag gcagggaagc tactggtagt gcccacggat gggagccact ggttcaccat 2340
gaggtcggtg gtggagaaac tcattctcag gg 2372

```

```

<210> 60
<211> 1229
<212> DNA
<213> Homo sapiens

<220>
<221> allele
<222> (1)...(1229)
<223> UGT1A7*1

```

```

<400> 60
atggctcgtg caggggtggac tggcctcctt ccactatatg tgtgtctact gctgacctgt 60
ggctttgcca aggcaggga gctgctggta gtgccatgg atgggagcca ctgggttcacc 120
atgcagtcgg tgggtggaga actcatcctc agggggcatg aggtggctgt agtcatgcca 180
gaggtgagtt ggcaactggg aagatcactg aattgcaacg tgaagaotta ctcaacctca 240
tacactctgg aggatcagga ccgggagttc atggtttttg ccgatgctcg ctggacggca 300
ccattgcaaa gtgcattttc tctattaaca agttcatcca atgggtattt tgacttattt 360
ttttcaaatt gcaggagttt gtttaatgac cgaaaattag tagaatactt aaaggagagt 420
tgttttgatg cagtgtttct cgatcctttt gatgcctgtg gcttaattgt tgccaaatat 480
ttctccctcc cctctgtggt ctctgccagg ggaatatatt gccactatct tgaagaagg 540
gcacagtgcc ctgctcctct ttctatgtc ccagacttc tcttaggggt ctcagacgcc 600
atgactttta aggagagagt atggaaccac atcatgcaat tggaggaaca tttattttgc 660
ccctattttt tcaaaaatgt cttagaaata gcctctgaaa ttctocaaac cctgtcagc 720
gcatatgatc tctacagcca cacatcaatt tgggtgtgtg gaactgactt tgttttgagg 780
tatcccaaac ccgtgatgcc caatatgatc ttcatgtgtg gtatcaactg tcatcaggga 840
aagccagtgc ctatggtaag ttatctccc ttttagacat taagaataat ctggcttttg 900
aaattaaaag atttcttaca gaatcataat ttatcattta catttgtccc atttggaatt 960
tctttctggt ttttaaggatt cttttgtacc aattcactta attgttgggt agcaaatgt 1020
ataaagcagc tcttgttgat atgtaagtgt atacaattga tataattgta gatcatact 1080
aggctgcaat ctaaagtcta tttttggaaa aatacaaaaa aaccacagta agaaatgaaa 1140
cttccctttt tttgctaatt ctacactacc ccagaggaa aatattctta gcagttttgt 1200

```

32/40

gtgaattggtt ttcaatTTTT ttgaaatta

1229

&lt;210&gt; 61

&lt;211&gt; 1229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(1229)

&lt;223&gt; UGT1A7\*2

&lt;400&gt; 61

atggctcgtg	caggggtggac	tggcctcctt	ccactatatg	tgtgtctact	gctgacctgt	60
ggctttgcc	aggcagggaa	gctgctggta	gtgccatgg	atgggagcca	ctggttcacc	120
atgcagtcgg	tgggtggagaa	actcatcctc	agggggcatg	agggtggtcgt	agtcatgcc	180
gaggtgagtt	ggcaactggg	aagatcactg	aattgcacag	tgaagactta	ctcaacctca	240
tacactctgg	aggatcagga	ccgggagttc	atgggttttg	ccgatgctcg	ctggacggca	300
ccattgcgaa	gtgcattttc	tctattaaca	agttcatcca	atggatattt	tgacttattt	360
ttttcaaatt	gcaggagttt	gtttaaggac	aaaaaattag	tagaatactt	aaaggagagt	420
tgttttgatg	cagtgtttct	cgatcctttt	gatgcctgtg	gcttaattgt	tgccaaatat	480
ttctccctcc	cctctgtggt	cttcgccagg	ggaatatttt	gccactatct	tgaagaaggt	540
gcacagtgcc	ctgctcctct	ttcctatgtc	cccagacttc	tcttaggggt	ctcagacgcc	600
atgactttca	aggagagagt	atggaaccac	atcatgcact	tggaggaaca	tttattttgc	660
ccctattttt	tcaaaaatgt	cttagaaata	gcctctgaaa	ttctocaaac	ccctgtcacg	720
gcatatgata	tctacagcca	cacatcaatt	tggttgttgc	gaactgactt	tgttttggag	780
tatcccaaac	ccgtgatgcc	caatatgata	ttcattggtg	gtatcaactg	tcatcagggg	840
aagccagtgc	ctatggttaag	ttatctcccc	tttagcacat	taagaataat	ctggccttgg	900
aaattaaaag	atttcttaca	gaatcataat	ttatcattta	cattttgtccc	atttgggaatt	960
tctttctggt	ttaagggaatt	cttttgtacc	aattcactta	attgttgggt	agcaaattgt	1020
ataaagcagc	tcttgttgat	atgtaagtgt	atacaattga	tataattgta	gatcatatct	1080
aggctgcaat	ctaaatgcta	tttttggaaa	aatacaaaaa	aaccacagta	agaaatgaaa	1140
cttccctttt	tttgcataatt	ctacactacc	cccagaggaa	aatattctta	gcagttttgt	1200
gtgaattggtt	ttcaatTTTT	ttgaaatta				1229

&lt;210&gt; 62

&lt;211&gt; 1229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(1229)

&lt;223&gt; UGT1A7\*3

&lt;400&gt; 62

atggctcgtg	caggggtggac	tggcctcctt	ccactatatg	tgtgtctact	gctgacctgt	60
ggctttgcc	aggcagggaa	gctgctggta	gtgccatgg	atgggagcca	ctggttcacc	120
atgcagtcgg	tgggtggagaa	actcatcctc	agggggcatg	agggtggtcgt	agtcatgcc	180
gaggtgagtt	ggcaactggg	aagatcactg	aattgcacag	tgaagactta	ctcaacctca	240
tacactctgg	aggatcagga	ccgggagttc	atgggttttg	ccgatgctcg	ctggacggca	300
ccattgcgaa	gtgcattttc	tctattaaca	agttcatcca	atggatattt	tgacttattt	360
ttttcaaatt	gcaggagttt	gtttaaggac	aaaaaattag	tagaatactt	aaaggagagt	420
tgttttgatg	cagtgtttct	cgatcctttt	gatgcctgtg	gcttaattgt	tgccaaatat	480
ttctccctcc	cctctgtggt	cttcgccagg	ggaatatttt	gccactatct	tgaagaaggt	540
gcacagtgcc	ctgctcctct	ttcctatgtc	cccagacttc	tcttaggggt	ctcagacgcc	600
atgactttca	aggagagagt	acggaaccac	atcatgcact	tggaggaaca	tttattttgc	660

33/40

```

ccctattttt tcaaaaatgt cttagaaata gcctctgaaa ttctccaaac ccctgtcacg      720
gcatatgac tctacagcca cacatcaatt tgggtgttgc gaactgactt tgttttggag      780
tatcccaaac ccgtgatgcc caatatgac ttcatgtgtg gtatcaactg tcatcaggga      840
aagccagtgc ctatggttaag ttatctcccc tttagcacat taagaataat ctggcctttgg      900
aaattaaaag atttcttaca gaatcataat ttatcattta catttgtccc atttgggaatt      960
tctttctggg ttaaggaatt cttttgtacc aattcactta attgttgggt agcaaattgt     1020
ataaagcagc tcttgttgat atgtaagtgt atacaattga tataattgta gatcatatct     1080
aggctgcaat ctaaagtcta tttttggaaa aatacaaaaa aaccacagta agaaatgaaa     1140
cttccctttt tttgctaatt ctacactacc ccagaggaa aatattctta gcagttttgt     1200
gtgaattgtt ttcaattttt ttgaaatta                                     1229

```

<210> 63  
 <211> 1229  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> (1)...(1229)  
 <223> UGT1A7\*4

```

<400> 63
atggctcgtg caggggtggac tggcctcctt ccactatatg tgtgtctact gctgacctgt      60
ggctttgcc aaggcaggaa gctgctggta gtgccatgg atgggagcca ctggttcacc      120
atgcagtcgg tggaggagaa actcatcctc agggggcatg aggtggtcgt agtcatgcca      180
gaggtgagtt ggcaactggg aagatcactg aattgcacag tgaagactta ctcaacctca      240
tacactctgg aggatcagga ccgggagttc atgggttttg ccgatgctcg ctggacggca      300
ccattgcgaa gtgcattttc tctattaaca agttcatcca atgggtatttt tgacttattt      360
ttttcaaatt gcaggagttt gtttaatgac cgaattatag tagaatactt aaaggagagt      420
tgttttgatg cagtgtttct cgatcctttt gatgectgtg gcttaattgt tgccaaatat      480
ttctccctcc cctctgtggg cttcgccagg ggaatatttt gccactatct tgaagaagggt      540
gcacagtgcc ctgctcctct ttcttatgtc ccagacttc tcttaggggt ctacagcgcc      600
atgactttca aggagagagt acggaaccac atcatgcact tggagggaaca tttattttgc      660
ccctattttt tcaaaaatgt cttagaaata gcctctgaaa ttctccaaac ccctgtcacg      720
gcatatgac tctacagcca cacatcaatt tgggtgttgc gaactgactt tgttttggag      780
tatcccaaac ccgtgatgcc caatatgac ttcatgtgtg gtatcaactg tcatcaggga      840
aagccagtgc ctatggttaag ttatctcccc tttagcacat taagaataat ctggcctttgg      900
aaattaaaag atttcttaca gaatcataat ttatcattta catttgtccc atttgggaatt      960
tctttctggg ttaaggaatt cttttgtacc aattcactta attgttgggt agcaaattgt     1020
ataaagcagc tcttgttgat atgtaagtgt atacaattga tataattgta gatcatatct     1080
aggotgcaat ctaaagtcta tttttggaaa aatacaaaaa aaccacagta agaaatgaaa     1140
cttccctttt tttgctaatt ctacactacc ccagaggaa aatattctta gcagttttgt     1200
gtgaattgtt ttcaattttt ttgaaatta                                     1229

```

<210> 64  
 <211> 1229  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> (1)...(1229)  
 <223> UGT1A7\*5

```

<400> 64
atggctcgtg caggggtggac tggcctcctt ccactatatg tgtgtctact gctgacctgt      60
ggctttgcc aaggcaggaa gctgctggta gtgccatgg atgggagcca ctggttcacc      120

```

34/40

atgcagtcgg	tgggtggagaa	actcatcctc	agggggcatg	aggtggctcg	agtcatgcc	180
gaggtgagtt	ggcaactggg	aagatcactg	aattgcacag	tgaagactta	ctcaacctca	240
tacactctgg	aggatcagga	cggggagtgc	atggtttttg	cogatgctcg	ctggacggca	300
ccattgcgaa	gtgcattttc	tctattaaca	agttcatcca	atagtatttt	tgacttattt	360
ttttcaaatt	gcaggagttt	gtttaatgac	cgaaaattag	tagaatactt	aaaggagagt	420
tgttttgatg	cagtgtttct	cgatcctttt	gatgcctgtg	gcttaattgt	tgccaaatat	480
ttctccctcc	cctctgtggg	cttcgccagg	ggaatatattt	gccactatct	tgaagaaggt	540
gcacagtgcc	ctgctcctct	ttcctatgtc	cccagacttc	tcttaggggt	ctcagacgcc	600
atgactttca	aggagagagt	atggaaccac	atcatgcact	tggaggaaca	tttattttgc	660
ccctattttt	tcaaaaatgt	cttagaaata	gcctctgaaa	ttctccaaac	ccctgtcacg	720
gcatatgac	tctacagcca	cacatcaatt	tggttggtgc	gaactgactt	tgttttggag	780
tatcccaaac	ccgtgatgcc	caatatgac	ttcattgggtg	gtatcaactg	tcacagggga	840
aagccagtgc	ctatggtaag	ttatctcccc	tttagcacat	taagaataat	ctggctttgg	900
aaattaaaag	atttcttaca	gaatcataat	ttatcattta	catttgctcc	atttgggaatt	960
tctttctggg	ttaaggaatt	cttttgtacc	aattcactta	attgttgggt	agcaaatgtt	1020
ataaagcagc	tcttgttgat	atgtaagtgt	atacaattga	tataattgta	gatcatatct	1080
aggctgcaat	ctaaatgcta	tttttggaag	aatacaaaaa	aaccacagta	agaaatgaaa	1140
cttccctttt	tttgctaatt	ctacactacc	cccagaggaa	aatattctta	gcagttttgt	1200
gtgaattggt	ttcaattttt	ttgaaatta				1229

&lt;210&gt; 65

&lt;211&gt; 1229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(1229)

&lt;223&gt; UGT1A7\*6

&lt;400&gt; 65

atggctcgtg	cagggtggac	tggcctcctt	ccactatatg	tgtgtctaet	gotgacctgt	60
ggctttgcca	aggcagggaa	gctgctggtg	gtgcccatgg	atgggagcca	ctggttcacc	120
atgcagtcgg	tgggtggagaa	actcatcctc	agggggcatg	aggtggctcg	agtcatgcc	180
gaggtgagtt	ggcaactggg	aagatcactg	aattgcacag	tgaagactta	ctcaacctca	240
tacactctgg	aggatcagga	cggggagtgc	atggtttttg	cogatgctcg	ctggacggca	300
ccattgcgaa	gtgcattttc	tctattaaca	agttcatcca	atggatattt	tgacttattt	360
ttttcaaatt	gcaggagttt	gtttaatgac	cgaaaattag	tagaatactt	aaaggacagt	420
tgttttgatg	cagtgtttct	cgatcctttt	gatgcctgtg	gcttaattgt	tgccaaatat	480
ttctccctcc	cctctgtggg	cttcgccagg	ggaatatattt	gccactatct	tgaagaaggt	540
gcacagtgcc	ctgctcctct	ttcctatgtc	cccagacttc	tcttaggggt	ctcagacgcc	600
atgactttca	aggagagagt	atggaaccac	atcatgcact	tggaggaaca	tttattttgc	660
ccctattttt	tcaaaaatgt	cttagaaata	gcctctgaaa	ttctccaaac	ccctgtcacg	720
gcatatgac	tctacagcca	cacatcaatt	tggttggtgc	gaactgactt	tgttttggag	780
tatcccaaac	ccgtgatgcc	caatatgac	ttcattgggtg	gtatcaactg	tcacagggga	840
aagccagtgc	ctatggtaag	ttatctcccc	tttagcacat	taagaataat	ctggctttgg	900
aaattaaaag	atttcttaca	gaatcataat	ttatcattta	catttgctcc	atttgggaatt	960
tctttctggg	ttaaggaatt	cttttgtacc	aattcactta	attgttgggt	agcaaatgtt	1020
ataaagcagc	tcttgttgat	atgtaagtgt	atacaattga	tataattgta	gatcatatct	1080
aggctgcaat	ctaaatgcta	tttttggaag	aatacaaaaa	aaccacagta	agaaatgaaa	1140
cttccctttt	tttgctaatt	ctacactacc	cccagaggaa	aatattctta	gcagttttgt	1200
gtgaattggt	ttcaattttt	ttgaaatta				1229

&lt;210&gt; 66

&lt;211&gt; 1229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

35/40

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(1229)

&lt;223&gt; UGT1A7\*7

&lt;400&gt; 66

atggctcgtg	caggggtggac	tggcctcctt	ccactatatg	tgtgtctact	gctgacctgt	60
ggctttgcca	aggcagggaa	gctgctggta	gtgcccatgg	atgggagcca	ctggttcacc	120
atgcagtcgg	tgggtggagaa	actcatcctc	agggggcatg	agggtggtcgt	agtcatgccca	180
gaggtgagtt	ggcaactggg	aagatcactg	aattgcacag	tgaagactta	ctcaacctca	240
tacactctgg	aggatcagga	cggggagtgc	atgggttttg	ccgatgctcg	ctggacggca	300
ccattgcgaa	gtgcattttc	tctattaaca	agttcatcca	atgggtatgtt	tgacttatgtt	360
ttttcaaatt	gcaggagttt	gtttaaggac	aaaaaattag	tagaatactt	aaaggacagt	420
tgttttgatg	cagtgtttct	cgatcctttt	gatgcctgtg	gcttaattgt	tgccaaatat	480
ttctccctcc	cctctgtggg	cttcgccagg	ggaatatttt	gccactatct	tgaagaagggt	540
gcacagtgcc	ctgctcctct	ttcctatgtc	cccagacttc	tcttaggggt	ctcagacgcc	600
atgactttca	aggagagagt	atggaaccac	atcatgcact	tggaggaaca	tttatgttgc	660
ccctatgttt	tcaaaaatgt	cttagaaaata	gcctctgaaa	ttctccaaac	ccctgtcacg	720
gcataatgat	tctacagcca	cacatcaatt	tgggtgttgc	gaactgactt	tgttttggag	780
tatcccaaac	ccgtgatgcc	caatatgatc	ttcattgggtg	gtatcaactg	tcatacaggga	840
aagccagtgc	ctatggttaag	ttatctcccc	tttagcacat	taagaataat	ctggctttgg	900
aaattaaaag	atttcttaca	gaatcataat	ttatcattta	catttgtccc	atttgggaatt	960
tctttctggt	ttaaggaatt	cttttgtacc	aattcactta	attgttgggt	agcaaattgt	1020
ataaagcagc	tcttgttgat	atgtaagtgt	atacaattga	tataattgta	gatcatatct	1080
aggctgcaat	ctaaatgcta	tttttggaaa	aatacaaaaa	aaccacagta	agaaatgaaa	1140
cttccctttt	tttgctaatt	ctacactacc	cccagaggaa	aatattctta	gcagttttgt	1200
gtgaattggt	ttcaattttt	ttgaaatta				1229

&lt;210&gt; 67

&lt;211&gt; 1229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)...(1229)

&lt;223&gt; UGT1A7\*8

&lt;400&gt; 67

atggctcgtg	caggggtggac	tggcctcctt	ccactatatg	tgtgtctact	gctgacctgt	60
ggctttgcca	aggcagggaa	gctgctggta	gtgcccatgg	atgggagcca	ctggttcacc	120
atgcagtcgg	tgggtggagaa	actcatcctc	agggggcatg	agggtggtcgt	agtcatgccca	180
gaggtgagtt	ggcaactggg	aagatcactg	aattgcacag	tgaagactta	ctcaacctca	240
tacactctgg	aggatcagga	cggggagtgc	atgggttttg	ccgatgctcg	ctggacggca	300
ccattgcgaa	gtgcattttc	tctattaaca	agttcatcca	atgggtatgtt	tgacttatgtt	360
ttttcaaatt	gcaggagttt	gtttaaggac	aaaaaattag	tagaatactt	aaaggacagt	420
tgttttgatg	cagtgtttct	cgatcctttt	gatgcctgtg	gcttaattgt	tgccaaatat	480
ttctccctcc	cctctgtggg	cttcgccagg	ggaatatttt	gccactatct	tgaagaagggt	540
gcacagtgcc	ctgctcctct	ttcctatgtc	cccagacttc	tcttaggggt	ctcagacgcc	600
atgactttca	aggagagagt	acggaaccac	atcatgcact	tggaggaaca	tttatgttgc	660
ccctatgttt	tcaaaaatgt	cttagaaaata	gcctctgaaa	ttctccaaac	ccctgtcacg	720
gcataatgat	tctacagcca	cacatcaatt	tgggtgttgc	gaactgactt	tgttttggag	780
tatcccaaac	ccgtgatgcc	caatatgatc	ttcattgggtg	gtatcaactg	tcatacaggga	840
aagccagtgc	ctatggttaag	ttatctcccc	tttagcacat	taagaataat	ctggctttgg	900
aaattaaaag	atttcttaca	gaatcataat	ttatcattta	catttgtccc	atttgggaatt	960
tctttctggt	ttaaggaatt	cttttgtacc	aattcactta	attgttgggt	agcaaattgt	1020



36/40

ataaagcagc tcttgttgat atgtaagtgt atacaattga tataattgta gatcatatct	1080
aggctgcaat ctaaatgcta tttttggaaa aatacaaaaa aaccacagta agaaatgaaa	1140
cttccctttt tttgctaatt ctacactacc cccagaggaa aatattctta gcagttttgt	1200
gtgaattggt ttcaattttt ttgaaatta	1229

&lt;210&gt; 68

&lt;211&gt; 1229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; (1)... (1229)

&lt;223&gt; UGT1A7\*9

&lt;400&gt; 68

atggctcgtg caggggtggac tggcctcctt ccactatatg tgtgtctact gctgacctgt	60
ggctttgccca aggcagggaa gctgctggta gtgcccattg atgggagcca ctggttcacc	120
atgcagtcgg tgggtggagaa actcatcctc agggggcatg aggtggctgt agtcatgccca	180
gaggtgagtt ggcaactggg aagatcactg aattgcacag tgaagactta ctcaacctca	240
tacactctgg aggatcagga cggggagttc atgggttttg ccgatgctcg ctggacggca	300
ccattgcgaa gtgcattttc tctattaaca agttcatcca atagtatttt tgacttattt	360
ttttcaaat gcaggagttt gtttaaggac aaaaaattag tagaatactt aaaggagagt	420
tgttttgatg cagtgtttct cgatcctttt gatgcctgtg gcttaattgt tgccaaatat	480
ttctccctcc cctctgtggt cttcgccagg ggaatatttt gccactatct tgaagaaggt	540
gcacagtgcc ctgctcctct ttcttatgtc cccagacttc tcttaggggt ctcagaagcc	600
atgactttca aggagagagt atggaaccac atcatgcaat tggaggaaca tttattttgc	660
ccctattttt tcaaaaatgt cttagaaata gcctctgaaa ttctocaaac ccctgtcacg	720
gcatatgac tctacagcca cacatcaatt tgggtgtgtg gaactgactt tgttttggag	780
tatoccaaac ccgtgatgcc caatatgac ttcatgtgtg gtatcaactg tcatcagga	840
aagccagtgc ctatggttaag ttatctcccc tttagcacat taagaataat ctggctttgg	900
aaattaaaag atttcttaca gaatcataat ttatcattta catttgtccc atttggaatt	960
tctttctggt ttaaggaatt cttttgtacc aattcactta attgttgggt agcaaattgt	1020
ataaagcagc tcttgttgat atgtaagtgt atacaattga tataattgta gatcatatct	1080
aggctgcaat ctaaatgcta tttttggaaa aatacaaaaa aaccacagta agaaatgaaa	1140
cttccctttt tttgctaatt ctacactacc cccagaggaa aatattctta gcagttttgt	1200
gtgaattggt ttcaattttt ttgaaatta	1229

&lt;210&gt; 69

&lt;211&gt; 530

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)... (530)

&lt;223&gt; UGT1A9\*1 protein

&lt;400&gt; 69

Met	Ala	Cys	Thr	Gly	Trp	Thr	Ser	Pro	Leu	Pro	Leu	Cys	Val	Cys	Leu
1				5					10					15	
Leu	Leu	Thr	Cys	Gly	Phe	Ala	Glu	Ala	Gly	Lys	Leu	Leu	Val	Val	Pro
			20					25					30		
Met	Asp	Gly	Ser	His	Trp	Phe	Thr	Met	Arg	Ser	Val	Val	Glu	Lys	Leu
		35					40						45		
Ile	Leu	Arg	Gly	His	Glu	Val	Val	Val	Val	Met	Pro	Glu	Val	Ser	Trp
	50					55					60				

37/40

Gln Leu Gly Arg Ser Leu Asn Cys Thr Val Lys Thr Tyr Ser Thr Ser  
 65 70 75 80  
 Tyr Thr Leu Glu Asp Leu Asp Arg Glu Phe Lys Ala Phe Ala His Ala  
 85 90 95  
 Gln Trp Lys Ala Gln Val Arg Ser Ile Tyr Ser Leu Leu Met Gly Ser  
 100 105 110  
 Tyr Asn Asp Ile Phe Asp Leu Phe Phe Ser Asn Cys Arg Ser Leu Phe  
 115 120 125  
 Lys Asp Lys Lys Leu Val Glu Tyr Leu Lys Glu Ser Ser Phe Asp Ala  
 130 135 140  
 Val Phe Leu Asp Pro Phe Asp Asn Cys Gly Leu Ile Val Ala Lys Tyr  
 145 150 155 160  
 Phe Ser Leu Pro Ser Val Val Phe Ala Arg Gly Ile Leu Cys His Tyr  
 165 170 175  
 Leu Glu Glu Gly Ala Gln Cys Pro Ala Pro Leu Ser Tyr Val Pro Arg  
 180 185 190  
 Ile Leu Leu Gly Phe Ser Asp Ala Met Thr Phe Lys Glu Arg Val Arg  
 195 200 205  
 Asn His Ile Met His Leu Glu His Leu Leu Cys His Arg Phe Phe  
 210 215 220  
 Lys Asn Ala Leu Glu Ile Ala Ser Glu Ile Leu Gln Thr Pro Val Thr  
 225 230 235 240  
 Glu Tyr Asp Leu Tyr Ser His Thr Ser Ile Trp Leu Leu Arg Thr Asp  
 245 250 255  
 Phe Val Leu Asp Tyr Pro Lys Pro Val Met Pro Asn Met Ile Phe Ile  
 260 265 270  
 Gly Gly Ile Asn Cys His Gln Gly Lys Pro Leu Pro Met Glu Phe Glu  
 275 280 285  
 Ala Tyr Ile Asn Ala Ser Gly Glu His Gly Ile Val Val Phe Ser Leu  
 290 295 300  
 Gly Ser Met Val Ser Glu Ile Pro Glu Lys Lys Ala Met Ala Ile Ala  
 305 310 315 320  
 Asp Ala Leu Gly Lys Ile Pro Gln Thr Val Leu Trp Arg Tyr Thr Gly  
 325 330 335  
 Thr Arg Pro Ser Asn Leu Ala Asn Asn Thr Ile Leu Val Lys Trp Leu  
 340 345 350  
 Pro Gln Asn Asp Leu Leu Gly His Pro Met Thr Arg Ala Phe Ile Thr  
 355 360 365  
 His Ala Gly Ser His Gly Val Tyr Glu Ser Ile Cys Asn Gly Val Pro  
 370 375 380  
 Met Val Met Met Pro Leu Phe Gly Asp Gln Met Asp Asn Ala Lys Arg  
 385 390 395 400  
 Met Glu Thr Lys Gly Ala Gly Val Thr Leu Asn Val Leu Glu Met Thr  
 405 410 415  
 Ser Glu Asp Leu Glu Asn Ala Leu Lys Ala Val Ile Asn Asp Lys Ser  
 420 425 430  
 Tyr Lys Glu Asn Ile Met Arg Leu Ser Ser Leu His Lys Asp Arg Pro  
 435 440 445  
 Val Glu Pro Leu Asp Leu Ala Val Phe Trp Val Glu Phe Val Met Arg  
 450 455 460  
 His Lys Gly Ala Pro His Leu Arg Pro Ala Ala His Asp Leu Thr Trp  
 465 470 475 480  
 Tyr Gln Tyr His Ser Leu Asp Val Ile Gly Phe Leu Leu Ala Val Val  
 485 490 495  
 Leu Thr Val Ala Phe Ile Thr Phe Lys Cys Cys Ala Tyr Gly Tyr Arg  
 500 505 510  
 Lys Cys Leu Gly Lys Lys Gly Arg Val Lys Lys Ala His Lys Ser Lys

38/40

515                      520                      525  
 Thr His  
 530  
  
 <210> 70  
 <211> 530  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> VARIANT  
 <222> (1)...(50)  
 <223> UGT1A9\*2 protein  
  
 <400> 70  
 Met Ala Tyr Thr Gly Trp Thr Ser Pro Leu Pro Leu Cys Val Cys Leu  
 1                      5                      10                      15  
 Leu Leu Thr Cys Gly Phe Ala Glu Ala Gly Lys Leu Leu Val Val Pro  
 20                      25                      30  
 Met Asp Gly Ser His Trp Phe Thr Met Arg Ser Val Val Glu Lys Leu  
 35                      40                      45  
 Ile Leu Arg Gly His Glu Val Val Val Met Pro Glu Val Ser Trp  
 50                      55                      60  
 Gln Leu Gly Arg Ser Leu Asn Cys Thr Val Lys Thr Tyr Ser Thr Ser  
 65                      70                      75                      80  
 Tyr Thr Leu Glu Asp Leu Asp Arg Glu Phe Lys Ala Phe Ala His Ala  
 85                      90                      95  
 Gln Trp Lys Ala Gln Val Arg Ser Ile Tyr Ser Leu Leu Met Gly Ser  
 100                      105                      110  
 Tyr Asn Asp Ile Phe Asp Leu Phe Phe Ser Asn Cys Arg Ser Leu Phe  
 115                      120                      125  
 Lys Asp Lys Lys Leu Val Glu Tyr Leu Lys Glu Ser Ser Phe Asp Ala  
 130                      135                      140  
 Val Phe Leu Asp Pro Phe Asp Asn Cys Gly Leu Ile Val Ala Lys Tyr  
 145                      150                      155                      160  
 Phe Ser Leu Pro Ser Val Val Phe Ala Arg Gly Ile Leu Cys His Tyr  
 165                      170                      175  
 Leu Glu Glu Gly Ala Gln Cys Pro Ala Pro Leu Ser Tyr Val Pro Arg  
 180                      185                      190  
 Ile Leu Leu Gly Phe Ser Asp Ala Met Thr Phe Lys Glu Arg Val Arg  
 195                      200                      205  
 Asn His Ile Met His Leu Glu Glu His Leu Leu Cys His Arg Phe Phe  
 210                      215                      220  
 Lys Asn Ala Leu Glu Ile Ala Ser Glu Ile Leu Gln Thr Pro Val Thr  
 225                      230                      235                      240  
 Glu Tyr Asp Leu Tyr Ser His Thr Ser Ile Trp Leu Leu Arg Thr Asp  
 245                      250                      255  
 Phe Val Leu Asp Tyr Pro Lys Pro Val Met Pro Asn Met Ile Phe Ile  
 260                      265                      270  
 Gly Gly Ile Asn Cys His Gln Gly Lys Pro Leu Pro Met Glu Phe Glu  
 275                      280                      285  
 Ala Tyr Ile Asn Ala Ser Gly Glu His Gly Ile Val Val Phe Ser Leu  
 290                      295                      300  
 Gly Ser Met Val Ser Glu Ile Pro Glu Lys Lys Ala Met Ala Ile Ala  
 305                      310                      315                      320  
 Asp Ala Leu Gly Lys Ile Pro Gln Thr Val Leu Trp Arg Tyr Thr Gly  
 325                      330                      335

39/40

Thr Arg Pro Ser Asn Leu Ala Asn Asn Thr Ile Leu Val Lys Trp Leu  
                   340                  345                  350  
 Pro Gln Asn Asp Leu Leu Gly His Pro Met Thr Arg Ala Phe Ile Thr  
                   355                  360                  365  
 His Ala Gly Ser His Gly Val Tyr Glu Ser Ile Cys Asn Gly Val Pro  
                   370                  375                  380  
 Met Val Met Met Pro Leu Phe Gly Asp Gln Met Asp Asn Ala Lys Arg  
 385                  390                  395                  400  
 Met Glu Thr Lys Gly Ala Gly Val Thr Leu Asn Val Leu Glu Met Thr  
                   405                  410                  415  
 Ser Glu Asp Leu Glu Asn Ala Leu Lys Ala Val Ile Asn Asp Lys Ser  
                   420                  425                  430  
 Tyr Lys Glu Asn Ile Met Arg Leu Ser Ser Leu His Lys Asp Arg Pro  
                   435                  440                  445  
 Val Glu Pro Leu Asp Leu Ala Val Phe Trp Val Glu Phe Val Met Arg  
                   450                  455                  460  
 His Lys Gly Ala Pro His Leu Arg Pro Ala Ala His Asp Leu Thr Trp  
 465                  470                  475                  480  
 Tyr Gln Tyr His Ser Leu Asp Val Ile Gly Phe Leu Leu Ala Val Val  
                   485                  490                  495  
 Leu Thr Val Ala Phe Ile Thr Phe Lys Cys Cys Ala Tyr Gly Tyr Arg  
                   500                  505                  510  
 Lys Cys Leu Gly Lys Lys Gly Arg Val Lys Lys Ala His Lys Ser Lys  
                   515                  520                  525  
 Thr His  
                   530

&lt;210&gt; 71

&lt;211&gt; 530

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(530)

&lt;223&gt; UGT1A9\*3 protein

&lt;400&gt; 71

Met Ala Cys Thr Gly Trp Thr Ser Pro Leu Pro Leu Cys Val Cys Leu  
   1                  5                  10                  15  
 Leu Leu Thr Cys Gly Phe Ala Glu Ala Gly Lys Leu Leu Val Val Pro  
                   20                  25                  30  
 Thr Asp Gly Ser His Trp Phe Thr Met Arg Ser Val Val Glu Lys Leu  
                   35                  40                  45  
 Ile Leu Arg Gly His Glu Val Val Val Met Pro Glu Val Ser Trp  
                   50                  55                  60  
 Gln Leu Gly Arg Ser Leu Asn Cys Thr Val Lys Thr Tyr Ser Thr Ser  
 65                  70                  75                  80  
 Tyr Thr Leu Glu Asp Leu Asp Arg Glu Phe Lys Ala Phe Ala His Ala  
                   85                  90                  95  
 Gln Trp Lys Ala Gln Val Arg Ser Ile Tyr Ser Leu Leu Met Gly Ser  
                   100                  105                  110  
 Tyr Asn Asp Ile Phe Asp Leu Phe Ser Asn Cys Arg Ser Leu Phe  
                   115                  120                  125  
 Lys Asp Lys Lys Leu Val Glu Tyr Leu Lys Glu Ser Ser Phe Asp Ala  
                   130                  135                  140  
 Val Phe Leu Asp Pro Phe Asp Asn Cys Gly Leu Ile Val Ala Lys Tyr

40/40

145 150 155 160  
Phe Ser Leu Pro Ser Val Val Phe Ala Arg Gly Ile Leu Cys His Tyr  
165 170 175  
Leu Glu Glu Gly Ala Gln Cys Pro Ala Pro Leu Ser Tyr Val Pro Arg  
180 185 190  
Ile Leu Leu Gly Phe Ser Asp Ala Met Thr Phe Lys Glu Arg Val Arg  
195 200 205  
Asn His Ile Met His Leu Glu Glu His Leu Leu Cys His Arg Phe Phe  
210 215 220  
Lys Asn Ala Leu Glu Ile Ala Ser Glu Ile Leu Gln Thr Pro Val Thr  
225 230 235 240  
Glu Tyr Asp Leu Tyr Ser His Thr Ser Ile Trp Leu Leu Arg Thr Asp  
245 250 255  
Phe Val Leu Asp Tyr Pro Lys Pro Val Met Pro Asn Met Ile Phe Ile  
260 265 270  
Gly Gly Ile Asn Cys His Gln Gly Lys Pro Leu Pro Met Glu Phe Glu  
275 280 285  
Ala Tyr Ile Asn Ala Ser Gly Glu His Gly Ile Val Val Phe Ser Leu  
290 295 300  
Gly Ser Met Val Ser Glu Ile Pro Glu Lys Lys Ala Met Ala Ile Ala  
305 310 315 320  
Asp Ala Leu Gly Lys Ile Pro Gln Thr Val Leu Trp Arg Tyr Thr Gly  
325 330 335  
Thr Arg Pro Ser Asn Leu Ala Asn Asn Thr Ile Leu Val Lys Trp Leu  
340 345 350  
Pro Gln Asn Asp Leu Leu Gly His Pro Met Thr Arg Ala Phe Ile Thr  
355 360 365  
His Ala Gly Ser His Gly Val Tyr Glu Ser Ile Cys Asn Gly Val Pro  
370 375 380  
Met Val Met Met Pro Leu Phe Gly Asp Gln Met Asp Asn Ala Lys Arg  
385 390 395 400  
Met Glu Thr Lys Gly Ala Gly Val Thr Leu Asn Val Leu Glu Met Thr  
405 410 415  
Ser Glu Asp Leu Glu Asn Ala Leu Lys Ala Val Ile Asn Asp Lys Ser  
420 425 430  
Tyr Lys Glu Asn Ile Met Arg Leu Ser Ser Leu His Lys Asp Arg Pro  
435 440 445  
Val Glu Pro Leu Asp Leu Ala Val Phe Trp Val Glu Phe Val Met Arg  
450 455 460  
His Lys Gly Ala Pro His Leu Arg Pro Ala Ala His Asp Leu Thr Trp  
465 470 475 480  
Tyr Gln Tyr His Ser Leu Asp Val Ile Gly Phe Leu Leu Ala Val Val  
485 490 495  
Leu Thr Val Ala Phe Ile Thr Phe Lys Cys Cys Ala Tyr Gly Tyr Arg  
500 505 510  
Lys Cys Leu Gly Lys Lys Gly Arg Val Lys Lys Ala His Lys Ser Lys  
515 520 525  
Thr His  
530

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
**WO 2004/027088 A3**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68,  
C12N 9/10

(21) International Application Number:  
PCT/CA2003/001269

(22) International Filing Date: 20 August 2003 (20.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/412,002 20 September 2002 (20.09.2002) US

(71) Applicant (for all designated States except US): UNI-  
VERSITÉ LAVAL [CA/CA]; Cité universitaire, Québec,  
Québec G1K 7P4 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): GUILLEMETTE,  
Chantal [CA/CA]; 7605 La Fraîcheur, Québec, Québec  
G2K 2C7 (CA).

(74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill  
College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
19 August 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR DETERMINING THE PREDISPOSITION OF PATIENTS TO TOXICITY OR LACK OF EFFICACY  
OF A DRUG

(57) Abstract: The present invention relates to a method for determining predisposition to a physiological reaction in a patient. Particularly, the present invention relates to a method for determining a predisposition to toxicity induced by a camptothecin analog or to an immunosuppressive mycophenolic acid-based therapy. This method comprises the characterization of nucleic acid sequences from the patient. The nucleic acid sequence encodes for an amino acid sequence or regulates the expression of UGT1A1, UGT1A7, UGT1A9 or their polymorphic variants. The method also comprises the analysis of haplotypic variation within these genes.



WO 2004/027088 A3

# INTERNATIONAL SEARCH REPORT

International Application No

POA 03/01269

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q1/68 C12N9/10

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 395 481 B1 (RATAIN MARK J ET AL) 28 May 2002 (2002-05-28) examples 1-7; table 1 column 6, line 54 - column 7, line 9 claims 9-26, 43-63	1-15, 23, 24
X	WO 02/48400 A (ANDO YU-UICHI ; SHIMOKATA KAORU (JP); HASEGAWA YOSHINORI (JP); NAGO) 20 June 2002 (2002-06-20) abstract; figure 4 claims 1-31 & EP 1 352 970 A (NAGOYA IND SCIENCE RES I) 15 October 2003 (2003-10-15) ----- -/--	1-15, 23, 24

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

19 March 2004

Date of mailing of the international search report

19.04.04

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hermann, P

# INTERNATIONAL SEARCH REPORT

International Application No

P A 03/01269

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GAGNE J-F ET AL: "COMMON HUMAN UGT1A POLYMORPHISMS AND THE ALTERED METABOLISM OF IRINOTECAN ACTIVE METABOLITE 7-ETHYL-10-HYDROXYCAMPTOTHECIN (SN-38)" MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 62, no. 3, September 2002 (2002-09), pages 608-617, XP009001388 ISSN: 0026-895X Experimental procedures Results Discussion</p>	1-15,23, 24
X	<p>-----</p> <p>ANDO Y ET AL: "Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan" THERAPEUTIC DRUG MONITORING, NEW YORK, NY, US, vol. 24, no. 1, February 2002 (2002-02), pages 111-116, XP002967773 ISSN: 0163-4356 the whole document</p>	1-15,23, 24
X	<p>-----</p> <p>INNOCENTI F ET AL: "PHARMACOGENETICS OF ANTICANCER AGENTS: LESSONS FROM AMONAFIDE AND IRINOTECAN" DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 29, no. 4, PART 2, April 2001 (2001-04), pages 596-600, XP001008560 ISSN: 0090-9556 the whole document</p>	1-15,23, 24
X	<p>-----</p> <p>ANDO Y ET AL: "POLYMORPHISMS OF UDP-GLUCURONOSYLTRANSFERASE GENE AND IRINOTECAN TOXICITY: A PHARMACOGENETIC ANALYSIS" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, 15 December 2000 (2000-12-15), pages 6921-6926, XP002909302 ISSN: 0008-5472 the whole document</p>	1-15,23, 24
X	<p>-----</p> <p>ANDO Y ET AL: "UGT1A1 GENOTYPES AND GLUCURONIDATION OF SN-38, THE ACTIVE METABOLITE OF IRINOTECAN" ANNALS OF ONCOLOGY, KLUWER, DORDRECHT, NL, vol. 9, 1998, pages 845-847, XP002909100 ISSN: 0923-7534 the whole document</p> <p style="text-align: center;">-----</p> <p style="text-align: center;">-/--</p>	1-15,23, 24



# INTERNATIONAL SEARCH REPORT

International Application No

PO 03/01269

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RAMIREZ J ET AL: "IN VITRO CHARACTERIZATION OF HEPATIC FLAVOPIRIDOL METABOLISM USING HUMAN LIVER MICROSOMES AND RECOMBINANT UGT ENZYMES" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 19, no. 5, May 2002 (2002-05), pages 588-594, XP009019622 ISSN: 0724-8741 the whole document	1-20, 25-29
X	VOGEL A ET AL: "GENETIC LINK OF HEPATOCELLULAR CARCINOMA WITH POLYMORPHISMS OF THE UDP-GLUCURONOSYLTRANSFERASE UGT147 GENE" GASTROENTEROLOGY, W.B.SAUNDERS COMPANY, PHILADELPHIA, US, vol. 121, no. 5, November 2001 (2001-11), pages 1136-1144, XP001119046 ISSN: 0016-5085 the whole document	1-15,21, 22,25,26
X	US 2002/016293 A1 (RATAIN MARK J ET AL) 7 February 2002 (2002-02-07) paragraph '0070! - paragraph '0073!; claims 77-83	1-20, 25-29
X	GUILLEMETTE C ET AL: "STRUCTURAL HETEROGENEITY AT THE UDP-GLUCURONOSYLTRANSFERASE 1 LOCUS: FUNCTIONAL CONSEQUENCES OF THREE NOVEL MISSENSE MUTATIONS IN THE HUMAN UGT1A7 GENE" PHARMACOGENETICS, CHAPMAN & HALL, LONDON, GB, vol. 10, no. 7, October 2000 (2000-10), pages 629-644, XP009002994 ISSN: 0960-314X the whole document	1-15,21, 22,25,26
X	ANDO MAKI ET AL: "Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients." JAPANESE JOURNAL OF CANCER RESEARCH : GANN. MAY 2002, vol. 93, no. 5, May 2002 (2002-05), pages 591-597, XP002273391 ISSN: 0910-5050 the whole document	1-15,21, 22,25,26
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/A 03/01269

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TUKEY R H ET AL: "HUMAN UDP-GLUCURONOSYLTRANSFERASES: METABOLISM, EXPRESSION, AND DISEASE" ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, ANNUAL REVIEW INC., PALO ALTO, CA, US, vol. 40, 2000, pages 581-616, 2PAGES, XP009003008 ISSN: 0362-1642 the whole document -----	1-15, 23, 24
A	MACKENZIE PETER I: "Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid" THERAPEUTIC DRUG MONITORING, vol. 22, no. 1, February 2000 (2000-02), pages 10-13, XP009019790 ISSN: 0163-4356 the whole document -----	11
A	WOOLLEY ADAM T ET AL: "Direct haplotyping of kilobase-size DNA using carbon nanotube probes" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 18, no. 7, July 2000 (2000-07), pages 760-763, XP002234415 ISSN: 1087-0156 the whole document -----	1-15, 21, 22, 25, 26

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 03/01269

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Claims Nos.: -

Claims 25- 29 lack clarity (Article 6 PCT) due to the expression "fragment thereof" which does not have any commonly well accepted definition in the art. Moreover the description is silent as regards a definition of said expression, or any length characterising the said fragments. Therefore the search for claims 25-29 has been limited to nucleic acids and molecules having the SEQ. IDs. recited in the claims and the complements thereof.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-15, 25 and 26 (all in part), 23 and 24 (in full)

Invention 1 relates to a method for determining the predisposition of patients to toxicity or lack of efficacy of a biologically active compound comprising detecting polymorphism or haplotic variation in UGT1A1 gene wherein the presence of said polymorphism or haplotic variation is indicative of said predisposition.

---

2. claims: 1-15, 25 and 26 (all in part), 21 and 22 (in full)

Invention 2 relates to i) a method for determining the predisposition of patients to toxicity or lack of efficacy of a biologically active compound comprising detecting polymorphism or haplotic variation in UGT1A7 gene wherein the presence of said polymorphism or haplotic variation is indicative of said predisposition; and ii) the isolated nucleotide sequence comprising sequences presenting said polymorphism or variation.

---

3. claims: 1-15, 25 and 26 (in part), 16-20 and 27-29 (in full)

Invention 3 relates to i) a method for determining the predisposition of patients to toxicity or lack of efficacy of a biologically active compound comprising detecting polymorphism or haplotic variation in UGT1A9 gene wherein the presence of said polymorphism or haplotic variation is indicative of said predisposition; ii) the isolated nucleotide sequence comprising sequences presenting said polymorphism or variation; and iii) the isolated amino acid sequence comprising the translation of said polymorphism or variation.

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 03/01269

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6395481	B1	28-05-2002	US 2002115097 A1	22-08-2002
WO 0248400	A	20-06-2002	AU 2111202 A	24-06-2002
			EP 1352970 A1	15-10-2003
			WO 0248400 A1	20-06-2002
EP 1352970	A	15-10-2003	AU 2111202 A	24-06-2002
			EP 1352970 A1	15-10-2003
			WO 0248400 A1	20-06-2002
US 2002016293	A1	07-02-2002	AU 5361801 A	07-11-2001
			WO 0180896 A2	01-11-2001

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**